{"row_id": 0, "sent_id": "0_0", "text": "BLA submitted to the FDA, noted January 2, 2024.", "triplets": [["regulatory", "BLA submitted", "POS"]]}
{"row_id": 1, "sent_id": "1_0", "text": "BLA submitted to the FDA, noted January 2, 2024.", "triplets": [["regulatory", "BLA submitted", "POS"]]}
{"row_id": 2, "sent_id": "2_0", "text": "Phase 1 was well-tolerated, and treatment-related adverse events (AEs) were all expected and generally dose-dependent, noted on January 2, 2024.", "triplets": [["safety", "well-tolerated", "POS"], ["phase", "well-tolerated", "POS"]]}
{"row_id": 3, "sent_id": "3_0", "text": "Phase 2/3 results missed a primary endpoint on the LS Mean difference (SE) points between treated and placebo, noted January 2, 2024.", "triplets": [["endpoint", "missed", "NEG"], ["effect", "missed", "NEG"], ["phase", "missed", "NEG"]]}
{"row_id": 4, "sent_id": "4_0", "text": "Phase 1b/2 enrollment completed, noted January 2, 2024.", "triplets": [["phase", "enrollment completed", "POS"], ["enrollment", "enrollment completed", "POS"]]}
{"row_id": 5, "sent_id": "5_0", "text": "Phase 3 dosing initiated, noted January 2, 2024.", "triplets": [["phase", "dosing initiated", "POS"], ["clinical", "dosing initiated", "POS"]]}
{"row_id": 6, "sent_id": "6_0", "text": "Phase 3 enrollment was completed, noted January 2, 2024.", "triplets": [["phase", "enrollment was completed", "POS"], ["enrollment", "enrollment was completed", "POS"]]}
{"row_id": 7, "sent_id": "7_0", "text": "Phase 1b third cohort completed, noted January 2, 2024.", "triplets": [["phase", "third cohort completed", "POS"], ["clinical", "third cohort completed", "POS"]]}
{"row_id": 8, "sent_id": "8_0", "text": "Phase 3 data reported that the trial met its primary endpoint and key secondary endpoints, noted January 3, 2024.", "triplets": [["endpoint", "met", "POS"], ["phase", "met", "POS"], ["financial", "met", "POS"]]}
{"row_id": 9, "sent_id": "9_0", "text": "Phase 3 data reported that the trial met its primary endpoint, noted January 3, 2024.", "triplets": [["endpoint", "met", "POS"], ["phase", "met", "POS"]]}
{"row_id": 10, "sent_id": "10_0", "text": "Phase 3 data reported that the trial met its primary endpoint, noted January 3, 2024.", "triplets": [["endpoint", "met", "POS"], ["phase", "met", "POS"]]}
{"row_id": 13, "sent_id": "13_0", "text": "Phase 2/3 trial enrollment completed, noted January 3, 2024.", "triplets": [["phase", "enrollment completed", "POS"], ["enrollment", "enrollment completed", "POS"]]}
{"row_id": 14, "sent_id": "14_0", "text": "Phase 3 enrollment completed, noted January 3, 2024.", "triplets": [["phase", "enrollment completed", "POS"], ["enrollment", "enrollment completed", "POS"]]}
{"row_id": 15, "sent_id": "15_0", "text": "Phase 2 early enrollment completed, noted January 3, 2023.", "triplets": [["phase", "enrollment completed", "POS"], ["enrollment", "enrollment completed", "POS"]]}
{"row_id": 16, "sent_id": "16_0", "text": "Additional Phase 1/2 data reported that an additional Ewing sarcoma patient treated with seclidemstat, topotecan and cyclophosphamide (TC) has achieved a partial response as demonstrated by at least a", "triplets": [["phase", "achieved", "POS"]]}
{"row_id": 19, "sent_id": "19_0", "text": "Phase 1 MAD results from 24 healthy volunteers showed that study was well tolerated in participants over the entire dose range and resulted in no safety signals of concern.", "triplets": [["safety", "well tolerated", "POS"], ["phase", "well tolerated", "POS"]]}
{"row_id": 24, "sent_id": "24_0", "text": "Phase 2 trial met its primary endpoint, noted January 4, 2024.", "triplets": [["endpoint", "met", "POS"], ["phase", "met", "POS"]]}
{"row_id": 28, "sent_id": "28_0", "text": "Phase 1 dosing initiated, noted January 4, 2024.", "triplets": [["phase", "dosing initiated", "POS"], ["clinical", "dosing initiated", "POS"]]}
{"row_id": 29, "sent_id": "29_0", "text": "Phase 3 topline data demonstrated that while a trend favored active treatment, the difference between active and placebo treated groups (0.30 ml/kg/min) was not statistically significant, noted Januar", "triplets": [["phase", "statistically significant", "NEU"], ["clinical", "statistically significant", "NEU"]]}
{"row_id": 30, "sent_id": "30_0", "text": "Phase 3 topline data demonstrated that while a trend favored active treatment, the difference between active and placebo treated groups (0.30 ml/kg/min) was not statistically significant, noted Januar", "triplets": [["phase", "statistically significant", "NEU"], ["clinical", "statistically significant", "NEU"]]}
{"row_id": 31, "sent_id": "31_0", "text": "Phase 4 data reported that the trial did not show a statistically significant difference between YUPELRI and Spiriva HandiHaler on the primary endpoint, noted January 5, 2024.", "triplets": [["endpoint", "statistically significant", "POS"]]}
{"row_id": 35, "sent_id": "35_0", "text": "NDA submitted to the FDA, noted January 5, 2024.", "triplets": [["regulatory", "NDA submitted", "POS"]]}
{"row_id": 36, "sent_id": "36_0", "text": "NDA submitted to the FDA, noted January 5, 2024.", "triplets": [["regulatory", "NDA submitted", "POS"]]}
{"row_id": 37, "sent_id": "37_0", "text": "FDA Approved on January 5, 2023.", "triplets": [["regulatory", "FDA Approved", "POS"]]}
{"row_id": 38, "sent_id": "38_0", "text": "FDA Approved on January 5, 2023.", "triplets": [["regulatory", "FDA Approved", "POS"]]}
{"row_id": 46, "sent_id": "46_0", "text": "Phase 2b trial met its primary endpoint, noted January 8, 2024.", "triplets": [["endpoint", "met", "POS"], ["phase", "met", "POS"]]}
{"row_id": 51, "sent_id": "51_0", "text": "Phase 2 data presented at the Biotech Showcase showed that dose was statistically significant drug effects were observed in FDA-recognized efficacy endpoints as early as the 15-day first visit after d", "triplets": [["phase", "statistically significant", "POS"]]}
{"row_id": 53, "sent_id": "53_0", "text": "Phase 2a trial did not meet its primary endpoint, noted January 8, 2024.", "triplets": [["endpoint", "did not meet", "NEG"], ["phase", "did not meet", "NEG"]]}
{"row_id": 56, "sent_id": "56_0", "text": "Phase 2 primary endpoint was met in its randomized, placebo-controlled study, noted on January 8, 2024.", "triplets": [["endpoint", "met", "POS"], ["phase", "met", "POS"]]}
{"row_id": 57, "sent_id": "57_0", "text": "Phase 3 trial met its primary endpoint, noted January 8, 2024.", "triplets": [["endpoint", "met", "POS"], ["phase", "met", "POS"]]}
{"row_id": 61, "sent_id": "61_0", "text": "Phase 1b data demonstrated potential best-in-class profile, including half-life >10 hours, robust target engagement and well tolerated safety profile, supporting advancement for combination developmen", "triplets": [["safety", "well tolerated", "POS"], ["phase", "well tolerated", "POS"]]}
{"row_id": 68, "sent_id": "68_0", "text": "IND cleared by the FDA, noted January 9, 2024", "triplets": [["regulatory", "cleared by the FDA", "POS"]]}
{"row_id": 69, "sent_id": "69_0", "text": "Phase 3 pivotal efficacy and safety study met the primary endpoint , noted January 9, 2024.", "triplets": [["endpoint", "met", "POS"], ["safety", "met", "POS"], ["phase", "met", "POS"]]}
{"row_id": 70, "sent_id": "70_0", "text": "Phase 3 pivotal efficacy and safety study met the primary endpoint , noted January 9, 2024.", "triplets": [["endpoint", "met", "POS"], ["safety", "met", "POS"], ["phase", "met", "POS"]]}
{"row_id": 71, "sent_id": "71_0", "text": "Phase 1 data reported that treatment was generally well tolerated, with no Grade 4 or 5 treatment-related adverse events (TRAEs) reported, noted January 10, 2025.", "triplets": [["safety", "well tolerated", "POS"], ["phase", "well tolerated", "POS"]]}
{"row_id": 72, "sent_id": "72_0", "text": "Phase 2 32-week interim data reported that 3E10 vg/eye achieved an 86% reduction in injection burden vs. projected on-label aflibercept 2mg Q8W and dose response with 61% reduction vs. 1E10 vg/eye, wi", "triplets": [["phase", "achieved", "POS"]]}
{"row_id": 74, "sent_id": "74_0", "text": "Phase 2b topline data on ATI-1777 2% QD showed a trend toward significance, ATI-1777 2% BID achieved a statistically significant result in the primary efficacy endpoint at week 4, noted January 10, 2", "triplets": [["phase", "achieved", "POS"], ["clinical", "achieved", "POS"]]}
{"row_id": 76, "sent_id": "76_0", "text": "Phase 2 dosing initiated, noted January 10, 2024.", "triplets": [["phase", "dosing initiated", "POS"], ["clinical", "dosing initiated", "POS"]]}
{"row_id": 77, "sent_id": "77_0", "text": "Phase 1 first cohort completed, noted January 10, 2024.", "triplets": [["phase", "first cohort completed", "POS"], ["clinical", "first cohort completed", "POS"]]}
{"row_id": 79, "sent_id": "79_0", "text": "FDA Approved on January 12, 2024.", "triplets": [["regulatory", "FDA Approved", "POS"]]}
{"row_id": 80, "sent_id": "80_0", "text": "Additional Phase 3 data reported that at Week 4, a statistically significant greater percentage of patients achieved a 50% reduction in EASI scores (EASI-50), with 69.2% of patients treated with roflu", "triplets": [["phase", "statistically significant", "POS"]]}
{"row_id": 81, "sent_id": "81_0", "text": "Approved January 16, 2024.", "triplets": [["catalyst", "Approved", "POS"]]}
{"row_id": 83, "sent_id": "83_0", "text": "Approved January 16, 2024.", "triplets": [["catalyst", "Approved", "POS"]]}
{"row_id": 84, "sent_id": "84_0", "text": "Approved January 16, 2024.", "triplets": [["catalyst", "Approved", "POS"]]}
{"row_id": 85, "sent_id": "85_0", "text": "FDA Approved on January 16, 2024.", "triplets": [["regulatory", "FDA Approved", "POS"]]}
{"row_id": 86, "sent_id": "86_0", "text": "FDA Approved on January 16, 2024.", "triplets": [["regulatory", "FDA Approved", "POS"]]}
{"row_id": 93, "sent_id": "93_1", "text": "Phase 1 trial enrollment completed, noted January 17, 2024", "triplets": [["phase", "enrollment completed", "POS"], ["enrollment", "enrollment completed", "POS"]]}
{"row_id": 94, "sent_id": "94_1", "text": "Phase 1 trial enrollment completed, noted January 17, 2024", "triplets": [["phase", "enrollment completed", "POS"], ["enrollment", "enrollment completed", "POS"]]}
{"row_id": 99, "sent_id": "99_0", "text": "Enrollment completed, noted January 17, 2024.", "triplets": [["enrollment", "Enrollment completed", "POS"]]}
{"row_id": 102, "sent_id": "102_0", "text": "Phase 2/3 IRB approved protocol to asses drug in patients, noted January 17, 2024.", "triplets": [["phase", "approved", "POS"]]}
{"row_id": 105, "sent_id": "105_0", "text": "Phase 2 data reported that the trial met primary endpoint with clinically meaningful and statistically significant decreases in urticaria disease activity across multiple dose groups, noted January 18", "triplets": [["endpoint", "met", "POS"], ["phase", "met", "POS"]]}
{"row_id": 106, "sent_id": "106_0", "text": "Phase 2 data presented at ASCO GI demonstrated early activity with 38% objective response rate including three complete responses, noted January 18, 2024.", "triplets": [["phase", "data presented at ASCO", "POS"], ["clinical", "data presented at ASCO", "POS"]]}
{"row_id": 109, "sent_id": "109_0", "text": "Phase 3 data presented at ASCO GI reported that treatment reduced the risk of disease progression or death by 23% compared to TACE alone, noted January 19, 2024.", "triplets": [["phase", "data presented at ASCO", "POS"], ["clinical", "data presented at ASCO", "POS"]]}
{"row_id": 110, "sent_id": "110_1", "text": "Alvotech believes it is in position to receive approval on BsUFA", "triplets": [["regulatory", "approval", "POS"]]}
{"row_id": 111, "sent_id": "111_1", "text": "Alvotech believes it is in position to receive approval on BsUFA", "triplets": [["regulatory", "approval", "POS"]]}
{"row_id": 112, "sent_id": "112_1", "text": "Alvotech believes it is in position to receive approval on BsUFA", "triplets": [["regulatory", "approval", "POS"]]}
{"row_id": 113, "sent_id": "113_1", "text": "Alvotech believes it is in position to receive approval on BsUFA", "triplets": [["regulatory", "approval", "POS"]]}
{"row_id": 116, "sent_id": "116_0", "text": "Phase 1b/2 trial approved by Netherlands, noted June 27, 2023.", "triplets": [["phase", "approved", "POS"]]}
{"row_id": 117, "sent_id": "117_0", "text": "Phase 1b/2 trial approved by Netherlands, noted June 27, 2023.", "triplets": [["phase", "approved", "POS"]]}
{"row_id": 120, "sent_id": "120_0", "text": "Phase 2 trial data presented at ASCO-GI showed a major tumor regression in 67.5% of patients.", "triplets": [["phase", "data presented at ASCO", "POS"], ["clinical", "data presented at ASCO", "POS"]]}
{"row_id": 120, "sent_id": "120_1", "text": "The study achieved durable elimination of ctDNA, a critical biomarker for cancer clearance and long-term d", "triplets": [["catalyst", "achieved", "POS"]]}
{"row_id": 121, "sent_id": "121_0", "text": "Phase 3 topline data met the primary endpoint with a statistically significant reduction in the rate of HAE attacks in patients treated every 4 weeks or patients treated every 8 weeks, noted January 2", "triplets": [["endpoint", "met", "POS"], ["phase", "met", "POS"], ["clinical", "met", "POS"]]}
{"row_id": 122, "sent_id": "122_0", "text": "Phase 2b enrollment completed exceeding target enrollment (100/90), noted January 22, 2024.", "triplets": [["phase", "enrollment completed", "POS"], ["enrollment", "enrollment completed", "POS"]]}
{"row_id": 124, "sent_id": "124_0", "text": "Phase 3 trial did not meet its primary endpoint, noted January 22, 2024.", "triplets": [["endpoint", "did not meet", "NEG"], ["phase", "did not meet", "NEG"]]}
{"row_id": 129, "sent_id": "129_0", "text": "FDA Approved on January 23, 2024.", "triplets": [["regulatory", "FDA Approved", "POS"]]}
{"row_id": 132, "sent_id": "132_0", "text": "Phase 1 data presented at the HEAL Initiative Scientific Meeting reported that the trial successfully met its overdose protection endpoints, noted January 25, 2024.", "triplets": [["phase", "met", "POS"]]}
{"row_id": 135, "sent_id": "135_0", "text": "Phase 2 sub-study data reported statistically significant improvements in measures of cardiac structure and function including left ventricular mass index (-11.4 g/m2 \u00c2\u00b119.4, p=0.03), maximum left vent", "triplets": [["pvalue", "statistically significant", "POS"], ["phase", "statistically significant", "POS"]]}
{"row_id": 136, "sent_id": "136_0", "text": "Phase 3 data presented at ASCO GU showed a reduction of the risk of disease progression or death by 35% in patients.", "triplets": [["phase", "data presented at ASCO", "POS"], ["clinical", "data presented at ASCO", "POS"]]}
{"row_id": 139, "sent_id": "139_0", "text": "Approved January 25, 2024.", "triplets": [["catalyst", "Approved", "POS"]]}
{"row_id": 140, "sent_id": "140_0", "text": "Approved January 25, 2024.", "triplets": [["catalyst", "Approved", "POS"]]}
{"row_id": 144, "sent_id": "144_0", "text": "Phase 3 results presented at ASCO GU reported that with subcutaneous nivolumab demonstrating an ORR of 24.2% vs. 18.2% with IV Opdivo, noted January 27, 2024.", "triplets": [["endpoint", "results presented at ASCO", "POS"], ["phase", "results presented at ASCO", "POS"], ["clinical", "results presented at ASCO", "POS"]]}
{"row_id": 145, "sent_id": "145_0", "text": "Phase 3 results presented at ASCO GU reported that with subcutaneous nivolumab demonstrating an ORR of 24.2% vs. 18.2% with IV Opdivo, noted January 27, 2024.", "triplets": [["endpoint", "results presented at ASCO", "POS"], ["phase", "results presented at ASCO", "POS"], ["clinical", "results presented at ASCO", "POS"]]}
{"row_id": 148, "sent_id": "148_0", "text": "IND was cleared by the FDA on January 29, 2024.", "triplets": [["regulatory", "cleared by the FDA", "POS"]]}
{"row_id": 151, "sent_id": "151_0", "text": "Preclinical data demonstrated PALI-2108 to be safe and well tolerated, noted January 29, 2024.", "triplets": [["safety", "well tolerated", "POS"]]}
{"row_id": 152, "sent_id": "152_0", "text": "FDA Approved on January 29, 2024.", "triplets": [["regulatory", "FDA Approved", "POS"]]}
{"row_id": 154, "sent_id": "154_0", "text": "Phase 1 study published at Journal of Parkinson's Disease showed that data demonstrated that Risvodetinib was well tolerated up to 7 days of daily dosing with no serious adverse events in healthy volu", "triplets": [["safety", "well tolerated", "NEU"], ["phase", "well tolerated", "NEU"]]}
{"row_id": 155, "sent_id": "155_0", "text": "Pk trial met its primary endpoints, noted January 29, 2024.", "triplets": [["endpoint", "met", "POS"]]}
{"row_id": 159, "sent_id": "159_0", "text": "Phase 3 data met the primary endpoint of non-inferiority to augmentin; and demonstrated statistical superiority, noted January 30, 2024.", "triplets": [["endpoint", "met", "POS"], ["phase", "met", "POS"]]}
{"row_id": 160, "sent_id": "160_0", "text": "Phase 3 trial data reported a statistically significant improvement on the primary endpoint of the time-weighted sum of the pain intensity difference from 0 to 48 hours (SPID48) compared to placebo, n", "triplets": [["endpoint", "statistically significant", "POS"], ["phase", "statistically significant", "POS"], ["clinical", "statistically significant", "POS"]]}
{"row_id": 161, "sent_id": "161_0", "text": "Phase 3 trial did not meet its primary endpoint, noted January 31, 2024.", "triplets": [["endpoint", "did not meet", "NEG"], ["phase", "did not meet", "NEG"]]}
{"row_id": 162, "sent_id": "162_0", "text": "Special Protocol Assessment (SPA) dosing initiated, noted January 31, 2024.", "triplets": [["clinical", "dosing initiated", "POS"]]}
{"row_id": 170, "sent_id": "170_0", "text": "Phase 1 trial initial data presented at the Angiogenesis, Exudation, and Degeneration reported that monthly dosing of KSI-501 was safe and well-tolerated, noted February 3, 2024.", "triplets": [["safety", "well-tolerated", "POS"], ["phase", "well-tolerated", "POS"]]}
{"row_id": 173, "sent_id": "173_0", "text": "Phase 2a data reported that 320 mg group met its primary and secondary endpoints demonstrating that bexotegrast was well tolerated over a 12-week treatment period, noted February 5, 2024.", "triplets": [["endpoint", "met", "POS"], ["safety", "met", "POS"], ["phase", "met", "POS"], ["financial", "met", "POS"]]}
{"row_id": 174, "sent_id": "174_0", "text": "Phase 1 data showed that it well-tolerated and delivered ustekinumab with high bioavailability.", "triplets": [["safety", "well-tolerated", "POS"], ["phase", "well-tolerated", "POS"]]}
{"row_id": 177, "sent_id": "177_0", "text": "Company submitted the clinical hold complete response to the FDA for conducting a Phase 2 trial of its low-dose oral interferon (IFN)-alpha formulation, noted February 5, 2024.", "triplets": [["phase", "clinical hold", "NEG"], ["regulatory", "clinical hold", "NEG"]]}
{"row_id": 178, "sent_id": "178_0", "text": "Phase 3 study met all primary and key secondary endpoints in two randomized controlled trials in people with CF ages 12 years and older, noted February 5, 2024.", "triplets": [["endpoint", "met", "POS"], ["phase", "met", "POS"], ["financial", "met", "POS"]]}
{"row_id": 180, "sent_id": "180_0", "text": "Phase 1/2 clinical data reported a statistically significant improvements in disease severity were reported in the Fabry Outcome Survey adaptation of the Mainz Severity Score Index (FOS-MSSI) age-adju", "triplets": [["phase", "statistically significant", "POS"]]}
{"row_id": 181, "sent_id": "181_0", "text": "Phase 2 trial met its primary endpoint, noted February 6, 2024.", "triplets": [["endpoint", "met", "POS"], ["phase", "met", "POS"]]}
{"row_id": 183, "sent_id": "183_0", "text": "Phase 3 trial was not successful, noted February 6, 2024.", "triplets": [["phase", "successful", "POS"]]}
{"row_id": 186, "sent_id": "186_0", "text": "Phase 1/2 data showed that agenT-797 holds significant promise in improving patient survival and reducing secondary infections, all while maintaining a favorable safety profile, noted February 6, 2024", "triplets": [["safety", "favorable safety", "POS"], ["phase", "favorable safety", "POS"], ["financial", "favorable safety", "POS"]]}
{"row_id": 188, "sent_id": "188_0", "text": "Phase 3 data presented at ASCO plenary series noted that the median PFS for patients who received fruquintinib plus paclitaxel was 5.6 months, compared to 2.7 months for those who received paclitaxel", "triplets": [["endpoint", "data presented at ASCO", "POS"], ["phase", "data presented at ASCO", "POS"], ["clinical", "data presented at ASCO", "POS"]]}
{"row_id": 192, "sent_id": "192_0", "text": "Breakthrough Therapy Designation granted by the FDA, noted February 7, 2024", "triplets": [["regulatory", "Breakthrough Therapy", "POS"]]}
{"row_id": 193, "sent_id": "193_0", "text": "Breakthrough Therapy Designation granted by the FDA, noted February 7, 2024", "triplets": [["regulatory", "Breakthrough Therapy", "POS"]]}
{"row_id": 195, "sent_id": "195_0", "text": "Phase 3 topline data reported that trial met primary endpoint, noted February 7, 2024.", "triplets": [["endpoint", "met", "POS"], ["phase", "met", "POS"], ["clinical", "met", "POS"]]}
{"row_id": 198, "sent_id": "198_0", "text": "Phase 2 dosing initiated, noted February 8, 2024.", "triplets": [["phase", "dosing initiated", "POS"], ["clinical", "dosing initiated", "POS"]]}
{"row_id": 199, "sent_id": "199_0", "text": "Phase 2 dosing initiated, noted February 8, 2024.", "triplets": [["phase", "dosing initiated", "POS"], ["clinical", "dosing initiated", "POS"]]}
{"row_id": 201, "sent_id": "201_1", "text": "Safety results showed Ampligen is generally well tolerated in the treatment o", "triplets": [["safety", "well tolerated", "POS"]]}
{"row_id": 203, "sent_id": "203_0", "text": "Phase 2 enrollment completed, noted February 8, 2024.", "triplets": [["phase", "enrollment completed", "POS"], ["enrollment", "enrollment completed", "POS"]]}
{"row_id": 205, "sent_id": "205_0", "text": "Phase 2b trial met its primary and secondary endpoints, noted February 9, 2024.", "triplets": [["endpoint", "met", "POS"], ["phase", "met", "POS"], ["financial", "met", "POS"]]}
{"row_id": 207, "sent_id": "207_0", "text": "IND cleared by the FDA, noted February 9, 2024.", "triplets": [["regulatory", "cleared by the FDA", "POS"]]}
{"row_id": 208, "sent_id": "208_0", "text": "hase 2b/3 enrollment completed, noted February 9, 2024.", "triplets": [["enrollment", "enrollment completed", "POS"]]}
{"row_id": 211, "sent_id": "211_0", "text": "Phase 2 study showed that treatment was generally well tolerated following repeated subcutaneous injections in patients in the 25 and 50 mg cohorts with no serious adverse events, noted February 12, 2", "triplets": [["safety", "well tolerated", "NEU"], ["phase", "well tolerated", "NEU"]]}
{"row_id": 212, "sent_id": "212_0", "text": "Fast Track designation granted by the FDA on February 12, 2024.", "triplets": [["regulatory", "Fast Track", "POS"]]}
{"row_id": 215, "sent_id": "215_0", "text": "FDA approved on February 12, 2024.", "triplets": [["regulatory", "FDA approved", "POS"]]}
{"row_id": 217, "sent_id": "217_0", "text": "Type-D meeting with the FDA agreed in a that data from a single, adequate, and well-controlled study may form the primary basis of approval of a BLA for isaralgagene civaparvovec, noted February 12, 2", "triplets": [["regulatory", "approval", "POS"]]}
{"row_id": 218, "sent_id": "218_0", "text": "FDA Cleared IND on February 12, 2024.", "triplets": [["regulatory", "FDA Cleared", "POS"]]}
{"row_id": 219, "sent_id": "219_0", "text": "Phase 1 2nd cohort dosing initiated, noted February 12, 2024.", "triplets": [["phase", "dosing initiated", "POS"], ["clinical", "dosing initiated", "POS"]]}
{"row_id": 222, "sent_id": "222_0", "text": "The FDA cleared IND and granted fast-track designation on February 13, 2024.", "triplets": [["regulatory", "fast-track", "POS"]]}
{"row_id": 223, "sent_id": "223_0", "text": "Phase 3 clinical trial met all primary and key secondary endpoints and demonstrated a favorable safety profile, noted February 13, 2024.", "triplets": [["endpoint", "met", "POS"], ["safety", "met", "POS"], ["phase", "met", "POS"], ["financial", "met", "POS"]]}
{"row_id": 224, "sent_id": "224_0", "text": "Fast track designation granted by the FDA on February 13, 2024.", "triplets": [["regulatory", "Fast track", "POS"]]}
{"row_id": 225, "sent_id": "225_0", "text": "INDa cleared by the FDA on February 13, 2024.", "triplets": [["regulatory", "cleared by the FDA", "POS"]]}
{"row_id": 227, "sent_id": "227_0", "text": "IND cleared by the FDA, noted February 13, 2024.", "triplets": [["regulatory", "cleared by the FDA", "POS"]]}
{"row_id": 231, "sent_id": "231_0", "text": "Approved February 13, 2024.", "triplets": [["catalyst", "Approved", "POS"]]}
{"row_id": 232, "sent_id": "232_0", "text": "Phase 3 patient enrollment completed, noted February 14, 2024.", "triplets": [["phase", "enrollment completed", "POS"], ["enrollment", "enrollment completed", "POS"]]}
{"row_id": 234, "sent_id": "234_1", "text": "No serious adverse events related to GLSI-100 have been reported to date, noted February 14 2024.", "triplets": [["safety", "serious adverse events", "NEG"]]}
{"row_id": 240, "sent_id": "240_0", "text": "The preclinical study demonstrated successful drug delivery, noted February 14, 2024.", "triplets": [["catalyst", "successful", "POS"]]}
{"row_id": 244, "sent_id": "244_0", "text": "Phase 1 dosing initiated, noted February 15, 2024.", "triplets": [["phase", "dosing initiated", "POS"], ["clinical", "dosing initiated", "POS"]]}
{"row_id": 245, "sent_id": "245_0", "text": "Phase 3 study met the interim primary endpoint, noted February 15, 2024.", "triplets": [["endpoint", "met", "POS"], ["phase", "met", "POS"]]}
{"row_id": 254, "sent_id": "254_0", "text": "Phase 1 dosing initiated in China, noted February 16, 2024.", "triplets": [["phase", "dosing initiated", "POS"], ["clinical", "dosing initiated", "POS"]]}
{"row_id": 255, "sent_id": "255_0", "text": "FDA Approved on February 16, 2024.", "triplets": [["regulatory", "FDA Approved", "POS"]]}
{"row_id": 256, "sent_id": "256_0", "text": "Approved February 17, 2024.", "triplets": [["catalyst", "Approved", "POS"]]}
{"row_id": 257, "sent_id": "257_0", "text": "Phase 3 data reported that the trial showed statistically significant and highly clinically meaningful improvement in progression-free survival (PFS), noted February 19, 2024.", "triplets": [["endpoint", "statistically significant", "POS"], ["phase", "statistically significant", "POS"]]}
{"row_id": 258, "sent_id": "258_1", "text": "Phase 2a trial placed on clinical hold February 20, 2024.", "triplets": [["phase", "clinical hold", "NEG"], ["regulatory", "clinical hold", "NEG"]]}
{"row_id": 260, "sent_id": "260_0", "text": "Fast Track Designation granted by the FDA on February 20, 2024.", "triplets": [["regulatory", "Fast Track", "POS"]]}
{"row_id": 261, "sent_id": "261_1", "text": "FDA granted Fast Track designation, noted February 20, 2024.", "triplets": [["regulatory", "Fast Track", "POS"]]}
{"row_id": 266, "sent_id": "266_0", "text": "Supplemental approval granted by the FDA, noted February 20, 2024.", "triplets": [["regulatory", "approval", "POS"]]}
{"row_id": 268, "sent_id": "268_0", "text": "Phase 1 trial met its primary endpoint, noted February 21, 2024.", "triplets": [["endpoint", "met", "POS"], ["phase", "met", "POS"]]}
{"row_id": 269, "sent_id": "269_0", "text": "Phase 2 enrollment completed, noted February 21, 2024.", "triplets": [["phase", "enrollment completed", "POS"], ["enrollment", "enrollment completed", "POS"]]}
{"row_id": 272, "sent_id": "272_0", "text": "Phase 2a data demonstrated a statistically significant benefit in killing ticks compared to placebo, noted February 22, 2024.", "triplets": [["phase", "statistically significant", "POS"]]}
{"row_id": 276, "sent_id": "276_0", "text": "Phase 2 open-label extension data reported that both both doses of VTX002 achieved nominal statistical significance for all key secondary endpoints, noted February 22, 2024.", "triplets": [["endpoint", "achieved", "POS"], ["phase", "achieved", "POS"], ["financial", "achieved", "POS"]]}
{"row_id": 277, "sent_id": "277_0", "text": "PDUFA Priority Review date June 27, 2024.", "triplets": [["regulatory", "Priority Review", "POS"]]}
{"row_id": 280, "sent_id": "280_0", "text": "Phase 1/2a approval to commence dosing, noted February 23, 2024.", "triplets": [["phase", "approval", "POS"], ["regulatory", "approval", "POS"]]}
{"row_id": 282, "sent_id": "282_0", "text": "Approved February 23, 2024.", "triplets": [["catalyst", "Approved", "POS"]]}
{"row_id": 283, "sent_id": "283_0", "text": "Approved February 23, 2024.", "triplets": [["catalyst", "Approved", "POS"]]}
{"row_id": 286, "sent_id": "286_0", "text": "EAGLE-1 trial met its primary endpoint, noted February 26, 2024.", "triplets": [["endpoint", "met", "POS"]]}
{"row_id": 287, "sent_id": "287_0", "text": "Phase 1 data reported that no severe or serious adverse events were observed in patients treated in Cohort 1, noted February 26, 2024.", "triplets": [["safety", "serious adverse events", "NEG"], ["phase", "serious adverse events", "NEG"]]}
{"row_id": 288, "sent_id": "288_0", "text": "Preclinical data reported that treatment achieved comparable or superior efficacy and was shown to have a distinctive multi-modal mechanism of action versus empagliflozin, noted February 26, 2024.", "triplets": [["catalyst", "achieved", "POS"]]}
{"row_id": 289, "sent_id": "289_0", "text": "Approval noted February 26, 2024.", "triplets": [["regulatory", "Approval", "POS"]]}
{"row_id": 290, "sent_id": "290_0", "text": "Phase 1 presented at Tandem Meetings showed that all eight (100%) treatment-arm patients are relapse-free and have achieved and maintained complete donor chimerism following treatment, noted February", "triplets": [["phase", "achieved", "POS"]]}
{"row_id": 292, "sent_id": "292_0", "text": "Phase 1 updated clinical data at KOL illustrated a potential best-in-class profile: promising efficacy with favorable safety profile in heavily pretreated subjects with late-stage mCRPC, noted Februar", "triplets": [["safety", "favorable safety", "POS"], ["phase", "favorable safety", "POS"]]}
{"row_id": 294, "sent_id": "294_0", "text": "Approved for expanded indication to treat people with HIV (PWH) who have suppressed viral loads with known or suspected M184V/I resistance, noted February 26, 2024.", "triplets": [["catalyst", "Approved", "POS"]]}
{"row_id": 295, "sent_id": "295_0", "text": "CRL issued by the FDA, noted February 27, 2024.", "triplets": [["regulatory", "CRL", "NEG"]]}
{"row_id": 296, "sent_id": "296_0", "text": "Phase 2 study met primary and all secondary endpoints, demonstrating reductions in body weight, noted February 27, 2024.", "triplets": [["endpoint", "met", "POS"], ["phase", "met", "POS"], ["financial", "met", "POS"]]}
{"row_id": 297, "sent_id": "297_0", "text": "Phase 2a topline data reported statistically significant improvements (p<0.05) in inflammatory lesions and Investigator's Global Assessment (IGA) score compared to vehicle at Week 12 TP-04 was genera", "triplets": [["pvalue", "statistically significant", "POS"], ["phase", "statistically significant", "POS"], ["clinical", "statistically significant", "POS"]]}
{"row_id": 299, "sent_id": "299_0", "text": "Phase 3 dosing initiated, noted February 27, 2024.", "triplets": [["phase", "dosing initiated", "POS"], ["clinical", "dosing initiated", "POS"]]}
{"row_id": 300, "sent_id": "300_0", "text": "Phase 2 was well tolerated with anti-tumor activity at relevant higher dose levels observed with 29% Objective Response Rate (ORR) and 71% Disease Control Rate (DCR), noted February 27, 2024.", "triplets": [["endpoint", "well tolerated", "POS"], ["safety", "well tolerated", "POS"], ["phase", "well tolerated", "POS"]]}
{"row_id": 301, "sent_id": "301_0", "text": "Phase 1 dosing initiated, noted February 27, 2024.", "triplets": [["phase", "dosing initiated", "POS"], ["clinical", "dosing initiated", "POS"]]}
{"row_id": 302, "sent_id": "302_0", "text": "Phase 3 final results reported met the first co-primary endpoint in the Intent-to-Treat Analysis, however did not meet the co-primary endpoint showing superiority over vehicle, noted February 28, 2024.", "triplets": [["endpoint", "met", "NEU"], ["phase", "met", "NEU"]]}
{"row_id": 303, "sent_id": "303_0", "text": "Phase 2 topline data reported that the trial met its primary endpoint, noted February 28, 2024.", "triplets": [["endpoint", "met", "POS"], ["phase", "met", "POS"], ["clinical", "met", "POS"]]}
{"row_id": 304, "sent_id": "304_0", "text": "Preclinical data reported that CTX-8371 demonstrates enhanced anti-tumor activity relative to approved anti-PD-1 blockers and anti-PD-L1 blockers in a series of in vitro and in vivo experimental settings, noted February 28, 2024.", "triplets": [["catalyst", "approved", "POS"]]}
{"row_id": 306, "sent_id": "306_0", "text": "Phase 2 topline FL results reported that the trial met its primary endpoint, noted February 28, 2024.", "triplets": [["endpoint", "met", "POS"], ["phase", "met", "POS"]]}
{"row_id": 314, "sent_id": "314_0", "text": "Phase 3 top-line data reported that the trial met its primary endpoint, however two key secondary endpoints were specific to colon-in-continuity patients in assessing at least one day/week off PS versus baseline and reaching enteral autonomy at week 48, both of which were not achieved, noted February 29, 2024.", "triplets": [["endpoint", "met", "POS"], ["phase", "met", "POS"], ["financial", "met", "POS"], ["clinical", "met", "POS"]]}
{"row_id": 315, "sent_id": "315_0", "text": "Phase 2 full clinical results presented at ACTRIMS Forum reported that treatment demonstrated significant improvement of vision as measured by low contrast letter acuity (LCLA) through 35 months from randomization, noted February 29, 2024.", "triplets": [["phase", "significant improvement", "POS"], ["clinical", "significant improvement", "POS"]]}
{"row_id": 321, "sent_id": "321_0", "text": "IND cleared by the FDA, noted February 29, 2024", "triplets": [["regulatory", "cleared by the FDA", "POS"]]}
{"row_id": 323, "sent_id": "323_0", "text": "Additional Phase 2a data reported significant improvement of -2.4 points for the sleep/fatigue domain of the Non-Motor Symptom Scale (NMSS) in Parkinson's Disease, whereas placebo patients experienced a worsening of +1.0 points, noted March 1, 2024", "triplets": [["phase", "significant improvement", "POS"], ["clinical", "significant improvement", "POS"]]}
{"row_id": 324, "sent_id": "324_0", "text": "Additional Phase 3 data reported that due to the exclusion of data from so many sites the trial missed statistical significance but showed promising directional data on cognitive and functional measures.", "triplets": [["phase", "missed", "NEG"]]}
{"row_id": 325, "sent_id": "325_0", "text": "IND Cleared by the FDA, noted March 1, 2024", "triplets": [["regulatory", "Cleared by the FDA", "POS"]]}
{"row_id": 326, "sent_id": "326_3", "text": "This is the first time that a relapsed/refractory (r/r) AML patient achieved a CR with CDK9 inhibition monotherapy.", "triplets": [["endpoint", "achieved", "POS"]]}
{"row_id": 326, "sent_id": "326_5", "text": "All key study objectives were met regarding pharmacokinetic (PK), pharmacodynamic (PD), safety, and clinical activity, noted March 1, 2024.", "triplets": [["safety", "met", "POS"]]}
{"row_id": 327, "sent_id": "327_0", "text": "FDA approved on March 1, 2024.", "triplets": [["regulatory", "FDA approved", "POS"]]}
{"row_id": 332, "sent_id": "332_0", "text": "Phase 1 data reported the complete remission was achieved in 64% of patients, with an ORR of 73%, noted March 4, 2024.", "triplets": [["endpoint", "achieved", "POS"], ["phase", "achieved", "POS"]]}
{"row_id": 337, "sent_id": "337_0", "text": "FDA approved on March 4, 2024.", "triplets": [["regulatory", "FDA approved", "POS"]]}
{"row_id": 338, "sent_id": "338_0", "text": "Phase 2/3 last patient dosed, noted March 4, 2024.", "triplets": [["phase", "last patient dosed", "POS"], ["clinical", "last patient dosed", "POS"]]}
{"row_id": 339, "sent_id": "339_0", "text": "Phase 2 enrollment completed, noted March 4, 2024.", "triplets": [["phase", "enrollment completed", "POS"], ["enrollment", "enrollment completed", "POS"]]}
{"row_id": 345, "sent_id": "345_0", "text": "Phase 3 trial stopped early due to efficacy, based on a recommendation from an Independent Data Monitoring Committee.", "triplets": [["phase", "stopped early due to efficacy", "POS"]]}
{"row_id": 345, "sent_id": "345_1", "text": "The trial achieved its primary endpoint by demonstrating a statistically significant and superior reduction in kidney disease progression, major adverse cardiovascular events (MACE) and death of 24% for people treated with semaglutide 1.0 mg compared to placebo, noted March 5, 2024.", "triplets": [["endpoint", "achieved", "POS"]]}
{"row_id": 348, "sent_id": "348_0", "text": "Phase 2 trial met the primary endpoint, noted March 5, 2024.", "triplets": [["endpoint", "met", "POS"], ["phase", "met", "POS"]]}
{"row_id": 356, "sent_id": "356_0", "text": "IND cleared by the FDA noted, March 5, 2024.", "triplets": [["regulatory", "cleared by the FDA", "POS"]]}
{"row_id": 357, "sent_id": "357_0", "text": "Phase 1 pilot study experienced a marked decrease in the burden of infection, and the procedures were found to be safe and well tolerated, noted March 5, 2024.", "triplets": [["safety", "well tolerated", "POS"], ["phase", "well tolerated", "POS"]]}
{"row_id": 360, "sent_id": "360_0", "text": "FDA biosimilar of Xgeva (denosumab) and Prolia (denosumab) approved on March 5, 2024.", "triplets": [["catalyst", "approved", "POS"]]}
{"row_id": 362, "sent_id": "362_0", "text": "CRL issued by FDA on March 6, 2024.", "triplets": [["regulatory", "CRL", "NEG"]]}
{"row_id": 366, "sent_id": "366_0", "text": "Phase 1 dosing initiated, noted March 6, 2024.", "triplets": [["phase", "dosing initiated", "POS"], ["clinical", "dosing initiated", "POS"]]}
{"row_id": 367, "sent_id": "367_0", "text": "Phase 1 dosing initiated, noted March 6, 2024.", "triplets": [["phase", "dosing initiated", "POS"], ["clinical", "dosing initiated", "POS"]]}
{"row_id": 370, "sent_id": "370_0", "text": "Phase 2 third-line ombination THIO 180mg + cemiplimab achieved 38% overall response rate (ORR) in difficult-to-treat, noted March 6, 2024", "triplets": [["endpoint", "achieved", "POS"], ["phase", "achieved", "POS"]]}
{"row_id": 371, "sent_id": "371_0", "text": "Phase 2 third-line ombination THIO 180mg + cemiplimab achieved 38% overall response rate (ORR) in difficult-to-treat, noted March 6, 2024", "triplets": [["endpoint", "achieved", "POS"], ["phase", "achieved", "POS"]]}
{"row_id": 376, "sent_id": "376_0", "text": "Phase 3 data reported that 97% percent (71/73) of participants treated with Biktarvy achieved viral suppression (HIV-1 RNA < 50 copies /ml) as did 97% (36/37) of participants treated with the DTG-based regimen, noted March 6, 2024.", "triplets": [["phase", "achieved", "POS"]]}
{"row_id": 378, "sent_id": "378_0", "text": "Approved March 7, 2024.", "triplets": [["catalyst", "Approved", "POS"]]}
{"row_id": 379, "sent_id": "379_0", "text": "Phase 2b data 12-week data reported that the trial met its key secondary endpoint and maintained a clinically and statistically significant HAM-A reductions compared to placebo at 12 weeks with a 65% clinical response rate and 48% clinical remission rate, noted March 7, 2024.", "triplets": [["endpoint", "met", "POS"], ["phase", "met", "POS"], ["financial", "met", "POS"]]}
{"row_id": 380, "sent_id": "380_0", "text": "Phase 1 data reported well-tolerated and 50% of patients achieved stable disease or better with two partial responses and two complete responses lasting 7.5 and 66+ months, noted March 7, 2024.", "triplets": [["safety", "achieved", "POS"], ["phase", "achieved", "POS"]]}
{"row_id": 381, "sent_id": "381_0", "text": "Phase 1 data reported well-tolerated and 50% of patients achieved stable disease or better with two partial responses and two complete responses lasting 7.5 and 66+ months, noted March 7, 2024.", "triplets": [["safety", "achieved", "POS"], ["phase", "achieved", "POS"]]}
{"row_id": 382, "sent_id": "382_0", "text": "Phase 3 trial met its primary endpoint, noted March 7, 2024", "triplets": [["endpoint", "met", "POS"], ["phase", "met", "POS"]]}
{"row_id": 387, "sent_id": "387_0", "text": "Phase 3 topline results did not meet the primary endpoint, noted March 8, 2024.", "triplets": [["endpoint", "did not meet", "NEG"], ["phase", "did not meet", "NEG"], ["clinical", "did not meet", "NEG"]]}
{"row_id": 389, "sent_id": "389_0", "text": "Approved March 8, 2024.", "triplets": [["catalyst", "Approved", "POS"]]}
{"row_id": 394, "sent_id": "394_0", "text": "Phase 2b 24-week data reported that 52% of patients achieved ACR50+PASI100 and up to 61% of patients achieved Minimal Disease Activity (MDA), noted March 10, 2024.", "triplets": [["phase", "achieved", "POS"]]}
{"row_id": 397, "sent_id": "397_0", "text": "Phase 3 results data presented at AAD reported that 56.3% of patients who received Otezla through week 52 achieved static Physician Global Assessment (sPGA) response, noted March 11, 2024.", "triplets": [["phase", "achieved", "POS"]]}
{"row_id": 398, "sent_id": "398_0", "text": "Phase 2 additional data reported that more than three quarters (79.2%) of on-treatment patients achieved at least a 50% reduction in AN count (AN50), 54.2% achieved a 75% reduction (AN75), 20.8% achieved 90% reduction (AN90), and 20.8% achieved complete clearance (100% reduction, AN100), surpassing the 56.3%, 25.0%, 12.5% and 12.5% reductions, respectively, in the vehicle control group, noted March 11, 2024.", "triplets": [["phase", "achieved", "POS"]]}
{"row_id": 399, "sent_id": "399_0", "text": "Phase 2 data reported that the trial met its primary endpoint, noted March 11, 2024.", "triplets": [["endpoint", "met", "POS"], ["phase", "met", "POS"]]}
{"row_id": 400, "sent_id": "400_0", "text": "Phase 1a/1b clinical hold lifted by the FDA, noted March 11, 2024.", "triplets": [["regulatory", "clinical hold", "NEG"]]}
{"row_id": 402, "sent_id": "402_0", "text": "IND cleared by the FDA, noted March 11, 2024.", "triplets": [["regulatory", "cleared by the FDA", "POS"]]}
{"row_id": 403, "sent_id": "403_0", "text": "Phase 3 data reported that 68% of people experienced significant improvement of at least 75% in disease extent and severity (EASI-75), noted March 11, 2024.", "triplets": [["phase", "significant improvement", "POS"], ["clinical", "significant improvement", "POS"]]}
{"row_id": 404, "sent_id": "404_0", "text": "Phase 1 clinical update presented at virtual investor event showed that treatment was well-tolerated with no dose-limiting toxicities identified.", "triplets": [["safety", "well-tolerated", "POS"], ["phase", "well-tolerated", "POS"]]}
{"row_id": 414, "sent_id": "414_0", "text": "CRL announced March 11, 2024.", "triplets": [["regulatory", "CRL", "NEG"]]}
{"row_id": 415, "sent_id": "415_0", "text": "Phase 3 study did not meet its primary endpoint, noted March 11, 2024.", "triplets": [["endpoint", "did not meet", "NEG"], ["phase", "did not meet", "NEG"]]}
{"row_id": 417, "sent_id": "417_0", "text": "Phase 2 OLE dosing initiated, noted March 11, 2024.", "triplets": [["phase", "dosing initiated", "POS"], ["clinical", "dosing initiated", "POS"]]}
{"row_id": 420, "sent_id": "420_0", "text": "Phase 3 data reported a statistically significant and clinically meaningful improvement in overall survival (OS) compared to lenalidomide and rituximab plus placebo, noted March 12, 2024.", "triplets": [["endpoint", "statistically significant", "POS"], ["phase", "statistically significant", "POS"]]}
{"row_id": 422, "sent_id": "422_0", "text": "Additional Phase 2 durability data reported with significant improvement in depression symptoms at four months with 75% of patients in remission from depression after two doses, noted March 13, 2024.", "triplets": [["phase", "significant improvement", "POS"], ["clinical", "significant improvement", "POS"]]}
{"row_id": 423, "sent_id": "423_0", "text": "Phase 2 study met its primary endpoint, noted March 13, 2024.", "triplets": [["endpoint", "met", "POS"], ["phase", "met", "POS"]]}
{"row_id": 425, "sent_id": "425_0", "text": "Preclinical data reported robust penetration of the BBB and widespread transgene expression throughout the brain, and the treatment was well tolerated in NHPs, with no notable treatment related pathological findings in brain, spinal cord or peripheral tissues, noted March 13, 2024.", "triplets": [["safety", "well tolerated", "POS"]]}
{"row_id": 426, "sent_id": "426_0", "text": "Preclinical data reported robust penetration of the BBB and widespread transgene expression throughout the brain, and the treatment was well tolerated in NHPs, with no notable treatment related pathological findings in brain, spinal cord or peripheral tissues, noted March 13, 2024.", "triplets": [["safety", "well tolerated", "POS"]]}
{"row_id": 427, "sent_id": "427_0", "text": "Phase 2 topline data reported that treatment was safe and well tolerated, with all mezagitamab doses tested demonstrated a higher platelet response rate than placebo, noted March 13, 2024.", "triplets": [["safety", "well tolerated", "POS"], ["phase", "well tolerated", "POS"], ["clinical", "well tolerated", "POS"]]}
{"row_id": 428, "sent_id": "428_0", "text": "Phase 2 topline data reported that treatment was safe and well tolerated, with all mezagitamab doses tested demonstrated a higher platelet response rate than placebo, noted March 13, 2024.", "triplets": [["safety", "well tolerated", "POS"], ["phase", "well tolerated", "POS"], ["clinical", "well tolerated", "POS"]]}
{"row_id": 430, "sent_id": "430_0", "text": "Phase 2b top-line data reported that trial did not meet its primary endpoint, noted March 13, 2024.", "triplets": [["endpoint", "did not meet", "NEG"], ["phase", "did not meet", "NEG"], ["clinical", "did not meet", "NEG"]]}
{"row_id": 431, "sent_id": "431_0", "text": "Phase 2 top-line data reported that 73% of all patients (22 of 30 patients) met the efficacy endpoint of A4 or GC reduction from baseline at 12 weeks with no treatment-related SAEs reported, noted March 13, 2024.", "triplets": [["safety", "met", "POS"], ["sample", "met", "POS"], ["phase", "met", "POS"], ["clinical", "met", "POS"]]}
{"row_id": 432, "sent_id": "432_0", "text": "Approval announced March 13, 2024.", "triplets": [["regulatory", "Approval", "POS"]]}
{"row_id": 435, "sent_id": "435_0", "text": "Phase 2 achieved statistically significant liver histologic improvement as measured by at least a 2-point reduction in NAFLD Activity Score (NAS), noted March 13, 2024.", "triplets": [["phase", "achieved", "POS"]]}
{"row_id": 437, "sent_id": "437_0", "text": "Phase 1/2 dosing initiated March 13, 2024.", "triplets": [["phase", "dosing initiated", "POS"], ["clinical", "dosing initiated", "POS"]]}
{"row_id": 441, "sent_id": "441_0", "text": "Approved on March 14, 2024.", "triplets": [["catalyst", "Approved", "POS"]]}
{"row_id": 442, "sent_id": "442_0", "text": "Approved March 14, 2024.", "triplets": [["catalyst", "Approved", "POS"]]}
{"row_id": 443, "sent_id": "443_0", "text": "Approved March 14, 2024.", "triplets": [["catalyst", "Approved", "POS"]]}
{"row_id": 444, "sent_id": "444_0", "text": "Approved March 14, 2024.", "triplets": [["catalyst", "Approved", "POS"]]}
{"row_id": 445, "sent_id": "445_0", "text": "Phase 3 trial met all primary and secondary pharmacokinetic endpoints, noted March 15, 2024.", "triplets": [["phase", "met", "POS"], ["financial", "met", "POS"]]}
{"row_id": 446, "sent_id": "446_0", "text": "Additional Phase 1/2 data reported that all six patients with Fanconi Anemia treated with briquilimab achieved full donor engraftment and full blood count recovery and briquilimab was well tolerated, noted March 15, 2024.", "triplets": [["safety", "achieved", "POS"], ["phase", "achieved", "POS"]]}
{"row_id": 454, "sent_id": "454_0", "text": "Phase 2a achieved its primary efficacy endpoint by significantly lowering HbA1c level in both the lanifibranor arm and in the lanifibranor with empagliflozin arm compared to placebo, noted March 18, 2", "triplets": [["phase", "achieved", "POS"]]}
{"row_id": 458, "sent_id": "458_0", "text": "Approved March 19, 2024.", "triplets": [["catalyst", "Approved", "POS"]]}
{"row_id": 459, "sent_id": "459_0", "text": "Phase 3 topline data reported that the trial met its primary endpoint, noted March 19, 2024.", "triplets": [["endpoint", "met", "POS"], ["phase", "met", "POS"], ["clinical", "met", "POS"]]}
{"row_id": 462, "sent_id": "462_0", "text": "Phase 3 trial met the primary efficacy endpoint demonstrating non-inferiority of the incidence of acute kidney injury, noted March 19, 2024.", "triplets": [["phase", "met", "POS"]]}
{"row_id": 468, "sent_id": "468_0", "text": "FDA approved on March 19, 2024.", "triplets": [["regulatory", "FDA approved", "POS"]]}
{"row_id": 469, "sent_id": "469_0", "text": "Phase 1/2 clinical data from cohort one (low dose) showed that dosing was well-tolerated with no treatment-emergent SAEs as of 35-week assessment.", "triplets": [["safety", "well-tolerated", "POS"], ["phase", "well-tolerated", "POS"]]}
{"row_id": 471, "sent_id": "471_0", "text": "Phase 3 trial met primary endpoint, noted March 20, 2024.", "triplets": [["endpoint", "met", "POS"], ["phase", "met", "POS"]]}
{"row_id": 472, "sent_id": "472_0", "text": "PK data reported that the trial objective were met, with oral GLP-2 tablets exhibiting significant systemic exposure, noted March 20, 2024.", "triplets": [["catalyst", "met", "POS"]]}
{"row_id": 473, "sent_id": "473_0", "text": "PK data reported that the trial objective were met, with oral GLP-2 tablets exhibiting significant systemic exposure, noted March 20, 2024.", "triplets": [["catalyst", "met", "POS"]]}
{"row_id": 474, "sent_id": "474_0", "text": "Phase 2 data reported that eight out of eight patients have successfully transitioned from oral Tacrolimus to TFF TAC, with favorable safety results with no mortality or discontinuations due to advers", "triplets": [["safety", "favorable safety", "POS"], ["phase", "favorable safety", "POS"]]}
{"row_id": 475, "sent_id": "475_0", "text": "Phase 3 data reported that the trial did not meet its dual primary endpoints of overall survival (OS) and progression-free survival (PFS), noted March 21, 2024.", "triplets": [["endpoint", "did not meet", "NEG"], ["phase", "did not meet", "NEG"]]}
{"row_id": 477, "sent_id": "477_0", "text": "IND cleared by the FDA, noted March 21, 2024.", "triplets": [["regulatory", "cleared by the FDA", "POS"]]}
{"row_id": 480, "sent_id": "480_0", "text": "Approved March 22, 2024.", "triplets": [["catalyst", "Approved", "POS"]]}
{"row_id": 481, "sent_id": "481_0", "text": "Phase 2 additional efficacy data showed a statistically significant and durable reduction in ocular pain statistically significant improvement in Tear Film Break-Up Time (TFBUT) throughout the study,", "triplets": [["phase", "statistically significant", "POS"], ["clinical", "statistically significant", "POS"]]}
{"row_id": 484, "sent_id": "484_0", "text": "Full approval announced March 22, 2024.", "triplets": [["regulatory", "approval", "POS"]]}
{"row_id": 485, "sent_id": "485_0", "text": "EUA approval announced March 22, 2024.", "triplets": [["regulatory", "approval", "POS"]]}
{"row_id": 487, "sent_id": "487_0", "text": "Approved March 22, 2024.", "triplets": [["catalyst", "Approved", "POS"]]}
{"row_id": 491, "sent_id": "491_0", "text": "Phase 3 trial met its primary endpoint, noted March 25, 2024.", "triplets": [["endpoint", "met", "POS"], ["phase", "met", "POS"]]}
{"row_id": 492, "sent_id": "492_0", "text": "Approved March 25, 2024.", "triplets": [["catalyst", "Approved", "POS"]]}
{"row_id": 493, "sent_id": "493_0", "text": "FDA Approved on March 25, 2024.", "triplets": [["regulatory", "FDA Approved", "POS"]]}
{"row_id": 494, "sent_id": "494_0", "text": "Phase 1b/2 proof of concept data reported favorable safety and tolerability profile, mean monthly attack rate reduction of 90-96% for up to 6 months of follow up, noted March 25, 2024.", "triplets": [["effect", "favorable safety", "POS"], ["safety", "favorable safety", "POS"], ["phase", "favorable safety", "POS"]]}
{"row_id": 497, "sent_id": "497_0", "text": "CRL issued by FDA on March 25 2024.", "triplets": [["regulatory", "CRL", "NEG"]]}
{"row_id": 498, "sent_id": "498_0", "text": "CRL issued by FDA on March 25 2024.", "triplets": [["regulatory", "CRL", "NEG"]]}
{"row_id": 500, "sent_id": "500_0", "text": "Phase 1 trial dosing initiated, noted March 25, 2024.", "triplets": [["phase", "dosing initiated", "POS"], ["clinical", "dosing initiated", "POS"]]}
{"row_id": 501, "sent_id": "501_0", "text": "Phase 2 investigator-initiated trial (IIT) dosing initiated, noted March 25, 2024.", "triplets": [["phase", "dosing initiated", "POS"], ["clinical", "dosing initiated", "POS"]]}
{"row_id": 502, "sent_id": "502_0", "text": "Phase 2 investigator-initiated trial (IIT) dosing initiated, noted March 25, 2024.", "triplets": [["phase", "dosing initiated", "POS"], ["clinical", "dosing initiated", "POS"]]}
{"row_id": 503, "sent_id": "503_0", "text": "Phase 3 enrollment completed, noted March 25, 2024", "triplets": [["phase", "enrollment completed", "POS"], ["enrollment", "enrollment completed", "POS"]]}
{"row_id": 507, "sent_id": "507_0", "text": "ANDA Approval from the FDA, noted March 25, 2024.", "triplets": [["regulatory", "Approval", "POS"]]}
{"row_id": 508, "sent_id": "508_0", "text": "CRL issued March 25, 2024.", "triplets": [["regulatory", "CRL", "NEG"]]}
{"row_id": 509, "sent_id": "509_0", "text": "CRL issued March 25, 2024.", "triplets": [["regulatory", "CRL", "NEG"]]}
{"row_id": 510, "sent_id": "510_0", "text": "Phase 2 data reported a 100% complete response rate in the 45 mg cohort, and in the 15 mg cohort, 80% of patients achieved a complete response and 20% achieved a partial response, noted March 26, 2024", "triplets": [["phase", "achieved", "POS"]]}
{"row_id": 512, "sent_id": "512_0", "text": "Phase 1 data was shown to be safe and well-tolerated in the 28-day study with low rates of GI-related adverse events.", "triplets": [["safety", "well-tolerated", "POS"], ["phase", "well-tolerated", "POS"]]}
{"row_id": 513, "sent_id": "513_0", "text": "FDA has granted approval of 12-month shelf life for INTERCEPT Platelet Processing Sets, from the date of manufacture, effective immediately, noted March 26, 2024.", "triplets": [["regulatory", "approval", "POS"]]}
{"row_id": 518, "sent_id": "518_0", "text": "Approved March 26, 2024.", "triplets": [["catalyst", "Approved", "POS"]]}
{"row_id": 522, "sent_id": "522_0", "text": "Phase 3 final data clinical trial met its primary endpoint, demonstrating a statistically significant improvement in time to intracranial progression for adult patients treated with Tumor Treating Fie", "triplets": [["endpoint", "met", "POS"], ["phase", "met", "POS"], ["clinical", "met", "POS"]]}
{"row_id": 523, "sent_id": "523_0", "text": "Phase 3 final data clinical trial met its primary endpoint, demonstrating a statistically significant improvement in time to intracranial progression for adult patients treated with Tumor Treating Fie", "triplets": [["endpoint", "met", "POS"], ["phase", "met", "POS"], ["clinical", "met", "POS"]]}
{"row_id": 524, "sent_id": "524_0", "text": "Phase 2a initial results demonstrated that a single 10mg dose of BPL-003 was well-tolerated and resulted in a rapid onset and durable antidepressant effect in patients living with TRD, noted March 27,", "triplets": [["safety", "well-tolerated", "POS"], ["phase", "well-tolerated", "POS"]]}
{"row_id": 528, "sent_id": "528_0", "text": "Phase 2 data continue to demonstrate antifungal activity and a favorable safety and tolerability profile, noted March 27, 2024.", "triplets": [["safety", "favorable safety", "POS"], ["phase", "favorable safety", "POS"]]}
{"row_id": 533, "sent_id": "533_0", "text": "Approved March 28, 2024.", "triplets": [["catalyst", "Approved", "POS"]]}
{"row_id": 535, "sent_id": "535_0", "text": "NDA resubmitted to FDA, noted March 28, 2024.", "triplets": [["regulatory", "NDA resubmitted", "POS"]]}
{"row_id": 536, "sent_id": "536_0", "text": "Phase 2 initial data reported that treatment was well-tolerated with an acceptable safety profile, noted March 28, 2024.", "triplets": [["safety", "well-tolerated", "POS"], ["phase", "well-tolerated", "POS"]]}
{"row_id": 540, "sent_id": "540_0", "text": "Phase 2 enrollment completed, noted March 28, 2024.", "triplets": [["phase", "enrollment completed", "POS"], ["enrollment", "enrollment completed", "POS"]]}
{"row_id": 541, "sent_id": "541_0", "text": "Phase 1b preliminary data reported that VRON-0200 was safe and well tolerated, with no clinical or laboratory changes of concern, noted March 28, 2024.", "triplets": [["safety", "well tolerated", "POS"], ["phase", "well tolerated", "POS"]]}
{"row_id": 547, "sent_id": "547_0", "text": "Phase 1b showed that serial procedures were well tolerated without observed dose-limiting toxicity in first cohort, noted March 28, 2024.", "triplets": [["safety", "well tolerated", "POS"], ["phase", "well tolerated", "POS"]]}
{"row_id": 548, "sent_id": "548_0", "text": "Phase 3 trial met its primary endpoints, noted March 28, 2024.", "triplets": [["endpoint", "met", "POS"], ["phase", "met", "POS"]]}
{"row_id": 550, "sent_id": "550_1", "text": "More than 80% of subjects achieved >50% reduction in urine protein creatinine ratio (UPCR), noted", "triplets": [["catalyst", "achieved", "POS"]]}
{"row_id": 551, "sent_id": "551_0", "text": "Phase 2 long-term data presented at ASCO reported that the median OS and PFS were 19.6 months (95% CI, 17.9\u00e2\u20ac\u201c22.4) and 10.2 months, noted April 1, 2024.", "triplets": [["endpoint", "data presented at ASCO", "POS"], ["phase", "data presented at ASCO", "POS"], ["clinical", "data presented at ASCO", "POS"]]}
{"row_id": 552, "sent_id": "552_0", "text": "A District Court set aside the injunction and the FDA is no longer enjoined from issuing final approval of Liquidia's New Drug Application (NDA) for YUTREPIA (treprostinil) inhalation powder, noted Ap", "triplets": [["regulatory", "approval", "POS"]]}
{"row_id": 553, "sent_id": "553_0", "text": "FDA Approved on April 1, 2024.", "triplets": [["regulatory", "FDA Approved", "POS"]]}
{"row_id": 555, "sent_id": "555_0", "text": "Phase 2/3 trial part 3 dosing initiated with expanded access to include adolescents with AMKD ages 10 to 17 years.", "triplets": [["phase", "dosing initiated", "POS"], ["clinical", "dosing initiated", "POS"]]}
{"row_id": 556, "sent_id": "556_0", "text": "Phase 2 study met its primary endpoint.", "triplets": [["endpoint", "met", "POS"], ["phase", "met", "POS"]]}
{"row_id": 556, "sent_id": "556_1", "text": "Despite improved measures of light tolerance, including the key secondary endpoint, in both 20 mg and 60 mg dose groups, but it did not meet statistical signifi", "triplets": [["endpoint", "did not meet", "NEG"], ["financial", "did not meet", "NEG"]]}
{"row_id": 558, "sent_id": "558_0", "text": "Phase 1a demonstrated acceptable safety and tolerability with no reported serious adverse events, noted April 1, 2024.", "triplets": [["safety", "serious adverse events", "NEG"]]}
{"row_id": 560, "sent_id": "560_0", "text": "Phase 3 enrollment completed, noted April 1, 2024.", "triplets": [["phase", "enrollment completed", "POS"], ["enrollment", "enrollment completed", "POS"]]}
{"row_id": 564, "sent_id": "564_0", "text": "Phase 1a demonstrated acceptable safety and tolerability with no reported serious adverse events, noted April 1, 2024.", "triplets": [["safety", "serious adverse events", "NEG"]]}
{"row_id": 566, "sent_id": "566_0", "text": "Phase 3 enrollment completed, noted April 1, 2024.", "triplets": [["phase", "enrollment completed", "POS"], ["enrollment", "enrollment completed", "POS"]]}
{"row_id": 571, "sent_id": "571_0", "text": "Phase 2 cohort 4 data reported a a statistically significant reduction of approximately 40% in Rheumatoid Factor in the abiprubart group, noted April 2, 2024.", "triplets": [["phase", "statistically significant", "POS"]]}
{"row_id": 572, "sent_id": "572_0", "text": "Phase 1 US dosing initiated, noted April 2, 2024.", "triplets": [["phase", "dosing initiated", "POS"], ["clinical", "dosing initiated", "POS"]]}
{"row_id": 574, "sent_id": "574_0", "text": "Approved April 2, 2024.", "triplets": [["catalyst", "Approved", "POS"]]}
{"row_id": 576, "sent_id": "576_0", "text": "Phase 3 primary endpoint was met with 71% of participants dosed with LNZ100 achieving three-lines or greater improvement at 3 hours.", "triplets": [["endpoint", "met", "POS"], ["phase", "met", "POS"]]}
{"row_id": 581, "sent_id": "581_0", "text": "Phase 1/2 has been well tolerated in participants at the doses administered, with no dose-limiting toxicities observed.", "triplets": [["safety", "well tolerated", "POS"], ["phase", "well tolerated", "POS"]]}
{"row_id": 589, "sent_id": "589_0", "text": "Phase 2b study did not meet the pre-specified threshold of p\u00e2\u2030\u00a40.2.", "triplets": [["phase", "did not meet", "NEG"]]}
{"row_id": 591, "sent_id": "591_0", "text": "IND Cleared by the FDA, noted April 4, 2024.", "triplets": [["regulatory", "Cleared by the FDA", "POS"]]}
{"row_id": 596, "sent_id": "596_0", "text": "Phase 3 trial met the the dual primary endpoints of overall survival (OS) and progression-free survival (PFS), noted April 5, 2024.", "triplets": [["endpoint", "met", "POS"], ["phase", "met", "POS"]]}
{"row_id": 598, "sent_id": "598_0", "text": "Phase 1/2 Data and Safety Monitoring Board (DSMB) convened and approved to proceed dosing with the medium dose of OCU410 in the dose-escalation phase of the study, noted April 5, 2024.", "triplets": [["safety", "approved", "POS"], ["phase", "approved", "POS"]]}
{"row_id": 600, "sent_id": "600_0", "text": "Approved April 5, 2024.", "triplets": [["catalyst", "Approved", "POS"]]}
{"row_id": 603, "sent_id": "603_0", "text": "Preclinical data presented at AACR reported complete tumor regression in the MC38 mouse tumor model, noted April 5, 2024.", "triplets": [["clinical", "data presented at AACR", "POS"]]}
{"row_id": 604, "sent_id": "604_0", "text": "Preclinical data presented at AACR reported that treatment demonstrated inducibility and antitumor activity with regressions in the MC38 mouse tumor model, noted April 5, 2024.", "triplets": [["clinical", "data presented at AACR", "POS"]]}
{"row_id": 605, "sent_id": "605_0", "text": "FDA Approval on April 5, 2024.", "triplets": [["regulatory", "FDA Approval", "POS"]]}
{"row_id": 606, "sent_id": "606_0", "text": "FDA Approval on April 5, 2024.", "triplets": [["regulatory", "FDA Approval", "POS"]]}
{"row_id": 610, "sent_id": "610_0", "text": "Phase 1/2 open-label data presented at AACR reported an overall response rate (ORR) of 34.8 percent (8 of 23 evaluable patients, including 5 complete responses and 3 partial responses) with most respo", "triplets": [["endpoint", "data presented at AACR", "POS"], ["phase", "data presented at AACR", "POS"], ["clinical", "data presented at AACR", "POS"]]}
{"row_id": 613, "sent_id": "613_0", "text": "Phase 1 data presented at AACR reported that in 8 of 16 patients, autogene cevumeran elicited high-magnitude T cells specific to the encoded neoantigens.", "triplets": [["sample", "data presented at AACR", "POS"], ["phase", "data presented at AACR", "POS"], ["clinical", "data presented at AACR", "POS"]]}
{"row_id": 614, "sent_id": "614_0", "text": "Phase 3 trial met her primary endpoint, noted April 7, 2024.", "triplets": [["endpoint", "met", "POS"], ["phase", "met", "POS"]]}
{"row_id": 615, "sent_id": "615_0", "text": "Phase 1/2 trial has met primary endpoints of safety and immunogenicity and secondary endpoint for efficacy based on response rate, noted April 7, 2024.", "triplets": [["endpoint", "met", "POS"], ["safety", "met", "POS"], ["phase", "met", "POS"], ["financial", "met", "POS"]]}
{"row_id": 621, "sent_id": "621_0", "text": "Phase 1 initial data presented at AACR demonstrated positive signs of clinical activity, including tumor reduction, and an improved safety profile in heavily pretreated patients with metastatic solid", "triplets": [["safety", "data presented at AACR", "POS"], ["phase", "data presented at AACR", "POS"], ["clinical", "data presented at AACR", "POS"]]}
{"row_id": 622, "sent_id": "622_0", "text": "Phase 1/2 data presented at AACR showed enhanced clinical efficacy signal in bev na\u00c3\u00afve patients is consistent with results of randomized ONSEMBLE trial providing two independent data sets in second-li", "triplets": [["phase", "data presented at AACR", "POS"], ["clinical", "data presented at AACR", "POS"]]}
{"row_id": 623, "sent_id": "623_0", "text": "Preclinical data presented at AACR continue to support NVL-330's broad activity against HER2 oncogenic alterations, selectivity over wild-type EGFR, and differentiated brain-penetrant profile , Zidesa", "triplets": [["clinical", "data presented at AACR", "POS"]]}
{"row_id": 624, "sent_id": "624_0", "text": "Phase 2 data presented at AACR data show that Zeno is effective in tumor cell killing in vitro and in vivo in high NRG1 expressing cancer models representing multiple different tumor types, April 8, 2", "triplets": [["phase", "data presented at AACR", "POS"], ["clinical", "data presented at AACR", "POS"]]}
{"row_id": 625, "sent_id": "625_0", "text": "Phase 2 data presented at AACR data show that Zeno is effective in tumor cell killing in vitro and in vivo in high NRG1 expressing cancer models representing multiple different tumor types, April 8, 2", "triplets": [["phase", "data presented at AACR", "POS"], ["clinical", "data presented at AACR", "POS"]]}
{"row_id": 628, "sent_id": "628_0", "text": "Preclinical data presented at AACR showed that data further demonstrate Cogent's capability to discover and advance potential best-in-class novel therapies for rare disease populations with high unmet", "triplets": [["clinical", "data presented at AACR", "POS"]]}
{"row_id": 629, "sent_id": "629_0", "text": "Preclinical data presented at AACR reported that treatment demonstrated superior immune activation as monotherapy and in combination with PD-(L)1 blockade compared to conventional anti-TIGIT mAb, note", "triplets": [["clinical", "data presented at AACR", "POS"]]}
{"row_id": 630, "sent_id": "630_0", "text": "Phase 1b additional data presented at AACR reported that due to the incidence of TEAE judged related to Mipa and the preliminary activity observed, 15mg was selected as the highest dose to be tested i", "triplets": [["phase", "data presented at AACR", "POS"], ["clinical", "data presented at AACR", "POS"]]}
{"row_id": 631, "sent_id": "631_0", "text": "Phase 1 data presented at AACR reported that the combination results in high CR rates in patients with relapsed refractory iNHL, noted April 8, 2024.", "triplets": [["endpoint", "data presented at AACR", "POS"], ["phase", "data presented at AACR", "POS"], ["clinical", "data presented at AACR", "POS"]]}
{"row_id": 633, "sent_id": "633_0", "text": "Phase 1 trial data presented at AACR reported that a majority of patients who received ELI-002 booster immunizations maintained or increased mKRAS-specific T cell responses relative to baseline.", "triplets": [["phase", "data presented at AACR", "POS"], ["clinical", "data presented at AACR", "POS"]]}
{"row_id": 635, "sent_id": "635_0", "text": "Phase 3 results presented at the ASCRS Conference 2024 included co-Primary symptom endpoint of pain met statistical significance and 7 of 11 secondary symptom endpoints met statistical significance (p", "triplets": [["phase", "met", "POS"], ["financial", "met", "POS"]]}
{"row_id": 636, "sent_id": "636_0", "text": "CRL announced April 8, 2024.", "triplets": [["regulatory", "CRL", "NEG"]]}
{"row_id": 638, "sent_id": "638_0", "text": "FDA Approved on April 8, 2024.", "triplets": [["regulatory", "FDA Approved", "POS"]]}
{"row_id": 641, "sent_id": "641_0", "text": "Phase 1 data presented at AACR demonstrated that the combination reverses resistance to osimertinib versus osimertinib alone, noted April 8, 2024.", "triplets": [["phase", "data presented at AACR", "POS"], ["clinical", "data presented at AACR", "POS"]]}
{"row_id": 643, "sent_id": "643_0", "text": "Phase 3 enrollment completed, noted April 8, 2024.", "triplets": [["phase", "enrollment completed", "POS"], ["enrollment", "enrollment completed", "POS"]]}
{"row_id": 646, "sent_id": "646_0", "text": "Phase 1 data reported that the initial dose level was well tolerated and demonstrated durable objective responses after MT-601 treatment, noted April 8, 2024.", "triplets": [["safety", "well tolerated", "POS"], ["phase", "well tolerated", "POS"]]}
{"row_id": 650, "sent_id": "650_0", "text": "FDA granted orphan drug designation, noted April 9, 2024.", "triplets": [["regulatory", "FDA granted", "POS"]]}
{"row_id": 653, "sent_id": "653_0", "text": "Preclinical data presented at AACR demonstrated that combining IMM-1-104 with chemotherapies used in the treatment of first-line pancreatic cancer yielded deeper and more durable tumor growth inhibiti", "triplets": [["clinical", "data presented at AACR", "POS"]]}
{"row_id": 654, "sent_id": "654_0", "text": "Preclinical data presented at AACR suggest that the combination of CTX-009 and CTX-471 could re-establish anti-tumor immunity in patients whose tumors have either downregulated or lost MHC-I expressio", "triplets": [["clinical", "data presented at AACR", "POS"]]}
{"row_id": 656, "sent_id": "656_0", "text": "Phase 1/2 early data presented at AACR demonstrated the mechanism.", "triplets": [["phase", "data presented at AACR", "POS"], ["clinical", "data presented at AACR", "POS"]]}
{"row_id": 658, "sent_id": "658_0", "text": "Preclinical data presented at AACR demonstrated favorable tolerability and dose-dependent single agent activity in BRG1 mutated cancers preclinically, noted April 9, 2024.", "triplets": [["safety", "data presented at AACR", "POS"], ["clinical", "data presented at AACR", "POS"]]}
{"row_id": 659, "sent_id": "659_0", "text": "Preclinical data presented at AACR demonstrated favorable tolerability and dose-dependent single agent activity in BRG1 mutated cancers preclinically, noted April 9, 2024.", "triplets": [["safety", "data presented at AACR", "POS"], ["clinical", "data presented at AACR", "POS"]]}
{"row_id": 660, "sent_id": "660_0", "text": "Preclinical data presented at AACR supports potential for proprietary nsCAR platform to selectively eliminate cancer cells while preserving healthy tissue, noted April 9, 2024.", "triplets": [["clinical", "data presented at AACR", "POS"]]}
{"row_id": 662, "sent_id": "662_0", "text": "Phase 2 preliminary data presented at AACR demonstrate that FPI-2265 is active in heavily pretreated patients with progressive metastatic castration-resistant prostate cancer (mCRPC), including those", "triplets": [["phase", "FPI", "POS"], ["enrollment", "FPI", "POS"], ["clinical", "FPI", "POS"]]}
{"row_id": 663, "sent_id": "663_0", "text": "Preclinical data shared at AACR shows robust anti-tumor activity in vivo as monotherapy and in combination with chemotherapy, at well-tolerated doses, noted April 9, 2024.", "triplets": [["safety", "well-tolerated", "POS"]]}
{"row_id": 666, "sent_id": "666_0", "text": "Phase 3 dosing initiated, noted April 9, 2024.", "triplets": [["phase", "dosing initiated", "POS"], ["clinical", "dosing initiated", "POS"]]}
{"row_id": 667, "sent_id": "667_0", "text": "Phase 1b cohort 2 patient enrollment completed, noted April 9, 2024.", "triplets": [["phase", "enrollment completed", "POS"], ["enrollment", "enrollment completed", "POS"]]}
{"row_id": 668, "sent_id": "668_0", "text": "Phase 1 results demonstrated that for the first five patients (three of whom were PDAC patients), QN-302 is overall well-tolerated (no SAE) and they have reported a \"good\" quality of life during the d", "triplets": [["safety", "well-tolerated", "POS"], ["phase", "well-tolerated", "POS"]]}
{"row_id": 671, "sent_id": "671_0", "text": "Preclinical data presented at AACR reported that treatment effectively inhibits Nectin-4 expressing tumor growth both in vitro and in vivo, including in Enfortumab Vedotin (EV) refractory models, note", "triplets": [["clinical", "data presented at AACR", "POS"]]}
{"row_id": 672, "sent_id": "672_0", "text": "Phase 1 trial data presented at AACR reported that the best ORR of 94% and a CRR of 83%, noted April 9, 2024.", "triplets": [["endpoint", "data presented at AACR", "POS"], ["phase", "data presented at AACR", "POS"], ["clinical", "data presented at AACR", "POS"]]}
{"row_id": 673, "sent_id": "673_0", "text": "Preclinical data presented at AACR reported that the NPRL2 treatment by itself led to a marked decrease in the size of lung metastases but pembrolizumab had no effect, noted April 9, 2024.", "triplets": [["clinical", "data presented at AACR", "POS"]]}
{"row_id": 676, "sent_id": "676_0", "text": "Phase 3 trial met its primary endpoint, noted April 9, 2024.", "triplets": [["endpoint", "met", "POS"], ["phase", "met", "POS"]]}
{"row_id": 677, "sent_id": "677_0", "text": "Phase 2 data presented at AACR reported that in patients with untreated limited-stage SCLC, tislelizumab + cCRT yielded a trend of improvement in PFS and ORR vs cCRT; addition of ociperlimab did not s", "triplets": [["endpoint", "data presented at AACR", "POS"], ["phase", "data presented at AACR", "POS"], ["clinical", "data presented at AACR", "POS"]]}
{"row_id": 678, "sent_id": "678_0", "text": "Phase 1a data presented at AACR reported that BGB\u00e2\u20ac\u201810188 + tislelizumab showed preliminary antitumor activity and was generally safe and tolerable across doses in this heavily pretreated population of", "triplets": [["clinical", "data presented at AACR", "POS"]]}
{"row_id": 679, "sent_id": "679_0", "text": "Phase 1 data presented at AACR reported that selective targeting of EP300 with targeted protein degradation is a safe and effective treatment strategy for advanced tumors, noted April 9, 2024.", "triplets": [["phase", "data presented at AACR", "POS"], ["clinical", "data presented at AACR", "POS"]]}
{"row_id": 681, "sent_id": "681_0", "text": "Phase 1/2a trial shared at AACR reported that two of 12 patients achieved stable disease (SD): one patient from Dose level 1 (50 mg) who progressed on Day 112 and one patient from Dose level 3 (200 mg", "triplets": [["sample", "achieved", "POS"], ["phase", "achieved", "POS"]]}
{"row_id": 682, "sent_id": "682_0", "text": "Preclinical data presented at AACR reported that nab-sirolimus enhanced the cytotoxic effects of fulvestrant in HR+ breast cancer cells and PI3Ki in both HR+ and HR- breast cancer cells, noted April 1", "triplets": [["clinical", "data presented at AACR", "POS"]]}
{"row_id": 686, "sent_id": "686_0", "text": "Phase 1 demonstrated clinically meaningful and statistically significant improvements from baseline in mean sleep latency compared to placebo at all doses tested in both narcolepsy type 2 and idiopath", "triplets": [["phase", "statistically significant", "POS"]]}
{"row_id": 687, "sent_id": "687_0", "text": "Preclinical data presented at AACR reported that treatment was highly potent across multiple human tumor cell lines and patient-derived ex vivo tumor models, noted April 10, 2024.", "triplets": [["clinical", "data presented at AACR", "POS"]]}
{"row_id": 691, "sent_id": "691_0", "text": "Phase 1 trial preliminary results presented at AACR reported that BNT116 + DTX shows encouraging antitumor activity, consistent induction of immune responses, a manageable safety profile, and no signs", "triplets": [["safety", "manageable safety", "POS"], ["phase", "manageable safety", "POS"], ["clinical", "manageable safety", "POS"]]}
{"row_id": 692, "sent_id": "692_0", "text": "Phase 1 trial preliminary results presented at AACR reported that BNT116 + DTX shows encouraging antitumor activity, consistent induction of immune responses, a manageable safety profile, and no signs", "triplets": [["safety", "manageable safety", "POS"], ["phase", "manageable safety", "POS"], ["clinical", "manageable safety", "POS"]]}
{"row_id": 695, "sent_id": "695_0", "text": "Preclinical data presented at AACR reported that in robust tumor control, leading to significant prolongation of survival in AML xenograft models, noted April 10, 2024.", "triplets": [["clinical", "data presented at AACR", "POS"]]}
{"row_id": 696, "sent_id": "696_0", "text": "Phase 1b/2a 240mg data presented at the World Congress of Nephrology showed that treatment continues to be well tolerated in IgA nephropathy, with UPCR reductions of greater than 60% observed at 36 we", "triplets": [["safety", "well tolerated", "POS"], ["phase", "well tolerated", "POS"]]}
{"row_id": 697, "sent_id": "697_0", "text": "Phase 1b/2a 240mg data presented at the World Congress of Nephrology showed that treatment continues to be well tolerated in IgA nephropathy, with UPCR reductions of greater than 60% observed at 36 we", "triplets": [["safety", "well tolerated", "POS"], ["phase", "well tolerated", "POS"]]}
{"row_id": 699, "sent_id": "699_0", "text": "Phase 2 treatment resulted in statistically significant body composition improvement in men Increased lean mass (LM) by 4.4% and decreased fat mass (FM) by 6.7%.", "triplets": [["phase", "statistically significant", "POS"]]}
{"row_id": 700, "sent_id": "700_0", "text": "Fast track designation granted by the FDA, noted April 11, 2024.", "triplets": [["regulatory", "Fast track", "POS"]]}
{"row_id": 705, "sent_id": "705_0", "text": "FDA approved on April 11, 2024.", "triplets": [["regulatory", "FDA approved", "POS"]]}
{"row_id": 707, "sent_id": "707_0", "text": "Phase 3 did not meet pre-defined stopping criteria at the interim analysis; Marinus has completed RAISE enrollment at approximately 100 patients with topline results expected summer 2024.", "triplets": [["sample", "did not meet", "NEG"], ["phase", "did not meet", "NEG"], ["clinical", "did not meet", "NEG"]]}
{"row_id": 708, "sent_id": "708_0", "text": "Phase 3 did not meet pre-defined stopping criteria at the interim analysis; Marinus has completed RAISE enrollment at approximately 100 patients with topline results expected summer 2024.", "triplets": [["sample", "did not meet", "NEG"], ["phase", "did not meet", "NEG"], ["clinical", "did not meet", "NEG"]]}
{"row_id": 711, "sent_id": "711_0", "text": "Phase 2 enrollment completed, noted April 15, 2024.", "triplets": [["phase", "enrollment completed", "POS"], ["enrollment", "enrollment completed", "POS"]]}
{"row_id": 715, "sent_id": "715_0", "text": "Phase 3 data show clinically meaningful and statistically significant proteinuria reduction of 38.3% versus placebo, noted April 15, 2024.", "triplets": [["effect", "statistically significant", "POS"], ["phase", "statistically significant", "POS"]]}
{"row_id": 716, "sent_id": "716_0", "text": "Phase 3 data presented at AAN reported that 67% of patients treated with VYVGART Hytrulo demonstrated evidence of clinical improvement (ECI), including 40% who had achieved ECI by the earliest possibl", "triplets": [["phase", "achieved", "POS"]]}
{"row_id": 717, "sent_id": "717_0", "text": "Phase 3 data presented at AAN reported that 67% of patients treated with VYVGART Hytrulo demonstrated evidence of clinical improvement (ECI), including 40% who had achieved ECI by the earliest possibl", "triplets": [["phase", "achieved", "POS"]]}
{"row_id": 718, "sent_id": "718_0", "text": "Phase 3 data presented at AAN reported that 67% of patients treated with VYVGART Hytrulo demonstrated evidence of clinical improvement (ECI), including 40% who had achieved ECI by the earliest possibl", "triplets": [["phase", "achieved", "POS"]]}
{"row_id": 719, "sent_id": "719_0", "text": "Phase 3 topline results for the 42 mg Cohort achieved statistically significant and clinically meaningful results in both the primary and the key secondary endpoints, noted April 16, 2024.", "triplets": [["endpoint", "achieved", "POS"], ["phase", "achieved", "POS"], ["financial", "achieved", "POS"], ["clinical", "achieved", "POS"]]}
{"row_id": 720, "sent_id": "720_0", "text": "Phase 2 enrollment completed, noted April 16, 2024.", "triplets": [["phase", "enrollment completed", "POS"], ["enrollment", "enrollment completed", "POS"]]}
{"row_id": 723, "sent_id": "723_0", "text": "Phase 1 dosing initiated, noted April 16, 2024.", "triplets": [["phase", "dosing initiated", "POS"], ["clinical", "dosing initiated", "POS"]]}
{"row_id": 724, "sent_id": "724_0", "text": "Phase 1 additional data presented at AAN demonstrated a favorable safety and tolerability profile in participants with early AD with a relatively low incidence of ARIA-E, noted April 16, 2024.", "triplets": [["safety", "favorable safety", "POS"], ["phase", "favorable safety", "POS"]]}
{"row_id": 725, "sent_id": "725_0", "text": "Preclinical approval has been received from an independent third-party ethics review board, for human pilot study #2, noted April 16, 2024.", "triplets": [["regulatory", "approval", "POS"]]}
{"row_id": 728, "sent_id": "728_0", "text": "FDA approved on April 16, 2024.", "triplets": [["regulatory", "FDA approved", "POS"]]}
{"row_id": 729, "sent_id": "729_0", "text": "FDA approved on April 16, 2024.", "triplets": [["regulatory", "FDA approved", "POS"]]}
{"row_id": 730, "sent_id": "730_0", "text": "Phase 2 data did not show statistically significant differences versus placebo on the primary endpoint , noted April 17, 2024.", "triplets": [["endpoint", "statistically significant", "POS"], ["phase", "statistically significant", "POS"]]}
{"row_id": 731, "sent_id": "731_0", "text": "Phase 2 data did not show statistically significant differences versus placebo on the primary endpoint , noted April 17, 2024.", "triplets": [["endpoint", "statistically significant", "POS"], ["phase", "statistically significant", "POS"]]}
{"row_id": 736, "sent_id": "736_0", "text": "Phase 1a dosing initiated, noted April 17, 2024.", "triplets": [["clinical", "dosing initiated", "POS"]]}
{"row_id": 743, "sent_id": "743_0", "text": "Phase 3 trial met its primary endpoint, noted April 18, 2024.", "triplets": [["endpoint", "met", "POS"], ["phase", "met", "POS"]]}
{"row_id": 747, "sent_id": "747_0", "text": "Phase 1 data presented at AACR results suggest that SBP-101 in combination with doxorubicin may have a role in the clinical management of ovarian cancer, in particular the difficult to treat platinum-", "triplets": [["phase", "data presented at AACR", "POS"], ["clinical", "data presented at AACR", "POS"]]}
{"row_id": 749, "sent_id": "749_0", "text": "IND Cleared by the FDA, noted April 18, 2024.", "triplets": [["regulatory", "Cleared by the FDA", "POS"]]}
{"row_id": 750, "sent_id": "750_0", "text": "Phase 3 showed that upadacitinib (RINVOQ; 15 mg, once daily) in combination with a 26-week steroid taper regimen achieved its primary endpoint of sustained remissiona from week 12 through week 52, not", "triplets": [["endpoint", "achieved", "POS"], ["phase", "achieved", "POS"]]}
{"row_id": 751, "sent_id": "751_0", "text": "Phase 2b data presented at AAN reported that PrimeC met safety and tolerability measures as well as statistically significant slowing of disease progression as demonstrated by the ALSFRS-R by 37% (p=0", "triplets": [["pvalue", "met", "POS"], ["safety", "met", "POS"], ["phase", "met", "POS"]]}
{"row_id": 752, "sent_id": "752_0", "text": "Phase 1 data presented at AAOM resulted in no treatment-related serious adverse events or dose-limiting toxicities were reported, and all participants completed the study, noted April 18, 2024.", "triplets": [["safety", "serious adverse events", "NEG"], ["phase", "serious adverse events", "NEG"]]}
{"row_id": 753, "sent_id": "753_0", "text": "Additional Phase 1/2a met its primary endpoint, noted April 18, 2024.", "triplets": [["endpoint", "met", "POS"], ["phase", "met", "POS"]]}
{"row_id": 754, "sent_id": "754_0", "text": "Additional Phase 1/2a met its primary endpoint, noted April 18, 2024.", "triplets": [["endpoint", "met", "POS"], ["phase", "met", "POS"]]}
{"row_id": 755, "sent_id": "755_0", "text": "FDA Approved by the FDA, noted April 18, 2024.", "triplets": [["regulatory", "FDA Approved", "POS"]]}
{"row_id": 758, "sent_id": "758_0", "text": "IND cleared by the FDA, noted April 22, 2024", "triplets": [["regulatory", "cleared by the FDA", "POS"]]}
{"row_id": 759, "sent_id": "759_0", "text": "Phase 1 dosing initiated, noted April 22, 2024.", "triplets": [["phase", "dosing initiated", "POS"], ["clinical", "dosing initiated", "POS"]]}
{"row_id": 761, "sent_id": "761_0", "text": "Phase 3 additional results exhibited clinically meaningful and statistically significant improvements in hypertension, hyperglycemia and other key secondary and exploratory endpoints, noted April 22,", "triplets": [["phase", "statistically significant", "POS"], ["financial", "statistically significant", "POS"]]}
{"row_id": 763, "sent_id": "763_0", "text": "CRL issued by the FDA, noted April 22, 2024.", "triplets": [["regulatory", "CRL", "NEG"]]}
{"row_id": 767, "sent_id": "767_0", "text": "Approved April 22, 2024.", "triplets": [["catalyst", "Approved", "POS"]]}
{"row_id": 771, "sent_id": "771_0", "text": "Phase 2 study met its primary and key secondary endpoints, demonstrating that once-daily, oral administration of NBI-1065845 produced a statistically significant change from baseline in Montgomery \u00c3...sb", "triplets": [["endpoint", "met", "POS"], ["phase", "met", "POS"], ["financial", "met", "POS"]]}
{"row_id": 772, "sent_id": "772_0", "text": "Phase 2 study met its primary and key secondary endpoints, demonstrating that once-daily, oral administration of NBI-1065845 produced a statistically significant change from baseline in Montgomery \u00c3...sb", "triplets": [["endpoint", "met", "POS"], ["phase", "met", "POS"], ["financial", "met", "POS"]]}
{"row_id": 776, "sent_id": "776_0", "text": "FDA approved on April 23, 2024.", "triplets": [["regulatory", "FDA approved", "POS"]]}
{"row_id": 777, "sent_id": "777_0", "text": "FDA Approved on April 23, 2024.", "triplets": [["regulatory", "FDA Approved", "POS"]]}
{"row_id": 778, "sent_id": "778_0", "text": "IND cleared by the FDA, noted April 24, 2024.", "triplets": [["regulatory", "cleared by the FDA", "POS"]]}
{"row_id": 779, "sent_id": "779_0", "text": "Phase 3 trial met its primary endpoint, with results demonstrating therapeutic equivalence between AVT05 and Simponi.", "triplets": [["endpoint", "met", "POS"], ["phase", "met", "POS"]]}
{"row_id": 780, "sent_id": "780_0", "text": "Phase 2b enrollment completed, noted November 9, 2023.", "triplets": [["phase", "enrollment completed", "POS"], ["enrollment", "enrollment completed", "POS"]]}
{"row_id": 784, "sent_id": "784_0", "text": "FDA Approved, noted April 24, 2024.", "triplets": [["regulatory", "FDA Approved", "POS"]]}
{"row_id": 787, "sent_id": "787_0", "text": "Phase 1 data reported that treatment was generally well tolerated up to and including the highest planned dose level, and there were no serious adverse events, noted April 24, 2024.", "triplets": [["safety", "well tolerated", "NEU"], ["phase", "well tolerated", "NEU"]]}
{"row_id": 790, "sent_id": "790_0", "text": "Phase 2a data reported that treatment demonstrated a statistically significant improvement in reaction time compared to placebo and caffeine in sleep-deprived study participants, noted April 25, 2024.", "triplets": [["phase", "statistically significant", "POS"], ["clinical", "statistically significant", "POS"]]}
{"row_id": 791, "sent_id": "791_0", "text": "Trial met both primary endpoints, noted April 25, 2024.", "triplets": [["endpoint", "met", "POS"]]}
{"row_id": 794, "sent_id": "794_0", "text": "Phase 2 enrollment completed, noted April 25, 2024.", "triplets": [["phase", "enrollment completed", "POS"], ["enrollment", "enrollment completed", "POS"]]}
{"row_id": 795, "sent_id": "795_0", "text": "Phase 1 data presented at ECCMID showed that single (up to 2000 mg) and multiple (up to 800 mg Q12 for 7 days) doses of this potent, pan-coronavirus protease inhibitor were well tolerated in healthy v", "triplets": [["safety", "well tolerated", "POS"], ["phase", "well tolerated", "POS"]]}
{"row_id": 797, "sent_id": "797_0", "text": "Approval announced April 26, 2024.", "triplets": [["regulatory", "Approval", "POS"]]}
{"row_id": 798, "sent_id": "798_0", "text": "Approved for updated label on (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg tablets, B/F/TAF) to treat pregnant people with HIV-1 (PWH) with suppressed viral loads, noted April 2", "triplets": [["catalyst", "Approved", "POS"]]}
{"row_id": 799, "sent_id": "799_0", "text": "Phase 2a data presented at ESCMID reported that well tolerated and demonstrated statistically significant antiviral effects when administered as a single subcutaneous dose in healthy volunteers challe", "triplets": [["safety", "statistically significant", "POS"], ["phase", "statistically significant", "POS"]]}
{"row_id": 800, "sent_id": "800_0", "text": "Phase 2a data presented at ESCMID reported that well tolerated and demonstrated statistically significant antiviral effects when administered as a single subcutaneous dose in healthy volunteers challe", "triplets": [["safety", "statistically significant", "POS"], ["phase", "statistically significant", "POS"]]}
{"row_id": 801, "sent_id": "801_0", "text": "Phase 2 data presented at ESCMID reported that the EDP-235 400 mg arm achieved greater mean change in TSS compared with the placebo arm at all time points, noted April 27, 2024.", "triplets": [["phase", "achieved", "POS"]]}
{"row_id": 802, "sent_id": "802_0", "text": "Phase 3 data reported statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to standard-of-care chemotherapy, noted April 29, 2024", "triplets": [["endpoint", "statistically significant", "POS"], ["phase", "statistically significant", "POS"]]}
{"row_id": 803, "sent_id": "803_0", "text": "FDA Approved on April 29, 2024.", "triplets": [["regulatory", "FDA Approved", "POS"]]}
{"row_id": 804, "sent_id": "804_0", "text": "Approved April 29, 2024.", "triplets": [["catalyst", "Approved", "POS"]]}
{"row_id": 805, "sent_id": "805_0", "text": "IND cleared by the FDA, noted April 29, 2024.", "triplets": [["regulatory", "cleared by the FDA", "POS"]]}
{"row_id": 806, "sent_id": "806_0", "text": "Phase 2 trial did not meet its primary endpoint, noted April 29, 2024.", "triplets": [["endpoint", "did not meet", "NEG"], ["phase", "did not meet", "NEG"]]}
{"row_id": 807, "sent_id": "807_0", "text": "Phase 2 trial did not meet its primary endpoint, noted April 29, 2024.", "triplets": [["endpoint", "did not meet", "NEG"], ["phase", "did not meet", "NEG"]]}
{"row_id": 809, "sent_id": "809_0", "text": "NDA resubmitted to the FDA, noted April 29, 2024.", "triplets": [["regulatory", "NDA resubmitted", "POS"]]}
{"row_id": 811, "sent_id": "811_0", "text": "Phase 1b/2 first dose level is generally well tolerated, noted April 29, 2024.", "triplets": [["safety", "well tolerated", "POS"], ["phase", "well tolerated", "POS"]]}
{"row_id": 812, "sent_id": "812_0", "text": "Phase 1b/2 first dose level is generally well tolerated, noted April 29, 2024.", "triplets": [["safety", "well tolerated", "POS"], ["phase", "well tolerated", "POS"]]}
{"row_id": 818, "sent_id": "818_0", "text": "Approved April 29, 2024.", "triplets": [["catalyst", "Approved", "POS"]]}
{"row_id": 819, "sent_id": "819_0", "text": "Approved April 29, 2024.", "triplets": [["catalyst", "Approved", "POS"]]}
{"row_id": 822, "sent_id": "822_0", "text": "Phase 2 study met its primary and key secondary endpoints, noted April 2024.", "triplets": [["endpoint", "met", "POS"], ["phase", "met", "POS"], ["financial", "met", "POS"]]}
{"row_id": 823, "sent_id": "823_0", "text": "Phase 2 study met its primary and key secondary endpoints, noted April 2024.", "triplets": [["endpoint", "met", "POS"], ["phase", "met", "POS"], ["financial", "met", "POS"]]}
{"row_id": 824, "sent_id": "824_0", "text": "Updated label approved April 30, 2024.", "triplets": [["catalyst", "approved", "POS"]]}
{"row_id": 825, "sent_id": "825_0", "text": "MTD data reported that all doses were well-tolerated, noted April 30, 2024.", "triplets": [["safety", "well-tolerated", "POS"]]}
{"row_id": 827, "sent_id": "827_0", "text": "Phase 2/3 top line data reported that NRX-101 vs lurasidone demonstrated a promising, though not yet statistically significant 33% reduction in suicidality together with a 70% reduction (P=.076) reduc", "triplets": [["pvalue", "statistically significant", "POS"], ["phase", "statistically significant", "POS"], ["clinical", "statistically significant", "POS"]]}
{"row_id": 828, "sent_id": "828_0", "text": "Phase 1 topline data reported no vaccine-related serious adverse events (SAEs) and no dose-limiting pharmacotoxicity, noted April 30, 2024.", "triplets": [["safety", "serious adverse events", "NEG"], ["phase", "serious adverse events", "NEG"], ["clinical", "serious adverse events", "NEG"]]}
{"row_id": 829, "sent_id": "829_0", "text": "Phase 1b compassionate use data reported that treatment has been well-tolerated throughout the treatment period, with stable cognitive function observed in the patients.", "triplets": [["safety", "well-tolerated", "POS"], ["phase", "well-tolerated", "POS"]]}
{"row_id": 831, "sent_id": "831_0", "text": "Approved April 30, 2024.", "triplets": [["catalyst", "Approved", "POS"]]}
{"row_id": 833, "sent_id": "833_0", "text": "Phase 3 trial met its dual primary endpoint of overall survival (OS), noted May 1, 2024.", "triplets": [["endpoint", "met", "POS"], ["phase", "met", "POS"]]}
{"row_id": 834, "sent_id": "834_0", "text": "Preclinical successful completion of its analysis to determine the effects of bioactivated PALI-2108 on TNF-\u00ce\u00b1 production in a whole blood (WB) assay, noted May 1, 2024.", "triplets": [["catalyst", "successful", "POS"]]}
{"row_id": 835, "sent_id": "835_0", "text": "Phase 2 30 mg cohort showed a 100% overall response rate in patients with ASXL1 mutation, treatment exhibited strong anti-leukemic activity in 62% of patients with a favorable safety profile across al", "triplets": [["safety", "favorable safety", "POS"], ["phase", "favorable safety", "POS"]]}
{"row_id": 836, "sent_id": "836_0", "text": "Phase 2a enrollment completed, noted May 1, 2024.", "triplets": [["phase", "enrollment completed", "POS"], ["enrollment", "enrollment completed", "POS"]]}
{"row_id": 837, "sent_id": "837_0", "text": "Phase 2/3 trial enrollment completed noted May 1, 2024.", "triplets": [["phase", "enrollment completed", "POS"], ["enrollment", "enrollment completed", "POS"]]}
{"row_id": 839, "sent_id": "839_0", "text": "Phase 1 trial successful and complete, noted May 1, 2024.", "triplets": [["phase", "successful", "POS"]]}
{"row_id": 841, "sent_id": "841_0", "text": "Phase 3 data reported a statistically significant and clinically meaningful improvement in progression-free survival (PFS) versus standard of care, noted May 2, 2024.", "triplets": [["endpoint", "statistically significant", "POS"], ["phase", "statistically significant", "POS"]]}
{"row_id": 842, "sent_id": "842_0", "text": "IND Cleared by the FDA, noted May 2, 2024.", "triplets": [["regulatory", "Cleared by the FDA", "POS"]]}
{"row_id": 845, "sent_id": "845_0", "text": "Preclinical data reported statistically significant increase in anti-myostatin IgG antibody concentration, where myostatin is a key negative regulator of muscle growth, noted May 2, 2024.", "triplets": [["catalyst", "statistically significant", "POS"]]}
{"row_id": 846, "sent_id": "846_0", "text": "Phase 2 trial is well tolerated and has led to encouraging initial efficacy data.", "triplets": [["safety", "well tolerated", "POS"], ["phase", "well tolerated", "POS"]]}
{"row_id": 847, "sent_id": "847_0", "text": "Phase 2 trial did not meet its primary endpoint, noted May 3, 2024.", "triplets": [["endpoint", "did not meet", "NEG"], ["phase", "did not meet", "NEG"]]}
{"row_id": 848, "sent_id": "848_0", "text": "Phase 2 data from TPRREY trail published at the Lancet Respiratory Medicine journal confirmed results demonstrating a statistically significant improvement for seralutinib compared to placebo in the p", "triplets": [["phase", "statistically significant", "POS"], ["clinical", "statistically significant", "POS"]]}
{"row_id": 849, "sent_id": "849_0", "text": "Phase 2 data from TPRREY trail published at the Lancet Respiratory Medicine journal confirmed results demonstrating a statistically significant improvement for seralutinib compared to placebo in the p", "triplets": [["phase", "statistically significant", "POS"], ["clinical", "statistically significant", "POS"]]}
{"row_id": 851, "sent_id": "851_1", "text": "Also, patients achieved similar probabilities of DFS r", "triplets": [["catalyst", "achieved", "POS"]]}
{"row_id": 852, "sent_id": "852_0", "text": "Phase 2 data at APA reported clinically and statistically significant efficacy compared to placebo at its primary week 4 and secondary week 12 timepoints, noted May 4, 2024.", "triplets": [["phase", "statistically significant", "POS"], ["financial", "statistically significant", "POS"]]}
{"row_id": 855, "sent_id": "855_0", "text": "Preclinical data reported that in a lethal animal model of lung infection by Influenza A /H3N2 virus, NV-387 was found to have substantially superior antiviral effects compared to three approved anti-", "triplets": [["catalyst", "approved", "POS"]]}
{"row_id": 856, "sent_id": "856_0", "text": "Phase 2 trial did not meet the pre-specified primary endpoint, noted May 6, 2024.", "triplets": [["endpoint", "did not meet", "NEG"], ["phase", "did not meet", "NEG"]]}
{"row_id": 858, "sent_id": "858_0", "text": "Phase 2 data reported that treatment was generally well-tolerated and safety was consistent with the known profile, with two patient discontinuations, with both of these patients remain in CR at 10 an", "triplets": [["endpoint", "well-tolerated", "POS"], ["safety", "well-tolerated", "POS"], ["phase", "well-tolerated", "POS"]]}
{"row_id": 859, "sent_id": "859_0", "text": "IND Cleared by the FDA, noted April 6, 2024.", "triplets": [["regulatory", "Cleared by the FDA", "POS"]]}
{"row_id": 860, "sent_id": "860_0", "text": "Phase 3 data reported that the trial did not meet its primary endpoint of demonstrating statistically significant improvement compared to sham control in the composite score of the three cardinal symp", "triplets": [["endpoint", "statistically significant", "NEU"], ["phase", "statistically significant", "NEU"], ["clinical", "statistically significant", "NEU"]]}
{"row_id": 861, "sent_id": "861_0", "text": "IND cleared by the FDA, noted May 6 2024.", "triplets": [["regulatory", "cleared by the FDA", "POS"]]}
{"row_id": 862, "sent_id": "862_0", "text": "Preclinical data reported that a statistically significant (FDR adjusted p-value < 0.05) decline in secondary tumor growth rate was found at days 21, 25 and 29 in those mice that received Alpha DaRT", "triplets": [["financial", "statistically significant", "POS"]]}
{"row_id": 863, "sent_id": "863_0", "text": "Phase 2 final data reported statistically significant improvements in key secondary endpoints, such as progression-free survival, (PFS median 5 months versus 2.9 months; Hazard ratio= 0.58) and statis", "triplets": [["endpoint", "statistically significant", "POS"], ["phase", "statistically significant", "POS"], ["financial", "statistically significant", "POS"]]}
{"row_id": 868, "sent_id": "868_0", "text": "Phase 3 data showcased previously disclosed data that demonstrated that setmelanotide achieved 3.04 mean reduction in BMI-Z score and 18.4 percent mean reduction in BMI in 12 patients, noted May 6, 20", "triplets": [["sample", "achieved", "POS"], ["phase", "achieved", "POS"]]}
{"row_id": 869, "sent_id": "869_0", "text": "BLA accepted for priority review by the FDA, noted May 6, 2024.", "triplets": [["regulatory", "BLA accepted", "POS"]]}
{"row_id": 870, "sent_id": "870_0", "text": "BLA accepted for priority review by the FDA, noted May 6, 2024.", "triplets": [["regulatory", "BLA accepted", "POS"]]}
{"row_id": 871, "sent_id": "871_0", "text": "Fast track designation granted by the FDA, noted May 7, 2024.", "triplets": [["regulatory", "Fast track", "POS"]]}
{"row_id": 872, "sent_id": "872_0", "text": "Phase 2 data presented at ARVO demonstrated significant, broad-based protection from vision loss in foveal and non-foveal patients, and in low light settings, noted May 7, 2024.", "triplets": [["phase", "data presented at ARVO", "POS"], ["clinical", "data presented at ARVO", "POS"]]}
{"row_id": 873, "sent_id": "873_0", "text": "Phase 2 trial did not meet the primary endpoint, noted May 7, 2024.", "triplets": [["endpoint", "did not meet", "NEG"], ["phase", "did not meet", "NEG"]]}
{"row_id": 876, "sent_id": "876_0", "text": "Additional Phase 2b data analysis reported a statistically significant slowing of disease progression in high-risk ALS patients treated with PrimeC by 43% (p=0.02), noted May 7, 2024.", "triplets": [["pvalue", "statistically significant", "POS"], ["phase", "statistically significant", "POS"]]}
{"row_id": 880, "sent_id": "880_0", "text": "Phase 1 trial met its primary and secondary objectives, noted May 8, 2024.", "triplets": [["phase", "met", "POS"], ["financial", "met", "POS"]]}
{"row_id": 881, "sent_id": "881_0", "text": "Phase 3 trial data reported that the trial met its primary endpoint as measured by a change in the PANSS total score from baseline after 8 weeks compared to placebo, noted May 8, 2024.", "triplets": [["endpoint", "met", "POS"], ["phase", "met", "POS"]]}
{"row_id": 884, "sent_id": "884_0", "text": "Phase 1b dosing initiated, noted May 8, 2024.", "triplets": [["phase", "dosing initiated", "POS"], ["clinical", "dosing initiated", "POS"]]}
{"row_id": 886, "sent_id": "886_0", "text": "Phase 1 dosing initiated, noted May 8, 2024.", "triplets": [["phase", "dosing initiated", "POS"], ["clinical", "dosing initiated", "POS"]]}
{"row_id": 888, "sent_id": "888_0", "text": "Phase 1 data demonstrated a favorable safety profile with no cytokine release syndrome (CRS) of any grade observed in step-dosing cohorts and no grade >1 CRS observed overall, noted May 8, 2024.", "triplets": [["safety", "favorable safety", "POS"], ["phase", "favorable safety", "POS"]]}
{"row_id": 889, "sent_id": "889_0", "text": "Phase 2 enrollment completed, noted May 8, 2024.", "triplets": [["phase", "enrollment completed", "POS"], ["enrollment", "enrollment completed", "POS"]]}
{"row_id": 890, "sent_id": "890_0", "text": "Phase 3 study did not meet the study's pre-specified statistical criteria for DFS compared to placebo plus adjuvant chemotherapy, with or without radiotherapy, noted May 9, 2024.", "triplets": [["phase", "did not meet", "NEG"]]}
{"row_id": 892, "sent_id": "892_0", "text": "Phase 1 dosing initiated, noted May 9, 2024.", "triplets": [["phase", "dosing initiated", "POS"], ["clinical", "dosing initiated", "POS"]]}
{"row_id": 898, "sent_id": "898_0", "text": "Trial closed due to clinical hold, noted May 9, 2024.", "triplets": [["regulatory", "clinical hold", "NEG"]]}
{"row_id": 899, "sent_id": "899_0", "text": "Trial closed due to clinical hold, noted May 9, 2024.", "triplets": [["regulatory", "clinical hold", "NEG"]]}
{"row_id": 904, "sent_id": "904_0", "text": "Preclinical data presented at ARVO showed that intravitreal administration of 4D-175 to non-human primates (NHP) was safe and well tolerated and resulted in robust transgene expression in the retina a", "triplets": [["safety", "well tolerated", "POS"], ["clinical", "well tolerated", "POS"]]}
{"row_id": 905, "sent_id": "905_0", "text": "Phase 2 interim 24-week landmark data presented at ARVO demonstrated that a high dose of 4D-150 (3E10 vg/eye) resulted in robust reductions in overall treatment burden of 89%, percent of patients with", "triplets": [["phase", "data presented at ARVO", "POS"], ["clinical", "data presented at ARVO", "POS"]]}
{"row_id": 907, "sent_id": "907_0", "text": "Phase 2 topline results reported that serious adverse events occurred in 20.7% of TPIP-treated patients and 40.0% of placebo-treated patients, noted May 9, 2024.", "triplets": [["safety", "serious adverse events", "NEG"], ["phase", "serious adverse events", "NEG"], ["clinical", "serious adverse events", "NEG"]]}
{"row_id": 908, "sent_id": "908_0", "text": "Phase 2 data reported that sevasemten was well tolerated across all 21 participants and significantly reduced biomarkers of muscle damage associated with exercise with a mean post-exercise reduction o", "triplets": [["safety", "well tolerated", "POS"], ["sample", "well tolerated", "POS"], ["phase", "well tolerated", "POS"]]}
{"row_id": 909, "sent_id": "909_0", "text": "IND cleared by the FDA, noted May 9, 2024.", "triplets": [["regulatory", "cleared by the FDA", "POS"]]}
{"row_id": 912, "sent_id": "912_0", "text": "Phase 1 data reported robust and sustained efficacy in adults and the first pediatric patient infusion of RP-L301 was well tolerated, with engraftment achieved at day +15, noted May 19, 2023.", "triplets": [["safety", "achieved", "POS"], ["phase", "achieved", "POS"]]}
{"row_id": 917, "sent_id": "917_0", "text": "Phase 3 CheckMate -73L trial did not meet its primary endpoint of progression-free survival (PFS), noted May 10, 2024.", "triplets": [["endpoint", "did not meet", "NEG"], ["phase", "did not meet", "NEG"]]}
{"row_id": 919, "sent_id": "919_0", "text": "Phase 3 pre-planned analysis data showed that the primary endpoint of recurrence-free survival (RFS) met the pre-specified futility criteria.", "triplets": [["endpoint", "met", "NEU"], ["phase", "met", "NEU"]]}
{"row_id": 921, "sent_id": "921_0", "text": "FDA Granted Breakthrough Therapy Designation (BTD) on May 13, 2024.", "triplets": [["regulatory", "Breakthrough Therapy", "POS"]]}
{"row_id": 922, "sent_id": "922_0", "text": "FDA Granted Breakthrough Therapy Designation (BTD) on May 13, 2024.", "triplets": [["regulatory", "Breakthrough Therapy", "POS"]]}
{"row_id": 925, "sent_id": "925_0", "text": "Phase 2 trial met primary endpoint, noted May 13, 2024.", "triplets": [["endpoint", "met", "POS"], ["phase", "met", "POS"]]}
{"row_id": 928, "sent_id": "928_0", "text": "Phase GLOW2 dosing initiated, noted May 14, 2024.", "triplets": [["clinical", "dosing initiated", "POS"]]}
{"row_id": 930, "sent_id": "930_0", "text": "CRL announced May 14, 2024.", "triplets": [["regulatory", "CRL", "NEG"]]}
{"row_id": 931, "sent_id": "931_0", "text": "Preclinical antiviral activity study resulted in full survival of lethally infected animals was achieved, noted May 14, 2024.", "triplets": [["catalyst", "achieved", "POS"]]}
{"row_id": 935, "sent_id": "935_0", "text": "Phase 1/2 trial dosing initiated, noted May 14, 2024.", "triplets": [["phase", "dosing initiated", "POS"], ["clinical", "dosing initiated", "POS"]]}
{"row_id": 936, "sent_id": "936_0", "text": "Phase 2 data reported that 3 of 3 patients who were na\u00c3\u00afve to FLT3i treatment achieved objective response (2 CR, 1 MLFS), noted May 14, 2024.", "triplets": [["endpoint", "achieved", "POS"], ["phase", "achieved", "POS"]]}
{"row_id": 940, "sent_id": "940_0", "text": "Phase 1 data reported that denifanstat was well-tolerated and no safety signals were reported, noted May 15, 2024.", "triplets": [["safety", "well-tolerated", "POS"], ["phase", "well-tolerated", "POS"]]}
{"row_id": 942, "sent_id": "942_0", "text": "Phase 1b/2 data to be shared at ESMO Breast Cancer showed that treatment was well tolerated with no new safety signals or increased toxicity and no clinically meaningful impact on drug exposure of eit", "triplets": [["safety", "well tolerated", "POS"], ["phase", "well tolerated", "POS"]]}
{"row_id": 947, "sent_id": "947_0", "text": "BLA submitted on May 15, 2024.", "triplets": [["regulatory", "BLA submitted", "POS"]]}
{"row_id": 948, "sent_id": "948_0", "text": "Phase 3 data reported that trials met their primary endpoints, noted May 16, 2024.", "triplets": [["endpoint", "met", "POS"], ["phase", "met", "POS"]]}
{"row_id": 951, "sent_id": "951_0", "text": "Phase 3 data reported that the trial met both dual primary endpoints, noted May 16, 2024.", "triplets": [["endpoint", "met", "POS"], ["phase", "met", "POS"]]}
{"row_id": 952, "sent_id": "952_0", "text": "Phase 1b/2 enrollment completed, noted November 2, 2023.", "triplets": [["phase", "enrollment completed", "POS"], ["enrollment", "enrollment completed", "POS"]]}
{"row_id": 953, "sent_id": "953_0", "text": "Phase 1b/2 enrollment completed, noted November 2, 2023.", "triplets": [["phase", "enrollment completed", "POS"], ["enrollment", "enrollment completed", "POS"]]}
{"row_id": 954, "sent_id": "954_0", "text": "Phase 2 dosing initiated, noted May 16, 2024.", "triplets": [["phase", "dosing initiated", "POS"], ["clinical", "dosing initiated", "POS"]]}
{"row_id": 957, "sent_id": "957_0", "text": "Approved May 16, 2024.", "triplets": [["catalyst", "Approved", "POS"]]}
{"row_id": 958, "sent_id": "958_0", "text": "Approved May 16, 2024.", "triplets": [["catalyst", "Approved", "POS"]]}
{"row_id": 959, "sent_id": "959_0", "text": "Phase 1b data reported that treatment was well tolerated at the maximum administered dose and treatment with mPH-762 provided robust inhibition of tumor growth, noted May 16, 2024.", "triplets": [["safety", "well tolerated", "POS"], ["phase", "well tolerated", "POS"]]}
{"row_id": 961, "sent_id": "961_0", "text": "Phase 1b/2 last patient dosed completed, noted May 16, 2024.", "triplets": [["phase", "last patient dosed", "POS"], ["clinical", "last patient dosed", "POS"]]}
{"row_id": 963, "sent_id": "963_0", "text": "Approved May 17, 2024.", "triplets": [["catalyst", "Approved", "POS"]]}
{"row_id": 964, "sent_id": "964_0", "text": "Phase 3 enrollment completed, noted May 17, 2024.", "triplets": [["phase", "enrollment completed", "POS"], ["enrollment", "enrollment completed", "POS"]]}
{"row_id": 976, "sent_id": "976_0", "text": "Phase 3 data reported that 70% of patients achieved the composite response endpoint and 25% experienced ALP normalization, noted May 20, 2024.", "triplets": [["phase", "achieved", "POS"]]}
{"row_id": 981, "sent_id": "981_0", "text": "Phase 2 clinical hold removed, noted May 20, 2024.", "triplets": [["phase", "clinical hold", "NEG"], ["regulatory", "clinical hold", "NEG"]]}
{"row_id": 983, "sent_id": "983_0", "text": "Phase 1/2 additional results demonstrate that two 5 \u00ce\u00bcg doses of ARCT-154, sa-mRNA vaccine, were well-tolerated, immunogenic and provided significant protection against multiple strains of COVID-19, no", "triplets": [["safety", "well-tolerated", "POS"], ["phase", "well-tolerated", "POS"]]}
{"row_id": 986, "sent_id": "986_0", "text": "Phase 3 data reported that both trials met its primary endpoints, noted May 21, 2024.", "triplets": [["endpoint", "met", "POS"], ["phase", "met", "POS"]]}
{"row_id": 987, "sent_id": "987_0", "text": "Phase 3 topline data study met its primary endpoint with a statistically significant improvement in the time to failure event, noted May 21, 2024.", "triplets": [["endpoint", "met", "POS"], ["phase", "met", "POS"], ["clinical", "met", "POS"]]}
{"row_id": 988, "sent_id": "988_0", "text": "Phase 3 dosing initiated, noted May 21, 2024.", "triplets": [["phase", "dosing initiated", "POS"], ["clinical", "dosing initiated", "POS"]]}
{"row_id": 992, "sent_id": "992_0", "text": "Phase 2 results presented at DDW showed an 83% non-progression rate at 6 months and a statistically significant decrease in overall mean polyp burden at 6 months, noted May 21, 2024.", "triplets": [["phase", "statistically significant", "POS"]]}
{"row_id": 993, "sent_id": "993_0", "text": "Breakthrough Therapy designation (BTD) granted by the FDA, noted May 21, 2024.", "triplets": [["regulatory", "Breakthrough Therapy", "POS"]]}
{"row_id": 994, "sent_id": "994_0", "text": "Phase 3 data showed that nearly one-half of patients on mirikizumab achieved endoscopic response at 52 weeks; most of these patients were also in clinical remission, noted May 21, 2024.", "triplets": [["phase", "achieved", "POS"]]}
{"row_id": 995, "sent_id": "995_0", "text": "Phase 2 study met its primary endpoint, noted May 21, 2024.", "triplets": [["endpoint", "met", "POS"], ["phase", "met", "POS"]]}
{"row_id": 996, "sent_id": "996_0", "text": "Phase 2 study met its primary endpoint, noted May 21, 2024.", "triplets": [["endpoint", "met", "POS"], ["phase", "met", "POS"]]}
{"row_id": 998, "sent_id": "998_0", "text": "Phase 2a enrollment completed, noted May 21, 2024", "triplets": [["phase", "enrollment completed", "POS"], ["enrollment", "enrollment completed", "POS"]]}
{"row_id": 1003, "sent_id": "1003_0", "text": "Approved May 22, 2024.", "triplets": [["catalyst", "Approved", "POS"]]}
{"row_id": 1008, "sent_id": "1008_0", "text": "Phase 2a key findings noting that VTP-300 in combination with nivolumab has been generally well tolerated, with no observed treatment-related serious adverse events, and contributed to declines in hep", "triplets": [["safety", "well tolerated", "NEU"], ["phase", "well tolerated", "NEU"]]}
{"row_id": 1009, "sent_id": "1009_0", "text": "Phase 2a key findings noting that VTP-300 in combination with nivolumab has been generally well tolerated, with no observed treatment-related serious adverse events, and contributed to declines in hep", "triplets": [["safety", "well tolerated", "NEU"], ["phase", "well tolerated", "NEU"]]}
{"row_id": 1010, "sent_id": "1010_0", "text": "Phase 2a key findings noting that VTP-300 in combination with nivolumab has been generally well tolerated, with no observed treatment-related serious adverse events, and contributed to declines in hep", "triplets": [["safety", "well tolerated", "NEU"], ["phase", "well tolerated", "NEU"]]}
{"row_id": 1011, "sent_id": "1011_0", "text": "Phase 1a first-in-human trial confirms \"Pulse-Prime\" hypothesis targeting stimulation of innate and adaptive immune systems, this data to be presented at ASCO 24, noted May 22, 2024.", "triplets": [["clinical", "data to be presented at ASCO", "POS"]]}
{"row_id": 1017, "sent_id": "1017_0", "text": "Phase 1 data published at in video format showed that the study met its primary efficacy endpoint, showing a statistically significant reduction in the mean daily reflective Total Nasal Symptom Score", "triplets": [["phase", "met", "POS"]]}
{"row_id": 1028, "sent_id": "1028_0", "text": "Phase 1/2 study as of May 14, 2024, patients receiving the combination of avutometinib and defactinib with gemcitabine and Nab-paclitaxel in dose level 1 cohort achieved a confirmed overall response r", "triplets": [["phase", "achieved", "POS"]]}
{"row_id": 1031, "sent_id": "1031_0", "text": "Phase 1/2 updated data to be presented at ASCO on June 3, 2024.", "triplets": [["phase", "data to be presented at ASCO", "POS"], ["clinical", "data to be presented at ASCO", "POS"]]}
{"row_id": 1035, "sent_id": "1035_0", "text": "Phase 1/1b data from ASCO abstract reported that treatment was well tolerated and clinically active in patients with checkpoint inhibitor therapy relapsed/refractory cancers, noted May 23, 2024.", "triplets": [["safety", "well tolerated", "POS"], ["phase", "well tolerated", "POS"]]}
{"row_id": 1036, "sent_id": "1036_0", "text": "Phase 1 Dose Escalation and Dose Expansion, first-in-human monotherapy study in patients with metastatic or locally advanced malignancies who had progressed on approved PD-1 or PD-L1 inhibitors, noted", "triplets": [["phase", "approved", "POS"]]}
{"row_id": 1040, "sent_id": "1040_0", "text": "Phase 1b data to be presented at ASCO 2024, ASCO abstract released across different NLM sites, overall response rates (ORR) ranged from 18-33%, and disease control rates (DCR) ranged from 67-82%.", "triplets": [["endpoint", "data to be presented at ASCO", "POS"], ["phase", "data to be presented at ASCO", "POS"], ["clinical", "data to be presented at ASCO", "POS"]]}
{"row_id": 1049, "sent_id": "1049_0", "text": "Phase 2 ASCO abstract showed that treatment administered as a monotherapy was well tolerated and able to generate a ~100x mKRAS-specific expanded T cell response relative to baseline levels, noted May", "triplets": [["safety", "well tolerated", "POS"], ["phase", "well tolerated", "POS"]]}
{"row_id": 1051, "sent_id": "1051_0", "text": "Preclinical data from ASCO abstract reported that IPH6501, at well-tolerated doses, significantly boosted peripheral NK cell proliferation, drove their accumulation at tumor locations, and effectively", "triplets": [["safety", "well-tolerated", "POS"]]}
{"row_id": 1061, "sent_id": "1061_0", "text": "Phase 1 data from ASCO abstract reported that one patient achieved unconfirmed partial response, and stable disease was observed in 11 patients (24%), noted May 23, 2024.", "triplets": [["sample", "achieved", "POS"], ["phase", "achieved", "POS"]]}
{"row_id": 1063, "sent_id": "1063_0", "text": "NDA and accelerated approval application submitted May 24, 2024.", "triplets": [["regulatory", "approval", "POS"]]}
{"row_id": 1064, "sent_id": "1064_0", "text": "Phase 2 clinical efficacy update presented at ASCO abstract showed that monotherapy neoadjuvant treatment was generally well tolerated.", "triplets": [["safety", "well tolerated", "POS"], ["phase", "well tolerated", "POS"]]}
{"row_id": 1066, "sent_id": "1066_0", "text": "Phase 1 preliminary results from dose escalation in an ASCO abstract shown to have an acceptable safety profile with no dose-limiting toxicities (DLTs) in heavily pretreated patients with solid tumors", "triplets": [["safety", "DLTs", "NEG"], ["phase", "DLTs", "NEG"]]}
{"row_id": 1068, "sent_id": "1068_0", "text": "Phase 2 final results to be presented at ASCO 2024, abstract released resulted in a ITT CR rate 57% at 12mo, 83% any time.", "triplets": [["endpoint", "results to be presented at ASCO", "POS"], ["phase", "results to be presented at ASCO", "POS"], ["clinical", "results to be presented at ASCO", "POS"]]}
{"row_id": 1069, "sent_id": "1069_0", "text": "Phase 2 final results to be presented at ASCO 2024, abstract released resulted in a ITT CR rate 57% at 12mo, 83% any time.", "triplets": [["endpoint", "results to be presented at ASCO", "POS"], ["phase", "results to be presented at ASCO", "POS"], ["clinical", "results to be presented at ASCO", "POS"]]}
{"row_id": 1078, "sent_id": "1078_0", "text": "Phase 1 data to be presented at ASCO on June 1, 2024, with abstract data reporting that 96.6% of pts had \u00e2\u2030\u00a51 tx-emergent adverse events, and decreased ctCNA was seen in all complete responders (n=2) an", "triplets": [["safety", "data to be presented at ASCO", "POS"], ["phase", "data to be presented at ASCO", "POS"], ["clinical", "data to be presented at ASCO", "POS"]]}
{"row_id": 1079, "sent_id": "1079_0", "text": "Phase 1 data from ASCO abstract reported that SVR35 was achieved by all 3 evaluable pts receiving \u00e2\u2030\u00a510 mg monotherapy, and 3/12 achieved a best response of SVR35, noted May 24, 2024.", "triplets": [["phase", "achieved", "POS"]]}
{"row_id": 1086, "sent_id": "1086_0", "text": "Phase 3 data reported that trial met its primary endpoint, noted May 28, 2024.", "triplets": [["endpoint", "met", "POS"], ["phase", "met", "POS"]]}
{"row_id": 1087, "sent_id": "1087_0", "text": "Phase 3 topline data reported that the trial met its primary endpoint, noted May 28, 2024.", "triplets": [["endpoint", "met", "POS"], ["phase", "met", "POS"], ["clinical", "met", "POS"]]}
{"row_id": 1090, "sent_id": "1090_0", "text": "Phase 2 data to be presented at ASCO 2024, abstract released on May 23 showed that as of the March 6, 2024 data cutoff, the combination demonstrated a 67% overall response rate across PD-L1 expression", "triplets": [["phase", "data to be presented at ASCO", "POS"], ["clinical", "data to be presented at ASCO", "POS"]]}
{"row_id": 1091, "sent_id": "1091_0", "text": "Phase 2 data to be presented at ASCO 2024, abstract released on May 23 showed that as of the March 6, 2024 data cutoff, the combination demonstrated a 67% overall response rate across PD-L1 expression", "triplets": [["phase", "data to be presented at ASCO", "POS"], ["clinical", "data to be presented at ASCO", "POS"]]}
{"row_id": 1093, "sent_id": "1093_0", "text": "Phase 3 trial met its primary endpoint, noted May 28, 2024.", "triplets": [["endpoint", "met", "POS"], ["phase", "met", "POS"]]}
{"row_id": 1097, "sent_id": "1097_0", "text": "Phase 3 data reported a statistically significant 36.1% proteinuria (protein in urine) reduction vs. placebo + supportive care at 36 weeks, noted May 28, 2024.", "triplets": [["effect", "statistically significant", "POS"], ["phase", "statistically significant", "POS"]]}
{"row_id": 1098, "sent_id": "1098_0", "text": "Phase 3 data reported that patients treated with Fabhalta in addition to supportive care achieved a 35.1% reduction in proteinuria at 6 months when compared to placebo on top of supportive care, noted", "triplets": [["phase", "achieved", "POS"]]}
{"row_id": 1101, "sent_id": "1101_0", "text": "Phase 1 data from abstract continued to showed that study continues to be well tolerated in the dose expansion portion of the DRAGON trial (Part B), noted May 28, 2024.", "triplets": [["safety", "well tolerated", "POS"], ["phase", "well tolerated", "POS"]]}
{"row_id": 1102, "sent_id": "1102_0", "text": "Phase 2 data presented at American Epilepsy Society showed azetukalner 20mg achieved clinically meaningful reductions in depression scores on MADRS and HAM-D17 scales, with a 3.04 point difference vs", "triplets": [["phase", "achieved", "POS"]]}
{"row_id": 1103, "sent_id": "1103_1", "text": "The data showed NRX-101 achieved similar efficacy to lurasidone on dep", "triplets": [["catalyst", "achieved", "POS"]]}
{"row_id": 1105, "sent_id": "1105_0", "text": "Phase 1/2a Safety Review Committee has approved opening enrollment for the 800mg once daily dosing cohort after reviewing favorable safety and pharmacokinetic data from the 550mg cohort.", "triplets": [["safety", "favorable safety", "POS"], ["phase", "favorable safety", "POS"]]}
{"row_id": 1108, "sent_id": "1108_0", "text": "Preclinical canine study dosing initiated, noted May 28, 2024.", "triplets": [["clinical", "dosing initiated", "POS"]]}
{"row_id": 1110, "sent_id": "1110_0", "text": "Phase 1 update from ASCO reported that treatment was was generally well tolerated without hematologic adverse events seen with traditional MDM2 small molecule inhibitors, noted June 1, 2024.", "triplets": [["safety", "well tolerated", "POS"], ["phase", "well tolerated", "POS"]]}
{"row_id": 1111, "sent_id": "1111_0", "text": "Phase 1 full data presented at ASCO reported that one patient achieved an unconfirmed partial response and stable disease was observed in 14 additional patients, noted June 1, 2024.", "triplets": [["phase", "achieved", "POS"], ["clinical", "achieved", "POS"]]}
{"row_id": 1113, "sent_id": "1113_0", "text": "Phase 2 ASCO presentation reported a statistically significant positive correlation between neoantigen quality, as predicted by AI-Immunology\u00e2\u201e\u00a2, and vaccine-induced immune response was demonstrated, no", "triplets": [["phase", "statistically significant", "POS"]]}
{"row_id": 1114, "sent_id": "1114_0", "text": "Phase 2 ASCO presentation reported a statistically significant positive correlation between neoantigen quality, as predicted by AI-Immunology\u00e2\u201e\u00a2, and vaccine-induced immune response was demonstrated, no", "triplets": [["phase", "statistically significant", "POS"]]}
{"row_id": 1115, "sent_id": "1115_0", "text": "Phase 1 data presented at ASCO reported 92% of evaluable patients treated with INB-200 for GBM exceeded a median PFS of 7 months achieved with the standard-of-care regimen, noted June 1, 2024.", "triplets": [["endpoint", "achieved", "POS"], ["phase", "achieved", "POS"], ["clinical", "achieved", "POS"]]}
{"row_id": 1116, "sent_id": "1116_0", "text": "Phase 2 data presented at ASCO 2024 reported that results showed taletrectinib shrank tumors (confirmed objective response rate, cORR, as assessed by an independent review committee, IRC) in 91% of pa", "triplets": [["phase", "data presented at ASCO", "POS"], ["clinical", "data presented at ASCO", "POS"]]}
{"row_id": 1117, "sent_id": "1117_0", "text": "Phase 3 data presented at ASCO reported that median duration of follow-up of 36.9 months, selinexor-treated patients had a median PFS of 28.4 months compared to 5.2 months for patients receiving place", "triplets": [["endpoint", "data presented at ASCO", "POS"], ["phase", "data presented at ASCO", "POS"], ["clinical", "data presented at ASCO", "POS"]]}
{"row_id": 1118, "sent_id": "1118_0", "text": "Phase 1 initial results presented at ASCO reported one confirmed partial response was observed and eight patients experienced stable disease, noted June 1, 2024.", "triplets": [["phase", "results presented at ASCO", "POS"], ["clinical", "results presented at ASCO", "POS"]]}
{"row_id": 1120, "sent_id": "1120_0", "text": "Phase 2 data shared at ASCO reported that 60% of patients in the EDGE-Gastric study achieved progression-free survival at 12 months, noted June 1, 2024.", "triplets": [["phase", "achieved", "POS"]]}
{"row_id": 1121, "sent_id": "1121_0", "text": "Phase 2 data shared at ASCO reported that 60% of patients in the EDGE-Gastric study achieved progression-free survival at 12 months, noted June 1, 2024.", "triplets": [["phase", "achieved", "POS"]]}
{"row_id": 1122, "sent_id": "1122_0", "text": "Phase 1a presented at ASCO reported that 5 DLTs were observed with combo tx, no responders and disease control rate (DCR) was 35.0%, noted June 1 2024.", "triplets": [["safety", "DLTs", "NEG"]]}
{"row_id": 1123, "sent_id": "1123_0", "text": "Trial data presented at ASCO reported that the objective response rate [ORR] 1/20 [5%] pts; 7 pts with SD, noted June 1, 2024.", "triplets": [["endpoint", "data presented at ASCO", "POS"], ["clinical", "data presented at ASCO", "POS"]]}
{"row_id": 1124, "sent_id": "1124_0", "text": "Phase 1 data presented at ASCO reported to be 1 PR and 8 pts with a best response of SD, noted June 1, 2024.", "triplets": [["endpoint", "data presented at ASCO", "POS"], ["phase", "data presented at ASCO", "POS"], ["clinical", "data presented at ASCO", "POS"]]}
{"row_id": 1125, "sent_id": "1125_0", "text": "Phase 1 data presented at ASCO reported to be 1 PR and 8 pts with a best response of SD, noted June 1, 2024.", "triplets": [["endpoint", "data presented at ASCO", "POS"], ["phase", "data presented at ASCO", "POS"], ["clinical", "data presented at ASCO", "POS"]]}
{"row_id": 1126, "sent_id": "1126_0", "text": "Phase 1/1b initial combination dose escalation data reported that treatment was generally well-tolerated with enhanced immune activation in tumors, noted June 1, 2024.", "triplets": [["safety", "well-tolerated", "POS"], ["phase", "well-tolerated", "POS"]]}
{"row_id": 1127, "sent_id": "1127_0", "text": "Phase 1/1b initial combination dose escalation data reported that treatment was generally well-tolerated with enhanced immune activation in tumors, noted June 1, 2024.", "triplets": [["safety", "well-tolerated", "POS"], ["phase", "well-tolerated", "POS"]]}
{"row_id": 1129, "sent_id": "1129_0", "text": "Phase 1 initial dose expansion data presented at ASCO reported a median PFS of 14.4 months, noted June 2, 2024.", "triplets": [["endpoint", "data presented at ASCO", "POS"], ["phase", "data presented at ASCO", "POS"], ["clinical", "data presented at ASCO", "POS"]]}
{"row_id": 1132, "sent_id": "1132_0", "text": "Phase 3 data presented at ASCO showed TAGRISSO reduced the risk of disease progression or death by 84% compared to placebo (hazard ratio [HR] 0.16; 95% confidence interval [CI] 0.10-0.24; p<0.001) as", "triplets": [["pvalue", "data presented at ASCO", "POS"], ["phase", "data presented at ASCO", "POS"], ["clinical", "data presented at ASCO", "POS"]]}
{"row_id": 1133, "sent_id": "1133_0", "text": "Phase 1 trial data presented at ASCO reported 1 PR in Merkel cell carcinoma was observed at 25 mg Q3W, 1 complete response was observed in PD-L1+ NSCLC at the RDE 40 mg Q3W, and 3 pts were continuing", "triplets": [["endpoint", "data presented at ASCO", "POS"], ["phase", "data presented at ASCO", "POS"], ["clinical", "data presented at ASCO", "POS"]]}
{"row_id": 1134, "sent_id": "1134_0", "text": "Phase 1 trial data presented at ASCO reported 1 PR in Merkel cell carcinoma was observed at 25 mg Q3W, 1 complete response was observed in PD-L1+ NSCLC at the RDE 40 mg Q3W, and 3 pts were continuing", "triplets": [["endpoint", "data presented at ASCO", "POS"], ["phase", "data presented at ASCO", "POS"], ["clinical", "data presented at ASCO", "POS"]]}
{"row_id": 1135, "sent_id": "1135_0", "text": "Phase 1 trial data presented at ASCO reported 1 PR in Merkel cell carcinoma was observed at 25 mg Q3W, 1 complete response was observed in PD-L1+ NSCLC at the RDE 40 mg Q3W, and 3 pts were continuing", "triplets": [["endpoint", "data presented at ASCO", "POS"], ["phase", "data presented at ASCO", "POS"], ["clinical", "data presented at ASCO", "POS"]]}
{"row_id": 1136, "sent_id": "1136_0", "text": "Phase 1 trial data presented at ASCO reported 1 PR in Merkel cell carcinoma was observed at 25 mg Q3W, 1 complete response was observed in PD-L1+ NSCLC at the RDE 40 mg Q3W, and 3 pts were continuing", "triplets": [["endpoint", "data presented at ASCO", "POS"], ["phase", "data presented at ASCO", "POS"], ["clinical", "data presented at ASCO", "POS"]]}
{"row_id": 1137, "sent_id": "1137_0", "text": "Phase 1 safety and efficacy data presented at ASCO reported that anti-PD-1 naive patients reported a 48.0% (12/25) overall response rate (\"ORR\") as per RECIST 1.1(3 CR; 9 PR), noted June 2, 2024.", "triplets": [["endpoint", "data presented at ASCO", "POS"], ["safety", "data presented at ASCO", "POS"], ["phase", "data presented at ASCO", "POS"], ["clinical", "data presented at ASCO", "POS"]]}
{"row_id": 1138, "sent_id": "1138_0", "text": "Phase 3 data presented at ASCO reported statistically significant and clinically meaningful improvements in the dual primary endpoints of overall survival (OS) and progression-free survival (PFS), not", "triplets": [["endpoint", "statistically significant", "POS"], ["phase", "statistically significant", "POS"], ["clinical", "statistically significant", "POS"]]}
{"row_id": 1139, "sent_id": "1139_0", "text": "Phase 3 data presented at ASCO reported a reduced the risk of disease progression or death by 38% by blinded independent central review (BICR) versus chemotherapy in patients with HER2-low expression,", "triplets": [["phase", "data presented at ASCO", "POS"], ["clinical", "data presented at ASCO", "POS"]]}
{"row_id": 1140, "sent_id": "1140_0", "text": "Phase 1b/2 data presented at ASCO reported that treatment significantly reduced the risk of death by 63% and risk of disease progression by 73% compared to regorafenib, noted June 2, 2024.", "triplets": [["phase", "data presented at ASCO", "POS"], ["clinical", "data presented at ASCO", "POS"]]}
{"row_id": 1142, "sent_id": "1142_0", "text": "Phase 1b data presented at ASCO reported that the ORR per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) was 10.5% (95% CI, 2.9, 24.8); median progression free survival (mPFS)", "triplets": [["endpoint", "data presented at ASCO", "POS"], ["phase", "data presented at ASCO", "POS"], ["clinical", "data presented at ASCO", "POS"]]}
{"row_id": 1143, "sent_id": "1143_0", "text": "Phase 2 trial data presented at ASCO reported that ORR was 45.3% in patients with brain metastases and 32.6% in patients without brain metastases June 2, 2024.", "triplets": [["endpoint", "data presented at ASCO", "POS"], ["phase", "data presented at ASCO", "POS"], ["clinical", "data presented at ASCO", "POS"]]}
{"row_id": 1146, "sent_id": "1146_0", "text": "Phase 2a 12-week data from obesity cohort achieved a statistically significant placebo-adjusted mean weight loss of 6.2%, with 67% of patients achieving \u00e2\u2030\u00a56% weight loss.", "triplets": [["phase", "achieved", "POS"]]}
{"row_id": 1150, "sent_id": "1150_0", "text": "Phase 2 data presneted at ASCO In the newly diagnosed AML cohort, 75% of evaluable patients achieved complete remission or related responses.", "triplets": [["phase", "achieved", "POS"]]}
{"row_id": 1153, "sent_id": "1153_0", "text": "Additional Phase 2 data reported that patients on barzolvolimab experienced a > 8 point improvement in AAS7 (considered a clinically meaningful result) across all doses compared to placebo (p<0.05), n", "triplets": [["pvalue", "p<0.05", "POS"], ["phase", "p<0.05", "POS"]]}
{"row_id": 1155, "sent_id": "1155_0", "text": "Additional data presented at ASCO reported that at the end of one year, 71% (95% CI: 63-78) of patients in the belantamab mafodotin combination group compared to 51% (95% CI: 42-60) in the bortezomib", "triplets": [["clinical", "data presented at ASCO", "POS"]]}
{"row_id": 1156, "sent_id": "1156_0", "text": "Phase 2 data presented at ASCO resulted in an 83% intracranial objective response rate, median progression-free survival of 4.1 months in antibody-drug conjugate (ADC) resistant patients (double histo", "triplets": [["phase", "data presented at ASCO", "POS"], ["clinical", "data presented at ASCO", "POS"]]}
{"row_id": 1158, "sent_id": "1158_0", "text": "Phase 3 overall survival (OS) did not meet statistical significance at this analysis, neoadjuvant Opdivo with chemotherapy continued to show a clinically important OS improvement trend over chemothera", "triplets": [["endpoint", "did not meet", "NEG"], ["phase", "did not meet", "NEG"]]}
{"row_id": 1161, "sent_id": "1161_0", "text": "Phase 2b data presented at SLEEP reported statistically significant and clinically meaningful increased sleep latency on the Maintenance of Wakefulness Test (MWT) versus placebo across all doses (LS m", "triplets": [["phase", "statistically significant", "POS"]]}
{"row_id": 1162, "sent_id": "1162_0", "text": "Phase 1/2 presented art ASCO showed that study met the primary safety and efficacy endpoints, noted June 3, 2024.", "triplets": [["safety", "met", "POS"], ["phase", "met", "POS"]]}
{"row_id": 1163, "sent_id": "1163_0", "text": "Phase 3 topline data reported that the trial met its primary endpoint, note June 3, 2024.", "triplets": [["endpoint", "met", "POS"], ["phase", "met", "POS"], ["clinical", "met", "POS"]]}
{"row_id": 1165, "sent_id": "1165_0", "text": "Phase 1b/2a data presented at ASCO reported that treatment was safe and well tolerated.", "triplets": [["safety", "well tolerated", "POS"], ["phase", "well tolerated", "POS"], ["clinical", "well tolerated", "POS"]]}
{"row_id": 1166, "sent_id": "1166_0", "text": "Phase 3 data reported was observed but not statistically significant, noted June 3, 2024.", "triplets": [["phase", "statistically significant", "NEU"]]}
{"row_id": 1171, "sent_id": "1171_0", "text": "Phase 1 additional data shared at ASCO demonstrated a manageable safety profile with no observed DLTs or GvHD and with majority of patients treated in outpatient setting, noted June 3, 2024.", "triplets": [["safety", "manageable safety", "NEU"], ["phase", "manageable safety", "NEU"]]}
{"row_id": 1172, "sent_id": "1172_0", "text": "Phase 3 trial enrollment completed on May 16, 2023 Phase study achieved statistically significant median reductions in triglycerides up to 80% and mean reductions in APOC3 up to 94% at month 10, noted", "triplets": [["phase", "achieved", "POS"], ["enrollment", "achieved", "POS"]]}
{"row_id": 1174, "sent_id": "1174_0", "text": "Phase 2 trial data presented at ASCO reported that 12-month overall survival (\"OS\") rate of 69%, a median overall survival (mOS) of 17.5 months, and a 30% overall response rate (ORR) at the time of da", "triplets": [["endpoint", "data presented at ASCO", "POS"], ["phase", "data presented at ASCO", "POS"], ["clinical", "data presented at ASCO", "POS"]]}
{"row_id": 1175, "sent_id": "1175_0", "text": "Phase 1 data presented at SLEEP 2024 demonstrated clinically meaningful and statistically significant improvements from baseline in mean sleep latency compared to placebo at all doses tested, noted Ju", "triplets": [["phase", "statistically significant", "POS"]]}
{"row_id": 1182, "sent_id": "1182_0", "text": "Phase 3 data presented at ASCO showed that at 34.9 months it reduced the risk of recurrence or death by 49% and the risk of distant metastasis or death by 62% compared to KEYTRUDA alone in these patie", "triplets": [["phase", "data presented at ASCO", "POS"], ["clinical", "data presented at ASCO", "POS"]]}
{"row_id": 1183, "sent_id": "1183_0", "text": "Phase 3 data presented at ASCO showed that at 34.9 months it reduced the risk of recurrence or death by 49% and the risk of distant metastasis or death by 62% compared to KEYTRUDA alone in these patie", "triplets": [["phase", "data presented at ASCO", "POS"], ["clinical", "data presented at ASCO", "POS"]]}
{"row_id": 1184, "sent_id": "1184_0", "text": "Phase 2 data presented at ASCO from its 12-month study results demonstrated an overall response rate of 32.7% and duration of response consistent with the previously reported 6-month data, noted June", "triplets": [["phase", "data presented at ASCO", "POS"], ["clinical", "data presented at ASCO", "POS"]]}
{"row_id": 1187, "sent_id": "1187_0", "text": "Phase 3 full data presented at ASCO reported that the treatment improved the risk-to-benefit profile of the combination treatment, maintaining efficacy with significantly fewer acute and long-lasting", "triplets": [["phase", "data presented at ASCO", "POS"], ["clinical", "data presented at ASCO", "POS"]]}
{"row_id": 1188, "sent_id": "1188_0", "text": "Phase 2 interim analysis presented at ASCO reported that an ORR (25% vs 7%), disease control rate (DCR) (63% vs 40%), and decrease in CA19-9 level (61% decrease vs. 34% increase), noted June 3, 2024.", "triplets": [["endpoint", "analysis presented at ASCO", "POS"], ["phase", "analysis presented at ASCO", "POS"], ["clinical", "analysis presented at ASCO", "POS"]]}
{"row_id": 1190, "sent_id": "1190_0", "text": "Approved April 6, 2024.", "triplets": [["catalyst", "Approved", "POS"]]}
{"row_id": 1191, "sent_id": "1191_0", "text": "Preclinical data presented at ASCO demonstrated the potential of combining Celularity's placental-derived cell therapy platform with currently available antibody therapies to address difficult-to-trea", "triplets": [["clinical", "data presented at ASCO", "POS"]]}
{"row_id": 1192, "sent_id": "1192_0", "text": "Phase 2 data presented at ASCO reported that confirmed ORRs (and mDoR) were 13% (2 mo), 21% (6 mo), and 22% (NR), with 6-mo PFS rates of 0%, 18%, and 33% for arms A, B, and C, respectively, noted June", "triplets": [["endpoint", "data presented at ASCO", "POS"], ["phase", "data presented at ASCO", "POS"], ["clinical", "data presented at ASCO", "POS"]]}
{"row_id": 1197, "sent_id": "1197_0", "text": "Phase 2 full data presented at SLEEP 2024 showed that study was well tolerated and showed meaningful clinical improvements in patient-reported assessments of daytime sleepiness, sleep inertia, and bra", "triplets": [["safety", "well tolerated", "POS"], ["phase", "well tolerated", "POS"]]}
{"row_id": 1198, "sent_id": "1198_0", "text": "Phase 3 results published at ASCO showed that as of the cutoff, in 15 evaluable patients, the confirmed partial response rate was 53% (8/15), including 6/8 responses in TKI-na\u00c3\u00afve and 3/7 in prior MET", "triplets": [["phase", "MET", "POS"]]}
{"row_id": 1199, "sent_id": "1199_0", "text": "Phase 3 results published at ASCO showed that as of the cutoff, in 15 evaluable patients, the confirmed partial response rate was 53% (8/15), including 6/8 responses in TKI-na\u00c3\u00afve and 3/7 in prior MET", "triplets": [["phase", "MET", "POS"]]}
{"row_id": 1200, "sent_id": "1200_0", "text": "IND cleared by the FDA, noted June 3, 2024.", "triplets": [["regulatory", "cleared by the FDA", "POS"]]}
{"row_id": 1203, "sent_id": "1203_0", "text": "Phase 2 interim results presented at ASCO showed an verall response rate of 40% consistent across sarcoma indications; median duration of response ~11 months with patients still in response at time of", "triplets": [["phase", "results presented at ASCO", "POS"], ["clinical", "results presented at ASCO", "POS"]]}
{"row_id": 1210, "sent_id": "1210_0", "text": "Phase 1b combination expansion data presented at ASCO reported that the ORR was 40% with 3 of the 4 responses confirmed, noted June 3, 2024.", "triplets": [["endpoint", "data presented at ASCO", "POS"], ["phase", "data presented at ASCO", "POS"], ["clinical", "data presented at ASCO", "POS"]]}
{"row_id": 1211, "sent_id": "1211_0", "text": "Phase 1b combination expansion data presented at ASCO reported that the ORR was 40% with 3 of the 4 responses confirmed, noted June 3, 2024.", "triplets": [["endpoint", "data presented at ASCO", "POS"], ["phase", "data presented at ASCO", "POS"], ["clinical", "data presented at ASCO", "POS"]]}
{"row_id": 1216, "sent_id": "1216_0", "text": "Phase 2 data presented at ASCO showed an Overall Response Rate (ORR) of 60%, noted June 4, 2022.", "triplets": [["endpoint", "data presented at ASCO", "POS"], ["phase", "data presented at ASCO", "POS"], ["clinical", "data presented at ASCO", "POS"]]}
{"row_id": 1217, "sent_id": "1217_0", "text": "Phase 3 topline data of its single infusion 30 mg/kg dose met the primary endpoint with a highly statistically significant 2.4-fold improvement in GBS disability score versus placebo at week 8, noted", "triplets": [["endpoint", "met", "POS"], ["phase", "met", "POS"], ["clinical", "met", "POS"]]}
{"row_id": 1218, "sent_id": "1218_0", "text": "Phase 2b 52-week biopsy data showed that up to 75% of VK2809-treated patients achieved NASH resolution with no worsening of fibrosis, compared to 29% for placebo.", "triplets": [["phase", "achieved", "POS"]]}
{"row_id": 1218, "sent_id": "1218_1", "text": "Additionally, up to 57% achieved \u00e2\u2030\u00a51-", "triplets": [["catalyst", "achieved", "POS"]]}
{"row_id": 1219, "sent_id": "1219_0", "text": "Phase 2b 52-week biopsy data showed that up to 75% of VK2809-treated patients achieved NASH resolution with no worsening of fibrosis, compared to 29% for placebo.", "triplets": [["phase", "achieved", "POS"]]}
{"row_id": 1219, "sent_id": "1219_1", "text": "Additionally, up to 57% achieved \u00e2\u2030\u00a51-", "triplets": [["catalyst", "achieved", "POS"]]}
{"row_id": 1220, "sent_id": "1220_0", "text": "Phase 2 data cohort 5 from PROPEL 2 reported a statistically significant and sustained increase in annualized height velocity (AHV), with a mean change from baseline of +2.51cm/yr at Month 12, and +2.", "triplets": [["phase", "statistically significant", "POS"]]}
{"row_id": 1221, "sent_id": "1221_0", "text": "Phase 1 data presented at ASCO showed that at 9.03-mo median follow up achieves disease control rate (DCR) of 91.3% and objective response rate (ORR) of 56.5% for patients across all dose levels (DLs)", "triplets": [["endpoint", "data presented at ASCO", "POS"], ["phase", "data presented at ASCO", "POS"], ["clinical", "data presented at ASCO", "POS"]]}
{"row_id": 1222, "sent_id": "1222_0", "text": "Phase 2 top-line data showed that 20% of all patients and 29% of those with moderate to severe disease who completed 24 weeks of treatment achieved a SALT score \u00e2\u2030\u00a420 (reduction in hair loss).", "triplets": [["phase", "achieved", "POS"], ["clinical", "achieved", "POS"]]}
{"row_id": 1223, "sent_id": "1223_0", "text": "Phase 1 dose escalation data presented at ASCO 2024 showed an overall response rate (ORR) of 46% and 12-month overall survival (OS) of 96%, noted June 4, 2024.", "triplets": [["endpoint", "data presented at ASCO", "POS"], ["phase", "data presented at ASCO", "POS"], ["clinical", "data presented at ASCO", "POS"]]}
{"row_id": 1226, "sent_id": "1226_0", "text": "Phase 3 late-breaking data presented at ASCO demonstrated improved survival benefit compared to lenvatinib or sorafenib in this patient population.", "triplets": [["phase", "data presented at ASCO", "POS"], ["clinical", "data presented at ASCO", "POS"]]}
{"row_id": 1228, "sent_id": "1228_0", "text": "Fast Track designation granted by the FDA, noted June 4, 2024.", "triplets": [["regulatory", "Fast Track", "POS"]]}
{"row_id": 1230, "sent_id": "1230_0", "text": "Additional Phase 2 data presented at EASL reported that 50% (3 of 6) achieved the combined endpoint, noted June 5, 2024.", "triplets": [["phase", "achieved", "POS"]]}
{"row_id": 1231, "sent_id": "1231_0", "text": "Additional Phase 2 data presented at EASL reported that 50% (3 of 6) achieved the combined endpoint, noted June 5, 2024.", "triplets": [["phase", "achieved", "POS"]]}
{"row_id": 1236, "sent_id": "1236_0", "text": "Phase 3 data reported that 70% of patients treated with elafibranor achieved composite endpoint of slowing disease progression measured by biochemical response after 78-weeks, noted June 5, 2024.", "triplets": [["phase", "achieved", "POS"]]}
{"row_id": 1237, "sent_id": "1237_0", "text": "Fast track designation granted by the FDA, noted June 5, 2024.", "triplets": [["regulatory", "Fast track", "POS"]]}
{"row_id": 1238, "sent_id": "1238_0", "text": "Phase 3 interim results presented at EASL reported that 73% achieved the clinically meaningful composite response endpoint, with 42% experiencing ALP normalization, noted June 5, 2024.", "triplets": [["phase", "achieved", "POS"]]}
{"row_id": 1243, "sent_id": "1243_0", "text": "Phase 2 interim data reported that statistically significant increases in neutralizing antibody responses against multiple SARS-CoV-2 variants, ranging from the original Wuhan strain through Delta and", "triplets": [["phase", "statistically significant", "POS"]]}
{"row_id": 1246, "sent_id": "1246_0", "text": "Phase 3 trial met its primary endpoint, showing a statistically significant 87% reduction in the risk of IgG4-RD flare compared to placebo during the 52-week placebo-controlled period.", "triplets": [["endpoint", "met", "POS"], ["phase", "met", "POS"]]}
{"row_id": 1248, "sent_id": "1248_0", "text": "Phase 2b data reported that treatment statistically significant results on primary and secondary liver biopsy endpoints in the ITT population, noted June 6, 2024.", "triplets": [["phase", "statistically significant", "POS"], ["financial", "statistically significant", "POS"]]}
{"row_id": 1257, "sent_id": "1257_0", "text": "Full clinical hold place June 6, 2024.", "triplets": [["regulatory", "clinical hold", "NEG"]]}
{"row_id": 1258, "sent_id": "1258_0", "text": "Full clinical hold announced June 6, 2024.", "triplets": [["regulatory", "clinical hold", "NEG"]]}
{"row_id": 1259, "sent_id": "1259_0", "text": "Approved June 6, 2024.", "triplets": [["catalyst", "Approved", "POS"]]}
{"row_id": 1260, "sent_id": "1260_0", "text": "Phase 1a received IDMC recommendation to advance based on favorable safety profile observed in Phase 1a portion of trial, noted June 6, 2024.", "triplets": [["safety", "favorable safety", "POS"]]}
{"row_id": 1261, "sent_id": "1261_0", "text": "BLA submitted June 17, 2024.", "triplets": [["regulatory", "BLA submitted", "POS"]]}
{"row_id": 1262, "sent_id": "1262_0", "text": "Approved vaccine submitted to the FDA for review of its Spikevax 2024-2025 formula, targeting the SARS-CoV-2 variant JN.1., noted June 7, 2024.", "triplets": [["catalyst", "Approved", "POS"]]}
{"row_id": 1264, "sent_id": "1264_0", "text": "Approved June 7, 2024.", "triplets": [["catalyst", "Approved", "POS"]]}
{"row_id": 1265, "sent_id": "1265_0", "text": "Phase 2b 48-week data presented at EASL reported statistically significant improvements across key markers of liver health.", "triplets": [["phase", "statistically significant", "POS"]]}
{"row_id": 1266, "sent_id": "1266_0", "text": "Phase 3 data reported that the trial met its primary endpoints, noted June 10, 2024.", "triplets": [["endpoint", "met", "POS"], ["phase", "met", "POS"]]}
{"row_id": 1269, "sent_id": "1269_0", "text": "Phase 2a study did not meet the primary endpoint for lowering intraocular pressure, leading the company to discontinue the program and associated ophthalmology pipeline, noted June 10, 2024.", "triplets": [["endpoint", "did not meet", "NEG"], ["phase", "did not meet", "NEG"]]}
{"row_id": 1270, "sent_id": "1270_0", "text": "Phase 2a received approval from an Israeli review board to initiate open-label study, noted June 10, 2024.", "triplets": [["phase", "approval", "POS"], ["regulatory", "approval", "POS"]]}
{"row_id": 1272, "sent_id": "1272_0", "text": "Phase 2 dosing initiated, noted June 10, 2024.", "triplets": [["phase", "dosing initiated", "POS"], ["clinical", "dosing initiated", "POS"]]}
{"row_id": 1273, "sent_id": "1273_0", "text": "Phase 2 data reported that the efficacy estimandi showed 51.8%, 62.8% and 73.3% of participants taking 5 mg, 10 mg and 15 mg, respectively, achieved an absence of MASH with no worsening of fibrosis on", "triplets": [["phase", "achieved", "POS"]]}
{"row_id": 1274, "sent_id": "1274_0", "text": "Phase 2b data presented at EASL reported that \u00e2\u2030\u00a51-stage improvement in fibrosis with no worsening of MASH after 24 weeks of treatment for both the 50 mg EFX (41%, p<0.05) and 28 mg EFX (39%, p<0.05) do", "triplets": [["pvalue", "p<0.05", "POS"], ["phase", "p<0.05", "POS"]]}
{"row_id": 1275, "sent_id": "1275_0", "text": "Phase 2b data presented at EASL reported that \u00e2\u2030\u00a51-stage improvement in fibrosis with no worsening of MASH after 24 weeks of treatment for both the 50 mg EFX (41%, p<0.05) and 28 mg EFX (39%, p<0.05) do", "triplets": [["pvalue", "p<0.05", "POS"], ["phase", "p<0.05", "POS"]]}
{"row_id": 1280, "sent_id": "1280_0", "text": "Phase 2a enrollment was completed with initial data showing an overall response rate (ORR) of 33% and 50% achieved to date in 60 mg QW and 30 mg BIW cohorts, noted June 10, 2024.", "triplets": [["endpoint", "achieved", "POS"], ["phase", "achieved", "POS"], ["enrollment", "achieved", "POS"]]}
{"row_id": 1283, "sent_id": "1283_0", "text": "FDA approved on June 10, 2024.", "triplets": [["regulatory", "FDA approved", "POS"]]}
{"row_id": 1286, "sent_id": "1286_0", "text": "Phase 2 topline data reported that the study met its primary endpoint, noted June 11, 2024.", "triplets": [["endpoint", "met", "POS"], ["phase", "met", "POS"], ["clinical", "met", "POS"]]}
{"row_id": 1287, "sent_id": "1287_0", "text": "Phase 2 topline data reported that the study met its primary endpoint, noted June 11, 2024.", "triplets": [["endpoint", "met", "POS"], ["phase", "met", "POS"], ["clinical", "met", "POS"]]}
{"row_id": 1290, "sent_id": "1290_0", "text": "FDA Approved on June 11, 2024.", "triplets": [["regulatory", "FDA Approved", "POS"]]}
{"row_id": 1291, "sent_id": "1291_0", "text": "FDA Approved on June 11, 2024.", "triplets": [["regulatory", "FDA Approved", "POS"]]}
{"row_id": 1298, "sent_id": "1298_0", "text": "Phase 1 first cohort completed, noted June 11, 2024.", "triplets": [["phase", "first cohort completed", "POS"], ["clinical", "first cohort completed", "POS"]]}
{"row_id": 1304, "sent_id": "1304_0", "text": "Phase 2 trial initiated and IND cleared by the FDA, noted June 12, 2024.", "triplets": [["phase", "cleared by the FDA", "POS"], ["regulatory", "cleared by the FDA", "POS"]]}
{"row_id": 1305, "sent_id": "1305_0", "text": "Preclinical data presented at EULAR demonstrated selective enhancement of Treg Cell function through novel agonistic mechanism, noted June 12, 2024.", "triplets": [["clinical", "data presented at EULAR", "POS"]]}
{"row_id": 1306, "sent_id": "1306_0", "text": "Approved June 12, 2024.", "triplets": [["catalyst", "Approved", "POS"]]}
{"row_id": 1308, "sent_id": "1308_0", "text": "Phase 3 trial did met its primary endpoint, noted June 12, 2024.", "triplets": [["endpoint", "met", "POS"], ["phase", "met", "POS"]]}
{"row_id": 1309, "sent_id": "1309_0", "text": "Phase 3 trial did not meet its primary endpoint, noted June 12, 2024.", "triplets": [["endpoint", "did not meet", "NEG"], ["phase", "did not meet", "NEG"]]}
{"row_id": 1311, "sent_id": "1311_0", "text": "Phase 3 met its primary vaccine efficacy endpoint demonstrating non-inferior vaccine efficacy against COVID-19 compared to Spikevax in participants 12 years of age and older, noted June 13, 2024.", "triplets": [["phase", "met", "POS"]]}
{"row_id": 1314, "sent_id": "1314_0", "text": "Phase 1/2 data presented at EHA reported that treatment was well tolerated up to doses of 6 mg/kg QW with observed clinical benefit in adult pts with R/R AMLand a maximum response rate seen at a targ", "triplets": [["safety", "well tolerated", "POS"], ["phase", "well tolerated", "POS"]]}
{"row_id": 1315, "sent_id": "1315_0", "text": "Phase 1/2 data presented at EHA reported that treatment was well tolerated up to doses of 6 mg/kg QW with observed clinical benefit in adult pts with R/R AMLand a maximum response rate seen at a targ", "triplets": [["safety", "well tolerated", "POS"], ["phase", "well tolerated", "POS"]]}
{"row_id": 1316, "sent_id": "1316_0", "text": "Phase 3 data presented at EULAR reported significant improvement on the primary pain endpoint and on all six key secondary endpoints, noted June 14, 2024.", "triplets": [["endpoint", "significant improvement", "POS"], ["phase", "significant improvement", "POS"], ["financial", "significant improvement", "POS"], ["clinical", "significant improvement", "POS"]]}
{"row_id": 1317, "sent_id": "1317_0", "text": "Phase 2 trial data presented at EHA reported that 55.6% of the mITT24 patients achieved an overall erythroid response over the first 24 weeks of treatment, noted June 14, 2024.", "triplets": [["phase", "achieved", "POS"]]}
{"row_id": 1318, "sent_id": "1318_0", "text": "Phase 2 trial data presented at EHA reported that 55.6% of the mITT24 patients achieved an overall erythroid response over the first 24 weeks of treatment, noted June 14, 2024.", "triplets": [["phase", "achieved", "POS"]]}
{"row_id": 1322, "sent_id": "1322_0", "text": "Phase 1 initial data in healthy volunteers shared at EHA reported that mean serum iron reduction of more than 50% from baseline was achieved for both 150- and 300-mg doses, noted June 14, 2024.", "triplets": [["phase", "achieved", "POS"]]}
{"row_id": 1324, "sent_id": "1324_0", "text": "Phase 2 presented at EHA continues to be well-tolerated and has now demonstrated compelling efficacy results in two reporting cohorts, noted June 14, 2024.", "triplets": [["safety", "well-tolerated", "POS"], ["phase", "well-tolerated", "POS"]]}
{"row_id": 1328, "sent_id": "1328_0", "text": "Phase 1/2 manufacturing data presented at EHA reported that reproducibly met the high viability threshold across 14 development runs using healthy and sickle cell trait donor cells and nine GMP clinic", "triplets": [["phase", "met", "POS"]]}
{"row_id": 1330, "sent_id": "1330_0", "text": "Phase 1/2 data presented at EHA reported that treatment was well-tolerated and demonstrated a safety profile consistent with myeloablative conditioning with busulfan and autologous hematopoietic stem", "triplets": [["safety", "well-tolerated", "POS"], ["phase", "well-tolerated", "POS"]]}
{"row_id": 1334, "sent_id": "1334_0", "text": "Approved June 14, 2024.", "triplets": [["catalyst", "Approved", "POS"]]}
{"row_id": 1343, "sent_id": "1343_0", "text": "Phase 1 data presented at EULAR reported that treatment was generally well tolerated, with total B cell counts were dose-dependently reduced in all participants, noted June 14, 2024.", "triplets": [["safety", "well tolerated", "POS"], ["phase", "well tolerated", "POS"], ["clinical", "well tolerated", "POS"]]}
{"row_id": 1344, "sent_id": "1344_0", "text": "Phase 1/2 additional data presented at EHA showed that out of 20 evaluable subjects across all treatment lines, 45% achieved a composite complete remission (CRc), including 89% with poor prognosis cy", "triplets": [["phase", "achieved", "POS"]]}
{"row_id": 1346, "sent_id": "1346_0", "text": "Approved June 14, 2024.", "triplets": [["catalyst", "Approved", "POS"]]}
{"row_id": 1348, "sent_id": "1348_0", "text": "Phase 1b data reported that 100% of treated leukemia patients (n=10/10) achieved durable complete remission (CR) at 1-year, noted June 15, 2024.", "triplets": [["endpoint", "achieved", "POS"], ["sample", "achieved", "POS"], ["phase", "achieved", "POS"]]}
{"row_id": 1354, "sent_id": "1354_0", "text": "Phase 2b interim analysis demonstrated a statistically significant (-3.82, p<0.0001) improvement in pruritus for volixibat and a placebo-adjusted difference of -2.32 points in the primary endpoint, p=", "triplets": [["endpoint", "statistically significant", "POS"], ["pvalue", "statistically significant", "POS"], ["phase", "statistically significant", "POS"]]}
{"row_id": 1359, "sent_id": "1359_0", "text": "Phase 3 data presented at EHA reported that 42.3% (n=55/130) of patients in the mitapivat arm achieved a hemoglobin response, compared to 1.6% (n=1/64) of patients in the placebo arm, noted June 17, 2", "triplets": [["sample", "achieved", "POS"], ["phase", "achieved", "POS"]]}
{"row_id": 1361, "sent_id": "1361_0", "text": "Approved June 17, 2024.", "triplets": [["catalyst", "Approved", "POS"]]}
{"row_id": 1362, "sent_id": "1362_0", "text": "Phase 3 trial did not meet its primary endpoint, noted June 17, 2024.", "triplets": [["endpoint", "did not meet", "NEG"], ["phase", "did not meet", "NEG"]]}
{"row_id": 1363, "sent_id": "1363_0", "text": "Phase 3 trial did not meet its primary endpoint, noted June 17, 2024.", "triplets": [["endpoint", "did not meet", "NEG"], ["phase", "did not meet", "NEG"]]}
{"row_id": 1364, "sent_id": "1364_0", "text": "Approved June 17, 2024.", "triplets": [["catalyst", "Approved", "POS"]]}
{"row_id": 1365, "sent_id": "1365_0", "text": "Phase 3 topline data reported that it met its first co-primary endpoint demonstrating rapid cessation of status epilepticus in a highly refractory patient population but failed to achieve statistical", "triplets": [["endpoint", "met", "POS"], ["phase", "met", "POS"], ["clinical", "met", "POS"]]}
{"row_id": 1366, "sent_id": "1366_0", "text": "Phase 3 topline data reported that it met its first co-primary endpoint demonstrating rapid cessation of status epilepticus in a highly refractory patient population but failed to achieve statistical", "triplets": [["endpoint", "met", "POS"], ["phase", "met", "POS"], ["clinical", "met", "POS"]]}
{"row_id": 1367, "sent_id": "1367_0", "text": "Phase 2 placed on clinical hold due to 2 deaths in the DENALI study, noted June 18, 2024.", "triplets": [["phase", "clinical hold", "NEG"], ["regulatory", "clinical hold", "NEG"]]}
{"row_id": 1368, "sent_id": "1368_0", "text": "Phase 2 study placed in clinical hold after 2 recent deaths presumed sepsis in the study, noted June 18, 2024.", "triplets": [["phase", "clinical hold", "NEG"], ["regulatory", "clinical hold", "NEG"]]}
{"row_id": 1369, "sent_id": "1369_0", "text": "Phase 3 trial dosing initiated, noted June 18, 2024.", "triplets": [["phase", "dosing initiated", "POS"], ["clinical", "dosing initiated", "POS"]]}
{"row_id": 1370, "sent_id": "1370_0", "text": "Phase 3 trial did not meet the dual primary endpoints of improvement in overall survival (OS) versus paclitaxel in combination with placebo in either the overall trial population or in a subgroup of p", "triplets": [["endpoint", "did not meet", "NEG"], ["phase", "did not meet", "NEG"]]}
{"row_id": 1372, "sent_id": "1372_0", "text": "Phase 3 topline results reported that the trial met the primary endpoint of change from baseline at Week 6 on the Montgomery-\u00c3...sberg Depression Rating Scale (MADRS) total score versus placebo, noted Ju", "triplets": [["endpoint", "met", "POS"], ["phase", "met", "POS"], ["clinical", "met", "POS"]]}
{"row_id": 1375, "sent_id": "1375_0", "text": "Approved June 18, 2024.", "triplets": [["catalyst", "Approved", "POS"]]}
{"row_id": 1376, "sent_id": "1376_0", "text": "Approved June 18, 2024.", "triplets": [["catalyst", "Approved", "POS"]]}
{"row_id": 1378, "sent_id": "1378_0", "text": "Phase 1b dosing initiated, noted June 18, 2024.", "triplets": [["phase", "dosing initiated", "POS"], ["clinical", "dosing initiated", "POS"]]}
{"row_id": 1381, "sent_id": "1381_0", "text": "Phase 1/2 trial presented at the IRSF ASCEND 2024 Rett Syndrome National Summit showed that high-dose has been well-tolerated, and low-dose continues to show a favorable safety profile, the company al", "triplets": [["safety", "well-tolerated", "POS"], ["phase", "well-tolerated", "POS"]]}
{"row_id": 1382, "sent_id": "1382_0", "text": "Phase 1/2 data in the 65-subject Phase 2 portion, the Natrunix arm showed fewer overall adverse events, a 28% reduction in serious adverse events, 33% less hospitalization days, and improved symptoms", "triplets": [["safety", "serious adverse events", "NEG"], ["phase", "serious adverse events", "NEG"]]}
{"row_id": 1383, "sent_id": "1383_0", "text": "FDA Approval on June 18, 2024.", "triplets": [["regulatory", "FDA Approval", "POS"]]}
{"row_id": 1385, "sent_id": "1385_0", "text": "IND approved in China, noted June 19, 2024.", "triplets": [["catalyst", "approved", "POS"]]}
{"row_id": 1391, "sent_id": "1391_0", "text": "Phase 1/2a preliminary data from Phase 1, involving healthy participants, showed ELE-101 was well-tolerated with no serious adverse events, demonstrating a dose-proportional PK profile and inducing sh", "triplets": [["safety", "well-tolerated", "NEU"], ["phase", "well-tolerated", "NEU"]]}
{"row_id": 1392, "sent_id": "1392_0", "text": "Preclinical data demonstrated statistically significant, dose-dependent increases in seizure threshold and protection against induced seizures.", "triplets": [["catalyst", "statistically significant", "POS"]]}
{"row_id": 1392, "sent_id": "1392_1", "text": "While not statistically significant, preliminary data pr", "triplets": [["endpoint", "statistically significant", "NEU"]]}
{"row_id": 1394, "sent_id": "1394_0", "text": "IND cleared by the FDA, noted June 20, 2024.", "triplets": [["regulatory", "cleared by the FDA", "POS"]]}
{"row_id": 1396, "sent_id": "1396_0", "text": "NDA submitted to FDA, noted June 20, 2024.", "triplets": [["regulatory", "NDA submitted", "POS"]]}
{"row_id": 1397, "sent_id": "1397_0", "text": "NDA submitted to FDA, noted June 20, 2024.", "triplets": [["regulatory", "NDA submitted", "POS"]]}
{"row_id": 1398, "sent_id": "1398_1", "text": "MM120 met its primary and key secondary endpoints and demonstrated a rapid, clinically meaningful, and", "triplets": [["endpoint", "met", "POS"], ["financial", "met", "POS"]]}
{"row_id": 1399, "sent_id": "1399_0", "text": "Phase 2b trial did not meet primary endpoint, noted June 20, 2024.", "triplets": [["endpoint", "did not meet", "NEG"], ["phase", "did not meet", "NEG"]]}
{"row_id": 1400, "sent_id": "1400_0", "text": "FDA Approved on June 21, 2024.", "triplets": [["regulatory", "FDA Approved", "POS"]]}
{"row_id": 1401, "sent_id": "1401_0", "text": "NDA resubmitted to FDA, noted June 21, 2024.", "triplets": [["regulatory", "NDA resubmitted", "POS"]]}
{"row_id": 1403, "sent_id": "1403_0", "text": "Phase 3 trial data presented at ADA showed that tirzepatide achieved all primary and key secondary endpoints for both the efficacyi and treatment-regimenii estimands and demonstrated a mean reduction", "triplets": [["endpoint", "achieved", "POS"], ["phase", "achieved", "POS"], ["financial", "achieved", "POS"], ["clinical", "achieved", "POS"]]}
{"row_id": 1404, "sent_id": "1404_0", "text": "FDA approved on June 21, 2024.", "triplets": [["regulatory", "FDA approved", "POS"]]}
{"row_id": 1405, "sent_id": "1405_0", "text": "FDA approved on June 21, 2024.", "triplets": [["regulatory", "FDA approved", "POS"]]}
{"row_id": 1410, "sent_id": "1410_0", "text": "Preclinical data presented at ADA shown to be superior compared to tirzepatide, noted June 22, 2024.", "triplets": [["clinical", "data presented at ADA", "POS"]]}
{"row_id": 1411, "sent_id": "1411_0", "text": "Data presented at ADA proves inhaled insulin is as effective as usual care for adults living with T1D meeting the primary endpoint, noted June 22, 2024.", "triplets": [["endpoint", "Data presented at ADA", "POS"], ["clinical", "Data presented at ADA", "POS"]]}
{"row_id": 1414, "sent_id": "1414_0", "text": "Phase 2 data presented at ADA highlights the impressive lean mass preservation achieved with pemvidutide.", "triplets": [["phase", "achieved", "POS"], ["clinical", "achieved", "POS"]]}
{"row_id": 1416, "sent_id": "1416_0", "text": "Preclinical data presented at ADA showed that a single administration of Rejuva reduced fat mass and improved glycemia in the well-validated diet-induced obesity (DIO) mouse model.", "triplets": [["clinical", "data presented at ADA", "POS"]]}
{"row_id": 1418, "sent_id": "1418_0", "text": "Phase 1b data from cohort 3 in the 3 mg/kg dose showed a continued mechanistic dose response, with statistically significant increases in urinary PC1 and PC2 compared to placebo, noted June 24, 2024.", "triplets": [["phase", "statistically significant", "POS"]]}
{"row_id": 1419, "sent_id": "1419_1", "text": "Fast track designation granted by the FDA on June 24, 2024.", "triplets": [["regulatory", "Fast track", "POS"]]}
{"row_id": 1420, "sent_id": "1420_0", "text": "Phase 3 topline data reported that study met the main goal in a late-stage study testing it as a treatment for a type of heart disease, noted June 24, 2024.", "triplets": [["phase", "met", "POS"], ["clinical", "met", "POS"]]}
{"row_id": 1424, "sent_id": "1424_0", "text": "The IND cleared by the FDA on June 24, 2024", "triplets": [["regulatory", "cleared by the FDA", "POS"]]}
{"row_id": 1425, "sent_id": "1425_0", "text": "Phase 1 top-line data of gemini administration induced statistically significant, dose dependent changes in key biomarkers of activity, noted June 24, 2024.", "triplets": [["phase", "statistically significant", "POS"], ["clinical", "statistically significant", "POS"]]}
{"row_id": 1426, "sent_id": "1426_0", "text": "Phase 3 reported the successful treatment of a 22-year-old male with polymicrobial necrotizing fasciitis using MAT2203, their oral formulation of amphotericin B.", "triplets": [["phase", "successful", "POS"]]}
{"row_id": 1427, "sent_id": "1427_0", "text": "Phase 2b showed it was well-tolerated across 1,027 patients, with an adverse event profile comparable to placebo, noted June 24, 2024.", "triplets": [["safety", "well-tolerated", "NEU"], ["sample", "well-tolerated", "NEU"], ["phase", "well-tolerated", "NEU"]]}
{"row_id": 1428, "sent_id": "1428_0", "text": "Phase 2 data presented at Bi-Annual In-SIGHT ppeared safe and well-tolerated with a median 17% reduction in the total polyp burden at 12 months compared with baseline and an overall 75% non-progressio", "triplets": [["safety", "well-tolerated", "POS"], ["phase", "well-tolerated", "POS"]]}
{"row_id": 1431, "sent_id": "1431_0", "text": "FDA Approved on June 24, 2024.", "triplets": [["regulatory", "FDA Approved", "POS"]]}
{"row_id": 1433, "sent_id": "1433_0", "text": "IND cleared by the FDA, noted June 24, 2024.", "triplets": [["regulatory", "cleared by the FDA", "POS"]]}
{"row_id": 1434, "sent_id": "1434_0", "text": "Preclinical data recently found that its host-mimetic clinical drug candidate NV-387 was substantially superior to the three approved drugs against influenza, noted June 24, 2024.", "triplets": [["catalyst", "approved", "POS"]]}
{"row_id": 1436, "sent_id": "1436_0", "text": "Preclinical data presented at ADA support the potential of SRK-439 to increase lean mass and contribute to a favorable body composition following withdrawal from GLP-1 RA treatment, noted June 24, 202", "triplets": [["clinical", "withdrawal", "NEU"]]}
{"row_id": 1437, "sent_id": "1437_0", "text": "Preclinical data presented at ADA showed that treatment induces insulin production, improves insulin sensitivity and reduces insulin resistance in preclinical model of type 2 diabetes, noted June 24,", "triplets": [["clinical", "data presented at ADA", "POS"]]}
{"row_id": 1442, "sent_id": "1442_0", "text": "Phase 3 trial did not meet statistical significance for the primary endpoint of disease-free survival (DFS) versus placebo, noted June 25, 2024.", "triplets": [["endpoint", "did not meet", "NEG"], ["phase", "did not meet", "NEG"]]}
{"row_id": 1443, "sent_id": "1443_0", "text": "Phase 3 trial demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint, noted June 25, 2024.", "triplets": [["endpoint", "statistically significant", "POS"], ["phase", "statistically significant", "POS"]]}
{"row_id": 1444, "sent_id": "1444_0", "text": "Phase 3 dosing initiated, noted June 25, 2024.", "triplets": [["phase", "dosing initiated", "POS"], ["clinical", "dosing initiated", "POS"]]}
{"row_id": 1448, "sent_id": "1448_0", "text": "Phase 1b/2a data reported a 46% mean reduction in CSF mutant huntingtin (mHTT) protein compared to placebo, preservation of wild-type huntingtin (wtHTT) protein, and generally safe and well-tolerated", "triplets": [["safety", "well-tolerated", "POS"], ["phase", "well-tolerated", "POS"]]}
{"row_id": 1449, "sent_id": "1449_0", "text": "Phase 3 data showed no evidence of tachyphylaxis, tolerance, or withdrawal with the 180 mcg dose over seven days of as-needed treatment.", "triplets": [["phase", "withdrawal", "NEG"]]}
{"row_id": 1452, "sent_id": "1452_0", "text": "CRL issued June 25, 2024.", "triplets": [["regulatory", "CRL", "NEG"]]}
{"row_id": 1454, "sent_id": "1454_0", "text": "Pivotal trial topline results reported that the trial met its standard bioequivalence (BE) criteria, noted June 25, 2024.", "triplets": [["phase", "met", "POS"], ["clinical", "met", "POS"]]}
{"row_id": 1455, "sent_id": "1455_0", "text": "Phase 1 data treatment was well-tolerated, with rapid viral elimination and no disease progression observed.", "triplets": [["safety", "well-tolerated", "POS"], ["phase", "well-tolerated", "POS"]]}
{"row_id": 1460, "sent_id": "1460_0", "text": "Phase 3 data reported that the trial met its primary endpoint, noted June 26, 2024.", "triplets": [["endpoint", "met", "POS"], ["phase", "met", "POS"]]}
{"row_id": 1463, "sent_id": "1463_0", "text": "Phase 3 trial did not meet its primary endpoint, noted June 26, 2024.", "triplets": [["endpoint", "did not meet", "NEG"], ["phase", "did not meet", "NEG"]]}
{"row_id": 1464, "sent_id": "1464_0", "text": "Phase 1 data presented at ESMO GI reported an overall response (OR) across tumor types was 18.2% (n=33), including four confirmed and two unconfirmed partial responses (PR), noted June 26, 2024.", "triplets": [["endpoint", "data presented at ESMO", "POS"], ["sample", "data presented at ESMO", "POS"], ["phase", "data presented at ESMO", "POS"], ["clinical", "data presented at ESMO", "POS"]]}
{"row_id": 1465, "sent_id": "1465_0", "text": "Approved June 26, 2024.", "triplets": [["catalyst", "Approved", "POS"]]}
{"row_id": 1466, "sent_id": "1466_0", "text": "Approved June 26, 2024.", "triplets": [["catalyst", "Approved", "POS"]]}
{"row_id": 1467, "sent_id": "1467_0", "text": "CRL announced June 27, 2024.", "triplets": [["regulatory", "CRL", "NEG"]]}
{"row_id": 1468, "sent_id": "1468_0", "text": "Approved June 27, 2024.", "triplets": [["catalyst", "Approved", "POS"]]}
{"row_id": 1469, "sent_id": "1469_0", "text": "Approved June 27, 2024.", "triplets": [["catalyst", "Approved", "POS"]]}
{"row_id": 1470, "sent_id": "1470_0", "text": "Phase 2 data reported that 100% (6/6) of evaluable participants who had completed the six-month study achieved target ANC increase, noted June 27, 2024.", "triplets": [["phase", "achieved", "POS"]]}
{"row_id": 1472, "sent_id": "1472_0", "text": "Phase 1/2 demonstrates favorable safety and pharmacodynamic profile dosing 0.5 mg using a 21/7 schedule; currently assessing 0.75 mg dose level, noted June 27, 2024.", "triplets": [["safety", "favorable safety", "POS"], ["phase", "favorable safety", "POS"]]}
{"row_id": 1476, "sent_id": "1476_0", "text": "Second part of Phase 3 trial enrollment completed, noted June 27, 2024", "triplets": [["phase", "enrollment completed", "POS"], ["enrollment", "enrollment completed", "POS"]]}
{"row_id": 1477, "sent_id": "1477_0", "text": "Phase 2b data reported that the trial met with statistically significant dose response with up to 43.6% relative reduction (2.1 day improvement) in median time to solid food tolerance versus placebo i", "triplets": [["phase", "met", "POS"]]}
{"row_id": 1483, "sent_id": "1483_0", "text": "CRL issued June 28, 2024.", "triplets": [["regulatory", "CRL", "NEG"]]}
{"row_id": 1485, "sent_id": "1485_0", "text": "Phase 2 data reported that in the NEST-2 cohort, 78% (7/9) of MSS patients achieved pathologic responses of at least 50% tumor regression, with 56% (5/9) reaching complete pathologic responses, noted", "triplets": [["phase", "achieved", "POS"]]}
{"row_id": 1487, "sent_id": "1487_0", "text": "Phase 1 data reported that the trial met its objective, demonstrating a favorable safety and tolerability profile with no serious adverse events, noted July 1, 2024.", "triplets": [["safety", "met", "NEU"], ["phase", "met", "NEU"]]}
{"row_id": 1489, "sent_id": "1489_0", "text": "Phase 3 study showed that the objective response rate by blinded independent central review in the fully enrolled ENVASARC pivotal trial in the 82 evaluable patients is 5% (four responders) and did no", "triplets": [["phase", "fully enrolled", "POS"], ["enrollment", "fully enrolled", "POS"]]}
{"row_id": 1490, "sent_id": "1490_0", "text": "Phase 2 enrollment completed for the study in Europe at 0.3 mg/kg dose level, with data expected later this year.", "triplets": [["phase", "enrollment completed", "POS"], ["enrollment", "enrollment completed", "POS"]]}
{"row_id": 1492, "sent_id": "1492_0", "text": "Phase 1b study dosing initiated, noted July 1, 2024.", "triplets": [["phase", "dosing initiated", "POS"], ["clinical", "dosing initiated", "POS"]]}
{"row_id": 1493, "sent_id": "1493_0", "text": "Phase 1b study dosing initiated, noted July 1, 2024.", "triplets": [["phase", "dosing initiated", "POS"], ["clinical", "dosing initiated", "POS"]]}
{"row_id": 1494, "sent_id": "1494_0", "text": "Phase 2b trial met primary endpoint with statistical significance, noted July 2, 2024.", "triplets": [["endpoint", "met", "POS"], ["phase", "met", "POS"]]}
{"row_id": 1496, "sent_id": "1496_0", "text": "FDA approval for ANDA, noted July 2, 2024.", "triplets": [["regulatory", "FDA approval", "POS"]]}
{"row_id": 1497, "sent_id": "1497_0", "text": "Phase 3 update showed dose-dependent and statistically significant improvements in cognition in the overall enrolled PD population.", "triplets": [["phase", "statistically significant", "POS"]]}
{"row_id": 1497, "sent_id": "1497_1", "text": "Buntanetap's activity resulted in statistically significant improvem", "triplets": [["catalyst", "statistically significant", "POS"]]}
{"row_id": 1498, "sent_id": "1498_0", "text": "Fast track designation, granted by the FDA, noted July 2, 2024.", "triplets": [["regulatory", "Fast track", "POS"]]}
{"row_id": 1500, "sent_id": "1500_0", "text": "Phase 1 data presented at ISPNO 2024 showed that overall, the treatment was well tolerated by patients.", "triplets": [["safety", "well tolerated", "POS"], ["phase", "well tolerated", "POS"]]}
{"row_id": 1503, "sent_id": "1503_0", "text": "Approved July 2, 2024.", "triplets": [["catalyst", "Approved", "POS"]]}
{"row_id": 1505, "sent_id": "1505_0", "text": "Phase 3 additional results from study presented at the 7th World Bronchiectasis Conference confirmed that the study met its primary endpoint, with both 10 mg and 25 mg doses significantly reducing the", "triplets": [["endpoint", "met", "POS"], ["phase", "met", "POS"]]}
{"row_id": 1508, "sent_id": "1508_0", "text": "Phase 2 trial data reported significant improvement of the viability of segments from baseline to six months, noted July 8, 2024.", "triplets": [["phase", "significant improvement", "POS"], ["clinical", "significant improvement", "POS"]]}
{"row_id": 1509, "sent_id": "1509_0", "text": "Fast track designation granted by the FDA, noted July 8, 2024.", "triplets": [["regulatory", "Fast track", "POS"]]}
{"row_id": 1510, "sent_id": "1510_0", "text": "Phase 2b topline data reported that the trial did not meet its primary endpoint of efficacy against moderate or severe acute gastroenteritis (AGE) events due to GI.1 or GII.4 norovirus genotypes, note", "triplets": [["endpoint", "did not meet", "NEG"], ["phase", "did not meet", "NEG"], ["clinical", "did not meet", "NEG"]]}
{"row_id": 1516, "sent_id": "1516_0", "text": "Phase 2 trial ethic approval announced July 9, 2024.", "triplets": [["phase", "approval", "POS"], ["regulatory", "approval", "POS"]]}
{"row_id": 1517, "sent_id": "1517_0", "text": "BLA resubmitted on July 9, 2024.", "triplets": [["regulatory", "BLA resubmitted", "POS"]]}
{"row_id": 1518, "sent_id": "1518_0", "text": "BLA resubmitted on July 9, 2024.", "triplets": [["regulatory", "BLA resubmitted", "POS"]]}
{"row_id": 1521, "sent_id": "1521_1", "text": "No discontinuations or serious adverse events were reported, noted July 9, 2024.", "triplets": [["safety", "serious adverse events", "NEG"]]}
{"row_id": 1528, "sent_id": "1528_0", "text": "FDA Approved on July 9, 2024.", "triplets": [["regulatory", "FDA Approved", "POS"]]}
{"row_id": 1530, "sent_id": "1530_0", "text": "Swine Model data reported that treatment was well-tolerated by all of the pigs and demonstrated a long-term, slow-release profile, noted July 10, 2024.", "triplets": [["safety", "well-tolerated", "POS"]]}
{"row_id": 1531, "sent_id": "1531_0", "text": "Data reported a 68% improvement in responder rate results from patients who achieved both the conjunctival staining \"sign\" and ocular pain \"symptom\" endpoints, noted July 10, 2024.", "triplets": [["catalyst", "achieved", "POS"]]}
{"row_id": 1536, "sent_id": "1536_0", "text": "CRL announced July 10, 2024.", "triplets": [["regulatory", "CRL", "NEG"]]}
{"row_id": 1538, "sent_id": "1538_0", "text": "Phase 2 trial enrollment completed, noted July 11, 2024.", "triplets": [["phase", "enrollment completed", "POS"], ["enrollment", "enrollment completed", "POS"]]}
{"row_id": 1539, "sent_id": "1539_0", "text": "Fast Track designation application submitted to the FDA, noted July 11, 2024.", "triplets": [["regulatory", "Fast Track", "POS"]]}
{"row_id": 1541, "sent_id": "1541_0", "text": "Phase 1/2 dosing initiated in China, noted July 12, 2024.", "triplets": [["phase", "dosing initiated", "POS"], ["clinical", "dosing initiated", "POS"]]}
{"row_id": 1542, "sent_id": "1542_0", "text": "NDA submitted July 12, 2024.", "triplets": [["regulatory", "NDA submitted", "POS"]]}
{"row_id": 1545, "sent_id": "1545_0", "text": "Phase 1a data reported that treatment was well tolerated with no treatment-related serious adverse events, noted July 15, 2024.", "triplets": [["safety", "well tolerated", "NEU"]]}
{"row_id": 1549, "sent_id": "1549_0", "text": "FDA ANDA Approval on July 15, 2024.", "triplets": [["regulatory", "Approval", "POS"]]}
{"row_id": 1550, "sent_id": "1550_0", "text": "Phase 2a final 320mg data of the cohort met its primary endpoint of safety, demonstrating that bexotegrast was well tolerated up to 40 weeks of treatment, noted July 15, 2024.", "triplets": [["endpoint", "met", "POS"], ["safety", "met", "POS"], ["phase", "met", "POS"]]}
{"row_id": 1551, "sent_id": "1551_0", "text": "IND Cleared by the FDA, noted July 15, 2024.", "triplets": [["regulatory", "Cleared by the FDA", "POS"]]}
{"row_id": 1552, "sent_id": "1552_0", "text": "FDA granted Regenerative Medicine Advanced Therapies (RMAT) designation, noted July 15, 2024.", "triplets": [["regulatory", "FDA granted", "POS"]]}
{"row_id": 1555, "sent_id": "1555_0", "text": "Company received FDA approval to use a new crystalline form of their drug buntanetap in future clinical trials for neurodegenerative disorders following June's 2024 patent filings for the new crystal", "triplets": [["regulatory", "FDA approval", "POS"]]}
{"row_id": 1558, "sent_id": "1558_0", "text": "Phase 2a trial enrollment completed, noted July 16, 2024.", "triplets": [["phase", "enrollment completed", "POS"], ["enrollment", "enrollment completed", "POS"]]}
{"row_id": 1559, "sent_id": "1559_0", "text": "IND Cleared by the FDA, noted July 16, 2024.", "triplets": [["regulatory", "Cleared by the FDA", "POS"]]}
{"row_id": 1560, "sent_id": "1560_0", "text": "Phase 2 24-week data reported reduction in anti-VEGF injection treatment burden through Week 24 achieved in 30 patients at planned Phase 3 dose (3E10 vg/eye) with 89% reduction in annualized injection", "triplets": [["sample", "achieved", "POS"], ["phase", "achieved", "POS"]]}
{"row_id": 1566, "sent_id": "1566_0", "text": "Phase 3 enrollment completed, noted July 18, 2024", "triplets": [["phase", "enrollment completed", "POS"], ["enrollment", "enrollment completed", "POS"]]}
{"row_id": 1567, "sent_id": "1567_0", "text": "Phase 2 study update following a Type C Meeting with the FDA which stated that it was open to considering the accelerated approval pathway, noted July 18, 2024.", "triplets": [["phase", "approval", "POS"], ["regulatory", "approval", "POS"]]}
{"row_id": 1568, "sent_id": "1568_0", "text": "Phase 2 preliminary data showed a 19.4% overall response rate and 90% 6-month survival rate, and FDA advice against seeking Accelerated Approval.", "triplets": [["phase", "Approval", "POS"], ["regulatory", "Approval", "POS"]]}
{"row_id": 1569, "sent_id": "1569_1", "text": "A top responder patient achieved 9.1 months of progression-free survival, quadrupling the PFS of patients in similar studies.", "triplets": [["endpoint", "achieved", "POS"]]}
{"row_id": 1570, "sent_id": "1570_0", "text": "FDA Approved on July 18, 2024.", "triplets": [["regulatory", "FDA Approved", "POS"]]}
{"row_id": 1571, "sent_id": "1571_0", "text": "Phase 1 SAD data reported no serious adverse events or severe treatment-emergent adverse events, noted July 18, 2024.", "triplets": [["safety", "serious adverse events", "NEG"], ["phase", "serious adverse events", "NEG"]]}
{"row_id": 1572, "sent_id": "1572_0", "text": "Phase 3 trial met its primary end point, noted July 18, 2024.", "triplets": [["phase", "met", "POS"]]}
{"row_id": 1574, "sent_id": "1574_0", "text": "Phase 3 did not meet the primary endpoint of reduced acute pelvic pain compared to the Sham treatment at three months post-procedure.", "triplets": [["endpoint", "did not meet", "NEG"], ["phase", "did not meet", "NEG"]]}
{"row_id": 1577, "sent_id": "1577_0", "text": "IND Cleared by the FDA, noted July 22, 2024", "triplets": [["regulatory", "Cleared by the FDA", "POS"]]}
{"row_id": 1584, "sent_id": "1584_0", "text": "Phase 3 Type-C meeting FDA feedback resulted in successful preparatory regulatory interactions for the design of this registrational trial, noted July 22, 2024.", "triplets": [["phase", "successful", "POS"]]}
{"row_id": 1585, "sent_id": "1585_0", "text": "Phase 2 Run-in cohort enrollment completed, noted July 22, 2024.", "triplets": [["phase", "enrollment completed", "POS"], ["enrollment", "enrollment completed", "POS"]]}
{"row_id": 1586, "sent_id": "1586_0", "text": "Phase 2 Run-in cohort enrollment completed, noted July 22, 2024.", "triplets": [["phase", "enrollment completed", "POS"], ["enrollment", "enrollment completed", "POS"]]}
{"row_id": 1587, "sent_id": "1587_0", "text": "Phase 3 study did not meet its primary endpoint, noted July 23, 2023.", "triplets": [["endpoint", "did not meet", "NEG"], ["phase", "did not meet", "NEG"]]}
{"row_id": 1589, "sent_id": "1589_0", "text": "Phase 2 dosing initiated, noted July 23, 2024.", "triplets": [["phase", "dosing initiated", "POS"], ["clinical", "dosing initiated", "POS"]]}
{"row_id": 1590, "sent_id": "1590_0", "text": "Phase 2b/3 study met its primary safety and efficacy endpoints, including reducing medically attended lower respiratory infections (MALRI) caused by RSV through Day 150, noted July 23, 2024.", "triplets": [["safety", "met", "POS"], ["phase", "met", "POS"]]}
{"row_id": 1591, "sent_id": "1591_0", "text": "IND cleared by the FDA for collaborator Moffitt Cancer Center, noted July 23, 2024.", "triplets": [["regulatory", "cleared by the FDA", "POS"]]}
{"row_id": 1592, "sent_id": "1592_0", "text": "Phase 2 enrollment completed, noted July 23, 2024.", "triplets": [["phase", "enrollment completed", "POS"], ["enrollment", "enrollment completed", "POS"]]}
{"row_id": 1599, "sent_id": "1599_0", "text": "Fast Track Designation (FTD) granted by the FDA, noted July 23, 2024.", "triplets": [["regulatory", "Fast Track", "POS"]]}
{"row_id": 1601, "sent_id": "1601_0", "text": "Phase 3 data met its primary and key secondary objectives of superiority compared to prophylaxis, noted on July 24, 2024.", "triplets": [["phase", "met", "POS"], ["financial", "met", "POS"]]}
{"row_id": 1602, "sent_id": "1602_0", "text": "Fast track designation granted by the FDA, noted July 24, 2024.", "triplets": [["regulatory", "Fast track", "POS"]]}
{"row_id": 1603, "sent_id": "1603_0", "text": "Phase 3 study dosing initiated, noted July 24, 2024.", "triplets": [["phase", "dosing initiated", "POS"], ["clinical", "dosing initiated", "POS"]]}
{"row_id": 1604, "sent_id": "1604_0", "text": "Phase 3 study dosing initiated, noted July 24, 2024.", "triplets": [["phase", "dosing initiated", "POS"], ["clinical", "dosing initiated", "POS"]]}
{"row_id": 1605, "sent_id": "1605_0", "text": "Phase 2b topline data did not demonstrate a statistically significant dose-response relationship on the primary endpoint in participants with essential tremor, noted July 24, 2025.", "triplets": [["endpoint", "statistically significant", "POS"], ["phase", "statistically significant", "POS"], ["clinical", "statistically significant", "POS"]]}
{"row_id": 1606, "sent_id": "1606_0", "text": "Phase 2b topline data did not demonstrate a statistically significant dose-response relationship on the primary endpoint in participants with essential tremor, noted July 24, 2025.", "triplets": [["endpoint", "statistically significant", "POS"], ["phase", "statistically significant", "POS"], ["clinical", "statistically significant", "POS"]]}
{"row_id": 1608, "sent_id": "1608_0", "text": "Phase 1b/2a unblinded safety data indicated that SON-080 was well-tolerated at both doses, with no evidence of a pro-inflammatory cytokine response, noted July 24, 2024.", "triplets": [["safety", "well-tolerated", "POS"], ["phase", "well-tolerated", "POS"]]}
{"row_id": 1609, "sent_id": "1609_0", "text": "FDA supplemental Approval on July 24, 2024.", "triplets": [["regulatory", "Approval", "POS"]]}
{"row_id": 1614, "sent_id": "1614_0", "text": "Fast Track designation granted by the FDA, noted July 25, 2024.", "triplets": [["regulatory", "Fast Track", "POS"]]}
{"row_id": 1615, "sent_id": "1615_0", "text": "Fast Track designation granted by the FDA, noted July 25, 2024.", "triplets": [["regulatory", "Fast Track", "POS"]]}
{"row_id": 1616, "sent_id": "1616_0", "text": "FDA Approval of label expansion on patients 12 months and older, noted July 25, 2024.", "triplets": [["regulatory", "FDA Approval", "POS"]]}
{"row_id": 1617, "sent_id": "1617_0", "text": "Phase 2 topline 15-week data met its primary safety and tolerability endpoint and demonstrated anti-fibrotic, anti-inflammatory, and anti-cholestatic effects across multiple disease-related secondary", "triplets": [["safety", "met", "POS"], ["phase", "met", "POS"], ["financial", "met", "POS"]]}
{"row_id": 1622, "sent_id": "1622_0", "text": "IND cleared by the FDA, noted July 25, 2024.", "triplets": [["regulatory", "cleared by the FDA", "POS"]]}
{"row_id": 1624, "sent_id": "1624_0", "text": "Phase 3 data met all primary and secondary pharmacokinetic endpoints, study expected to be completed by late 3Q / early 4Q 2024.", "triplets": [["phase", "met", "POS"], ["financial", "met", "POS"]]}
{"row_id": 1624, "sent_id": "1624_1", "text": "NDA filing expected 4Q 2024/ early 1Q 2025, noted July 25, 2024.", "triplets": [["regulatory", "NDA filing", "POS"]]}
{"row_id": 1627, "sent_id": "1627_0", "text": "FDA Oncologic Drugs Advisory Committee (ODAC) acknowledged that treatment met the primary endpoint of event-free survival (EFS), noted July 25, 2024.", "triplets": [["endpoint", "met", "POS"]]}
{"row_id": 1628, "sent_id": "1628_0", "text": "Phase 1/2 trial FDA granted Orphan drug designation and Rare Pediatric Disease Designation, noted July 25, 2024.", "triplets": [["phase", "FDA granted", "POS"], ["regulatory", "FDA granted", "POS"]]}
{"row_id": 1629, "sent_id": "1629_0", "text": "Phase 1a topline data demonstrated a favorable safety profile and tolerability across four ascending dose levels in healthy volunteers and showed dose dependent levels of PMN310 antibody in Cerebrospi", "triplets": [["safety", "favorable safety", "POS"], ["clinical", "favorable safety", "POS"]]}
{"row_id": 1631, "sent_id": "1631_0", "text": "Phase 2b topline data met its primary endpoint, showing statistically significant improvement in ALP (Alkaline Phosphatase) for both doses tested versus placebo, noted July 26, 2024.", "triplets": [["endpoint", "met", "POS"], ["phase", "met", "POS"], ["clinical", "met", "POS"]]}
{"row_id": 1632, "sent_id": "1632_0", "text": "Phase 3 FDA placed a clinical hold based on the discovery of a chromatographic signal in a recent human absorption, distribution, metabolism, and excretion (ADME) study of cadisegliatin that could not", "triplets": [["phase", "clinical hold", "NEG"], ["regulatory", "clinical hold", "NEG"]]}
{"row_id": 1633, "sent_id": "1633_0", "text": "IND placed on clinical hold, noted July 26, 2024.", "triplets": [["regulatory", "clinical hold", "NEG"]]}
{"row_id": 1637, "sent_id": "1637_0", "text": "Phase 2 data presented at AAIC showed a consistent trend in cognitive improvement compared to placebo across multiple measures, with participants treated for six months demonstrating a 39% slowing of", "triplets": [["effect", "data presented at AAIC", "POS"], ["phase", "data presented at AAIC", "POS"], ["clinical", "data presented at AAIC", "POS"]]}
{"row_id": 1640, "sent_id": "1640_0", "text": "Phase 2 trial did not meet its primary endpoint of change from baseline in mean CDAI score in either VTX958 dose group, noted July 29, 2024.", "triplets": [["endpoint", "did not meet", "NEG"], ["phase", "did not meet", "NEG"]]}
{"row_id": 1641, "sent_id": "1641_0", "text": "Phase 1 dosing initiated, noted July 29, 2024.", "triplets": [["phase", "dosing initiated", "POS"], ["clinical", "dosing initiated", "POS"]]}
{"row_id": 1642, "sent_id": "1642_0", "text": "Phase 1 dosing initiated, noted July 29, 2024.", "triplets": [["phase", "dosing initiated", "POS"], ["clinical", "dosing initiated", "POS"]]}
{"row_id": 1643, "sent_id": "1643_0", "text": "IND cleared by the FDA, noted July 29, 2024.", "triplets": [["regulatory", "cleared by the FDA", "POS"]]}
{"row_id": 1644, "sent_id": "1644_0", "text": "IND cleared by the FDA, noted July 29, 2024.", "triplets": [["regulatory", "cleared by the FDA", "POS"]]}
{"row_id": 1646, "sent_id": "1646_0", "text": "Phase 2a data presented at AAIC reported that there was a mean 14.1 pg/mL increase in the placebo treatment group (N=13) vs. mean 10.6 pg/mL reduction with neflamapimod treatment, noted July 29, 2024.", "triplets": [["sample", "data presented at AAIC", "POS"], ["phase", "data presented at AAIC", "POS"], ["clinical", "data presented at AAIC", "POS"]]}
{"row_id": 1647, "sent_id": "1647_0", "text": "Phase 3 data reported a a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to standard-of-care chemoimmunotherapy, noted July 29, 2024.", "triplets": [["endpoint", "statistically significant", "POS"], ["phase", "statistically significant", "POS"]]}
{"row_id": 1648, "sent_id": "1648_0", "text": "Phase 2 study met its primary endpoint, showing statistically significant and clinically meaningful complete response rates in both dose groups compared to placebo.", "triplets": [["endpoint", "met", "POS"], ["phase", "met", "POS"]]}
{"row_id": 1650, "sent_id": "1650_0", "text": "FDA approved via 505(b)(2) pathway, noted July 29, 2024.", "triplets": [["regulatory", "FDA approved", "POS"]]}
{"row_id": 1651, "sent_id": "1651_0", "text": "FDA approved on July 29, 2024.", "triplets": [["regulatory", "FDA approved", "POS"]]}
{"row_id": 1652, "sent_id": "1652_0", "text": "Phase 2 trial met its primary endpoint, noted July 30, 2024.", "triplets": [["endpoint", "met", "POS"], ["phase", "met", "POS"]]}
{"row_id": 1653, "sent_id": "1653_0", "text": "Phase 2 trial met its primary endpoint, noted July 30, 2024.", "triplets": [["endpoint", "met", "POS"], ["phase", "met", "POS"]]}
{"row_id": 1654, "sent_id": "1654_0", "text": "Phase 2 trial met its primary endpoint, noted July 30, 2024.", "triplets": [["endpoint", "met", "POS"], ["phase", "met", "POS"]]}
{"row_id": 1658, "sent_id": "1658_0", "text": "NDA submitted to FDA, noted July 30, 2024.", "triplets": [["regulatory", "NDA submitted", "POS"]]}
{"row_id": 1659, "sent_id": "1659_0", "text": "Preclinical new biomarker data to be presented at AAIC showed the ability to reduce \u00ce\u00b1-synuclein levels in cerebrospinal fluid.", "triplets": [["clinical", "data to be presented at AAIC", "POS"]]}
{"row_id": 1662, "sent_id": "1662_0", "text": "Phase 2/3 data did not meet the primary endpoint of overall survival as determined by the protocol pre-specified Bayesian statistical analysis, noted July 30, 2024.", "triplets": [["endpoint", "did not meet", "NEG"], ["phase", "did not meet", "NEG"]]}
{"row_id": 1663, "sent_id": "1663_0", "text": "Phase 3 trial did not meet the primary endpoint of overall survival, noted July 30, 2024.", "triplets": [["endpoint", "did not meet", "NEG"], ["phase", "did not meet", "NEG"]]}
{"row_id": 1665, "sent_id": "1665_0", "text": "Approved July 31, 2024.", "triplets": [["catalyst", "Approved", "POS"]]}
{"row_id": 1667, "sent_id": "1667_0", "text": "Breakthrough Therapy Designation granted by the FDA, noted July 31, 2024.", "triplets": [["regulatory", "Breakthrough Therapy", "POS"]]}
{"row_id": 1668, "sent_id": "1668_0", "text": "Phase 1/2 trial met primary endpoint, noted July 31, 2024.", "triplets": [["endpoint", "met", "POS"], ["phase", "met", "POS"]]}
{"row_id": 1670, "sent_id": "1670_0", "text": "Phase 2 enrollment completed, noted July 31, 2024.", "triplets": [["phase", "enrollment completed", "POS"], ["enrollment", "enrollment completed", "POS"]]}
{"row_id": 1671, "sent_id": "1671_1", "text": "It was well tolerated, without reports of liver enzyme elevation or bleeding events, across once daily doses ranges for 10 days.", "triplets": [["safety", "well tolerated", "POS"]]}
{"row_id": 1673, "sent_id": "1673_0", "text": "Phase 3 data reported that 28.1% of patients in the mitapivat arm achieved the primary endpoint of transfusion reduction response, compared to 11.8% of patients in the placebo arm, noted August 1, 202", "triplets": [["endpoint", "achieved", "POS"], ["phase", "achieved", "POS"]]}
{"row_id": 1674, "sent_id": "1674_0", "text": "Phase 3 data reported a statistically significant improvements in both primary endpoints, noted August 1, 2024.", "triplets": [["endpoint", "statistically significant", "POS"], ["phase", "statistically significant", "POS"]]}
{"row_id": 1675, "sent_id": "1675_1", "text": "It achieved a statistically significant higher clinical remission rate at week 26 compared to the placebo, noted on August 1, 2024.", "triplets": [["catalyst", "achieved", "POS"]]}
{"row_id": 1677, "sent_id": "1677_0", "text": "Approved August 1, 2024.", "triplets": [["catalyst", "Approved", "POS"]]}
{"row_id": 1678, "sent_id": "1678_0", "text": "NDA resubmitted August 1, 2024.", "triplets": [["regulatory", "NDA resubmitted", "POS"]]}
{"row_id": 1679, "sent_id": "1679_0", "text": "Phase 2 update reported that treatment was well tolerated with no drug-related SAEs and no cases of intraocular inflammation, noted August 1, 2024.", "triplets": [["safety", "well tolerated", "POS"], ["phase", "well tolerated", "POS"]]}
{"row_id": 1680, "sent_id": "1680_0", "text": "Phase 2 update reported that treatment was well tolerated with no drug-related SAEs and no cases of intraocular inflammation, noted August 1, 2024.", "triplets": [["safety", "well tolerated", "POS"], ["phase", "well tolerated", "POS"]]}
{"row_id": 1688, "sent_id": "1688_0", "text": "Phase 3 study determined by the FDA that the trial is not adequate to support a BLA filing for Iomab-B despite its statistically significant primary endpoint, noted August 5, 2024.", "triplets": [["endpoint", "statistically significant", "POS"], ["phase", "statistically significant", "POS"], ["regulatory", "statistically significant", "POS"]]}
{"row_id": 1699, "sent_id": "1699_0", "text": "Approved August 6, 2024.", "triplets": [["catalyst", "Approved", "POS"]]}
{"row_id": 1700, "sent_id": "1700_0", "text": "Phase 2 data demonstrated stable or improved diabetic retinopathy severity scores (DRSS) and a favorable safety profile at nine-months., noted August 7, 2024.", "triplets": [["endpoint", "favorable safety", "POS"], ["safety", "favorable safety", "POS"], ["phase", "favorable safety", "POS"]]}
{"row_id": 1702, "sent_id": "1702_0", "text": "Approved August 7, 2024.", "triplets": [["catalyst", "Approved", "POS"]]}
{"row_id": 1703, "sent_id": "1703_0", "text": "Approved August 8, 2024.", "triplets": [["catalyst", "Approved", "POS"]]}
{"row_id": 1704, "sent_id": "1704_0", "text": "Phase 3 top-line data reported that the trial met its primary endpoint, noted August 8, 2024.", "triplets": [["endpoint", "met", "POS"], ["phase", "met", "POS"], ["clinical", "met", "POS"]]}
{"row_id": 1705, "sent_id": "1705_0", "text": "Phase 3 trial met primary endpoint, noted August 8, 2024.", "triplets": [["endpoint", "met", "POS"], ["phase", "met", "POS"]]}
{"row_id": 1706, "sent_id": "1706_0", "text": "Approved August 8, 2024.", "triplets": [["catalyst", "Approved", "POS"]]}
{"row_id": 1708, "sent_id": "1708_0", "text": "Phase 1 trial met primary endpoint, noted August 8, 2024.", "triplets": [["endpoint", "met", "POS"], ["phase", "met", "POS"]]}
{"row_id": 1709, "sent_id": "1709_0", "text": "Phase 2 trial met its primary endpoint, noted August 8, 2024.", "triplets": [["endpoint", "met", "POS"], ["phase", "met", "POS"]]}
{"row_id": 1711, "sent_id": "1711_0", "text": "Phase 1/2 5 mg/kg cohort data reported a statistically significant 37% increase in exon 44 skipping and up to 66% skipping with delpacibart zotadirsen 5 mg/kg at four months, noted August 9, 2024.", "triplets": [["phase", "statistically significant", "POS"]]}
{"row_id": 1712, "sent_id": "1712_0", "text": "Approved August 9, 2024.", "triplets": [["catalyst", "Approved", "POS"]]}
{"row_id": 1715, "sent_id": "1715_0", "text": "Phase 3 data reported that ABRYSVO was well-tolerated and generated strong neutralizing responses after a single dose in adults \u00e2\u2030\u00a5 18 years of age, noted August 12, 2024.", "triplets": [["safety", "well-tolerated", "POS"], ["phase", "well-tolerated", "POS"]]}
{"row_id": 1716, "sent_id": "1716_0", "text": "Approved August 12, 2024.", "triplets": [["catalyst", "Approved", "POS"]]}
{"row_id": 1717, "sent_id": "1717_0", "text": "Approved August 12, 2024.", "triplets": [["catalyst", "Approved", "POS"]]}
{"row_id": 1725, "sent_id": "1725_0", "text": "Phase 1b topline data reported that treatment demonstrated a favorable safety profile and was well tolerated, with all adverse events classified as either mild or moderate, and most resolving on the d", "triplets": [["safety", "favorable safety", "POS"], ["phase", "favorable safety", "POS"], ["clinical", "favorable safety", "POS"]]}
{"row_id": 1726, "sent_id": "1726_0", "text": "Trial data reported that the trial achieved its primary endpoint, demonstrating that CNSide influenced treatment decisions in over 90% of cases, surpassing the 20% primary endpoint target, noted Augus", "triplets": [["endpoint", "achieved", "POS"]]}
{"row_id": 1730, "sent_id": "1730_0", "text": "Phase 2 topline data reported that trial met primary endpoint, noted August 13, 2024.", "triplets": [["endpoint", "met", "POS"], ["phase", "met", "POS"], ["clinical", "met", "POS"]]}
{"row_id": 1732, "sent_id": "1732_0", "text": "Approved August 14, 2024.", "triplets": [["catalyst", "Approved", "POS"]]}
{"row_id": 1733, "sent_id": "1733_0", "text": "Approved August 14, 2024.", "triplets": [["catalyst", "Approved", "POS"]]}
{"row_id": 1734, "sent_id": "1734_0", "text": "Approved August 14, 2024.", "triplets": [["catalyst", "Approved", "POS"]]}
{"row_id": 1737, "sent_id": "1737_0", "text": "Approved 15, 2024.", "triplets": [["catalyst", "Approved", "POS"]]}
{"row_id": 1738, "sent_id": "1738_0", "text": "Approved 15, 2024.", "triplets": [["catalyst", "Approved", "POS"]]}
{"row_id": 1739, "sent_id": "1739_0", "text": "Phase 3 data reported that that it met its primary endpoint of progression free survival (PFS) in relapsed or refractory follicular lymphoma (FL), noted August 15, 2024.", "triplets": [["endpoint", "met", "POS"], ["phase", "met", "POS"]]}
{"row_id": 1740, "sent_id": "1740_0", "text": "Phase 3 data reported that that it met its primary endpoint of progression free survival (PFS) in relapsed or refractory follicular lymphoma (FL), noted August 15, 2024.", "triplets": [["endpoint", "met", "POS"], ["phase", "met", "POS"]]}
{"row_id": 1741, "sent_id": "1741_0", "text": "Phase 3 data reported that that it met its primary endpoint of progression free survival (PFS) in relapsed or refractory follicular lymphoma (FL), noted August 15, 2024.", "triplets": [["endpoint", "met", "POS"], ["phase", "met", "POS"]]}
{"row_id": 1742, "sent_id": "1742_0", "text": "Approved August 16, 2024.", "triplets": [["catalyst", "Approved", "POS"]]}
{"row_id": 1743, "sent_id": "1743_0", "text": "Phase 2 data reported that the primary endpoints for this qIRV first-generation candidate were not met in adults aged 65 and older, as statistical non-inferior relative vaccine efficacy (\"rVE\") compar", "triplets": [["endpoint", "met", "POS"], ["phase", "met", "POS"]]}
{"row_id": 1744, "sent_id": "1744_0", "text": "Tentative approval announced August 19, 2024.", "triplets": [["regulatory", "approval", "POS"]]}
{"row_id": 1747, "sent_id": "1747_0", "text": "Phase 1 dosing initiated, noted August 19, 2024.", "triplets": [["phase", "dosing initiated", "POS"], ["clinical", "dosing initiated", "POS"]]}
{"row_id": 1751, "sent_id": "1751_0", "text": "FDA approved on August 20, 2024.", "triplets": [["regulatory", "FDA approved", "POS"]]}
{"row_id": 1754, "sent_id": "1754_0", "text": "FDA approved under ANDA approval on August 20, 2024.", "triplets": [["regulatory", "FDA approved", "POS"]]}
{"row_id": 1758, "sent_id": "1758_0", "text": "Phase 2 analysis by the IDMC demonstrated that the study was unlikely to exceed an efficacy threshold necessary to support an accelerated approval, to preserve cash the company is halting the registra", "triplets": [["phase", "approval", "POS"], ["regulatory", "approval", "POS"]]}
{"row_id": 1759, "sent_id": "1759_0", "text": "CRL announced August 20, 2024.", "triplets": [["regulatory", "CRL", "NEG"]]}
{"row_id": 1763, "sent_id": "1763_0", "text": "Phase 2 dosing initiated, noted August 22, 2024.", "triplets": [["phase", "dosing initiated", "POS"], ["clinical", "dosing initiated", "POS"]]}
{"row_id": 1764, "sent_id": "1764_0", "text": "Approved August 22, 2024.", "triplets": [["catalyst", "Approved", "POS"]]}
{"row_id": 1765, "sent_id": "1765_0", "text": "Phase 3 trial did not meet its primary endpoint, noted August 22, 2024.", "triplets": [["endpoint", "did not meet", "NEG"], ["phase", "did not meet", "NEG"]]}
{"row_id": 1766, "sent_id": "1766_0", "text": "Approved August 22, 2024.", "triplets": [["catalyst", "Approved", "POS"]]}
{"row_id": 1767, "sent_id": "1767_0", "text": "Approved August 22, 2024.", "triplets": [["catalyst", "Approved", "POS"]]}
{"row_id": 1770, "sent_id": "1770_0", "text": "Trial data reported that treatment was safe and tolerable with significant improvement noted across many aspects of skin appearance, noted August 26, 2024.", "triplets": [["clinical", "significant improvement", "POS"]]}
{"row_id": 1771, "sent_id": "1771_0", "text": "FDA approved on August 26, 2024.", "triplets": [["regulatory", "FDA approved", "POS"]]}
{"row_id": 1772, "sent_id": "1772_1", "text": "At higher oral dose, Ketamir-2 achieved complete normalizat", "triplets": [["catalyst", "achieved", "POS"]]}
{"row_id": 1773, "sent_id": "1773_0", "text": "Phase 2b data published at the Journal of sexual medicine showed that topical Sildenafil Cream, 3.6% was safe and well tolerated by women and their partners across 1,357 sexual experiences.", "triplets": [["safety", "well tolerated", "POS"], ["phase", "well tolerated", "POS"]]}
{"row_id": 1774, "sent_id": "1774_0", "text": "Phase 3 topline data reported that the trial did not meet its primary endpoint, noted August 27, 2024.", "triplets": [["endpoint", "did not meet", "NEG"], ["phase", "did not meet", "NEG"], ["clinical", "did not meet", "NEG"]]}
{"row_id": 1778, "sent_id": "1778_0", "text": "IRB has approved a single and multiple doser study, noted August 27, 2024.", "triplets": [["catalyst", "approved", "POS"]]}
{"row_id": 1779, "sent_id": "1779_0", "text": "Phase 2 met the primary endpoint, showing significant improvement in PANSS scores versus placebo, and was well-tolerated.", "triplets": [["endpoint", "met", "POS"], ["safety", "met", "POS"], ["phase", "met", "POS"], ["clinical", "met", "POS"]]}
{"row_id": 1779, "sent_id": "1779_1", "text": "Secondary endpoints were also met, noted August 28, 2024.", "triplets": [["endpoint", "met", "POS"], ["financial", "met", "POS"]]}
{"row_id": 1781, "sent_id": "1781_0", "text": "Phase 3 data reported that the trial met its primary endpoints, demonstrating superiority of Leqvio (inclisiran) monotherapy vs both placebo and ezetimibe in LDL-C reduction, noted August 28, 2024.", "triplets": [["endpoint", "met", "POS"], ["phase", "met", "POS"]]}
{"row_id": 1782, "sent_id": "1782_0", "text": "Phase 3 data presented at MHSRS highlighted results from confirmatory Phase 3 RESILIENT study of TNX-102 SL (sublingual cyclobenzaprine HCl) treatment demonstrating statistically significant improveme", "triplets": [["phase", "statistically significant", "POS"]]}
{"row_id": 1785, "sent_id": "1785_0", "text": "Phase 1 data reported that single and multiple doses of GT-02287 were safe and generally well tolerated up to and including the highest planned dose levels across all age groups, with no discontinuati", "triplets": [["safety", "well tolerated", "POS"], ["phase", "well tolerated", "POS"]]}
{"row_id": 1786, "sent_id": "1786_0", "text": "BLA submitted August 29, 2024.", "triplets": [["regulatory", "BLA submitted", "POS"]]}
{"row_id": 1787, "sent_id": "1787_0", "text": "FDA final approval on August 29, 2024.", "triplets": [["regulatory", "approval", "POS"]]}
{"row_id": 1791, "sent_id": "1791_0", "text": "Approved August 30, 2024.", "triplets": [["catalyst", "Approved", "POS"]]}
{"row_id": 1798, "sent_id": "1798_0", "text": "NDA submitted to the FDA under 505(b)(2) pathway, noted September 3, 2024", "triplets": [["regulatory", "NDA submitted", "POS"]]}
{"row_id": 1802, "sent_id": "1802_0", "text": "Phase 1/2 topline data reported that at the high and middle doses, VAX-31 met or exceeded the regulatory immunogenicity criteria for all 31 serotypes and, at the low dose, for 29 of 31 serotypes, note", "triplets": [["phase", "met", "POS"], ["clinical", "met", "POS"]]}
{"row_id": 1804, "sent_id": "1804_0", "text": "Fast Track Designation granted by the FDA, noted September 3, 2024.", "triplets": [["regulatory", "Fast Track", "POS"]]}
{"row_id": 1807, "sent_id": "1807_0", "text": "Phase 2 trial met its primary endpoint, noted September 3, 2024.", "triplets": [["endpoint", "met", "POS"], ["phase", "met", "POS"]]}
{"row_id": 1809, "sent_id": "1809_0", "text": "Phase 2/3 topline data did not meet primary endpoint of GST and key secondary endpoints of cognition (ADAS-Cog11) and function (ADCS-ADL23), noted September 3, 2024.", "triplets": [["endpoint", "did not meet", "NEG"], ["phase", "did not meet", "NEG"], ["financial", "did not meet", "NEG"], ["clinical", "did not meet", "NEG"]]}
{"row_id": 1810, "sent_id": "1810_1", "text": "Phase 1 data to dosing initiated, noted Septem", "triplets": [["phase", "dosing initiated", "POS"], ["clinical", "dosing initiated", "POS"]]}
{"row_id": 1811, "sent_id": "1811_0", "text": "Phase 2b trial did not meet its primary or secondary endpoints, noted September 4, 2024.", "triplets": [["endpoint", "did not meet", "NEG"], ["phase", "did not meet", "NEG"], ["financial", "did not meet", "NEG"]]}
{"row_id": 1812, "sent_id": "1812_0", "text": "Phase 2/3 data reported statistically significant improvement compared to a prespecified matched sham control group, noted September 4, 2024.", "triplets": [["phase", "statistically significant", "POS"], ["clinical", "statistically significant", "POS"]]}
{"row_id": 1813, "sent_id": "1813_0", "text": "Phase 2/3 data reported statistically significant improvement compared to a prespecified matched sham control group, noted September 4, 2024.", "triplets": [["phase", "statistically significant", "POS"], ["clinical", "statistically significant", "POS"]]}
{"row_id": 1818, "sent_id": "1818_0", "text": "Phase 2 study enrollment completed, noted September 4, 2024.", "triplets": [["phase", "enrollment completed", "POS"], ["enrollment", "enrollment completed", "POS"]]}
{"row_id": 1819, "sent_id": "1819_0", "text": "Phase 3 data to be presented at the SSIEM Annual Symposium 2024 showed that study was well tolerated, noted September 5, 2024.", "triplets": [["safety", "well tolerated", "POS"], ["phase", "well tolerated", "POS"]]}
{"row_id": 1820, "sent_id": "1820_0", "text": "Phase 3 data to be presented at the SSIEM Annual Symposium 2024 showed that study was well tolerated, noted September 5, 2024.", "triplets": [["safety", "well tolerated", "POS"], ["phase", "well tolerated", "POS"]]}
{"row_id": 1821, "sent_id": "1821_0", "text": "Phase 1b enrollment completed, noted September 5, 2024.", "triplets": [["phase", "enrollment completed", "POS"], ["enrollment", "enrollment completed", "POS"]]}
{"row_id": 1822, "sent_id": "1822_0", "text": "Phase 1/2 FDA granted Fast Track designation, noted September 5, 2024", "triplets": [["phase", "Fast Track", "POS"], ["regulatory", "Fast Track", "POS"]]}
{"row_id": 1823, "sent_id": "1823_0", "text": "Phase 3 topline data reported that the trial met its primary endpoint of non-inferior A1C reduction with efsitora compared to insulin glargine at week 52, noted September 5, 2024.", "triplets": [["endpoint", "met", "POS"], ["phase", "met", "POS"], ["clinical", "met", "POS"]]}
{"row_id": 1824, "sent_id": "1824_0", "text": "Phase 3 topline data reported that the trial met its primary endpoint of non-inferior A1C reduction with efsitora compared to insulin degludec at week 26, noted September 5, 2024.", "triplets": [["endpoint", "met", "POS"], ["phase", "met", "POS"], ["clinical", "met", "POS"]]}
{"row_id": 1825, "sent_id": "1825_0", "text": "FDA granted orphan drug designation, noted September 5, 2024.", "triplets": [["regulatory", "FDA granted", "POS"]]}
{"row_id": 1826, "sent_id": "1826_0", "text": "Phase 2a data from study showed that during this first-of-its-kind human patient case, the patient was able to cease treatment after just one week due to the rapid and successful resolution of symptom", "triplets": [["phase", "successful", "POS"]]}
{"row_id": 1829, "sent_id": "1829_0", "text": "Approved September 5, 2024.", "triplets": [["catalyst", "Approved", "POS"]]}
{"row_id": 1830, "sent_id": "1830_0", "text": "Approved September 5, 2024.", "triplets": [["catalyst", "Approved", "POS"]]}
{"row_id": 1834, "sent_id": "1834_0", "text": "Phase 3 data reported that it met its primary endpoint with the addition of Nucala to inhaled maintenance therapy, noted September 6, 2024.", "triplets": [["endpoint", "met", "POS"], ["phase", "met", "POS"]]}
{"row_id": 1835, "sent_id": "1835_0", "text": "BLA submission completed, noted September 6, 2024.", "triplets": [["regulatory", "BLA submission", "POS"]]}
{"row_id": 1839, "sent_id": "1839_0", "text": "Additional Phase 3 data presented at WCLC reported a hazard ratio (HR) of 0.51, and a clinically meaningful benefit was demonstrated across clinical subgroups, noted September 8, 2024.", "triplets": [["phase", "data presented at WCLC", "POS"], ["clinical", "data presented at WCLC", "POS"]]}
{"row_id": 1846, "sent_id": "1846_0", "text": "Phase 2 patient dosing initiated, noted September 9, 2024.", "triplets": [["phase", "dosing initiated", "POS"], ["clinical", "dosing initiated", "POS"]]}
{"row_id": 1847, "sent_id": "1847_0", "text": "Phase 2 full data presented at ESMO reported that the median OS was 30 months (95% CI 18.4, NE) and the 12-month OS rate was 80%, noted September 9, 2024.", "triplets": [["endpoint", "data presented at ESMO", "POS"], ["phase", "data presented at ESMO", "POS"], ["clinical", "data presented at ESMO", "POS"]]}
{"row_id": 1848, "sent_id": "1848_0", "text": "Phase 1 update reported that two patients with recurrent /refractory EWS are experiencing ongoing complete responses (CR), two patients achieved stable disease (SD), and two patients withdrew from the", "triplets": [["endpoint", "achieved", "POS"], ["phase", "achieved", "POS"]]}
{"row_id": 1849, "sent_id": "1849_0", "text": "Phase 1 data presented at ESMO reported partial responses, tumor shrinkage and prolonged stable disease, noted September 9, 2024.", "triplets": [["phase", "data presented at ESMO", "POS"], ["clinical", "data presented at ESMO", "POS"]]}
{"row_id": 1850, "sent_id": "1850_0", "text": "Phase 1 data presented at ESMO reported partial responses, tumor shrinkage and prolonged stable disease, noted September 9, 2024.", "triplets": [["phase", "data presented at ESMO", "POS"], ["clinical", "data presented at ESMO", "POS"]]}
{"row_id": 1854, "sent_id": "1854_0", "text": "Phase 1 dosing initiated, noted September 9, 2024.", "triplets": [["phase", "dosing initiated", "POS"], ["clinical", "dosing initiated", "POS"]]}
{"row_id": 1858, "sent_id": "1858_0", "text": "Phase 1b data presented at WCLC showed an 81.8% ORR by BICR and 63.6% confirmed ORR by BICR at the 240 mg dose; 46.2% confirmed ORR in CNS Metastases, noted September 9, 2024.", "triplets": [["endpoint", "data presented at WCLC", "POS"], ["phase", "data presented at WCLC", "POS"], ["clinical", "data presented at WCLC", "POS"]]}
{"row_id": 1862, "sent_id": "1862_0", "text": "Phase 1b/2a study data presented at the European Respiratory Society (ERS) Congress reported that treatment was well tolerated and no adverse events of special interest, noted September 9, 2024.", "triplets": [["safety", "well tolerated", "POS"], ["phase", "well tolerated", "POS"]]}
{"row_id": 1864, "sent_id": "1864_0", "text": "Phase 3 data presented at EASD efsitora met the primary endpoint of non-inferior A1C reduction at week 26, noted September 9, 2024.", "triplets": [["endpoint", "met", "POS"], ["phase", "met", "POS"]]}
{"row_id": 1866, "sent_id": "1866_0", "text": "Phase 1 dose escalation data presented at ESMO reported that 1 pt had an unconfirmed partial response (uPR) and 7/14 (50%) efficacy evaluable pts had a best response of stable disease or better, noted", "triplets": [["phase", "data presented at ESMO", "POS"], ["clinical", "data presented at ESMO", "POS"]]}
{"row_id": 1871, "sent_id": "1871_0", "text": "Phase 1 data presented at ESMO reported that 7 pts had 9 \u00e2\u2030\u00a5 Gr 3 AEs assessed as potentially related to CVGBM, noted September 9, 2024.", "triplets": [["safety", "data presented at ESMO", "POS"], ["phase", "data presented at ESMO", "POS"], ["clinical", "data presented at ESMO", "POS"]]}
{"row_id": 1872, "sent_id": "1872_0", "text": "Phase 1 data reported a statistically significant mean weight loss up to 5.5% over 28 days, noted September 9, 2024.", "triplets": [["phase", "statistically significant", "POS"]]}
{"row_id": 1874, "sent_id": "1874_0", "text": "Phase 3 Outcomes study dosing initiated, noted September 9, 2024.", "triplets": [["phase", "dosing initiated", "POS"], ["clinical", "dosing initiated", "POS"]]}
{"row_id": 1875, "sent_id": "1875_0", "text": "Phase 3 Outcomes study dosing initiated, noted September 9, 2024.", "triplets": [["phase", "dosing initiated", "POS"], ["clinical", "dosing initiated", "POS"]]}
{"row_id": 1882, "sent_id": "1882_0", "text": "Phase 3 data presented at Webcast achieved all primary and secondary endpoints, noted September 10, 2024.", "triplets": [["endpoint", "achieved", "POS"], ["phase", "achieved", "POS"], ["financial", "achieved", "POS"]]}
{"row_id": 1884, "sent_id": "1884_0", "text": "Phase 1 study showed a favorable safety profile with no on-target adverse events commonly associated with other OX2R agonists, such as hepatotoxicity or visual disturbances.", "triplets": [["safety", "favorable safety", "POS"], ["phase", "favorable safety", "POS"]]}
{"row_id": 1888, "sent_id": "1888_0", "text": "FDA Granted RMAT designation, noted September 10, 2024.", "triplets": [["regulatory", "FDA Granted", "POS"]]}
{"row_id": 1889, "sent_id": "1889_1", "text": "The therapy was well-tolerated with no treatment-related serious adv", "triplets": [["safety", "well-tolerated", "POS"]]}
{"row_id": 1893, "sent_id": "1893_0", "text": "Phase 2a FDA granted Orphan drug designation, noted Septemeber 11, 2024.", "triplets": [["phase", "FDA granted", "POS"], ["regulatory", "FDA granted", "POS"]]}
{"row_id": 1894, "sent_id": "1894_0", "text": "Phase 3 met its primary and secondary endpoints, noted September 11, 2024.", "triplets": [["endpoint", "met", "POS"], ["phase", "met", "POS"], ["financial", "met", "POS"]]}
{"row_id": 1895, "sent_id": "1895_0", "text": "Phase 1/2 trial did not meet the study's primary efficacy objective, noted September 11, 2024.", "triplets": [["phase", "did not meet", "NEG"]]}
{"row_id": 1896, "sent_id": "1896_0", "text": "Phase 3 met its primary and key secondary endpoints, noted September 11, 2024.", "triplets": [["endpoint", "met", "POS"], ["phase", "met", "POS"], ["financial", "met", "POS"]]}
{"row_id": 1897, "sent_id": "1897_0", "text": "Phase 3 met its primary and key secondary endpoints, noted September 11, 2024.", "triplets": [["endpoint", "met", "POS"], ["phase", "met", "POS"], ["financial", "met", "POS"]]}
{"row_id": 1898, "sent_id": "1898_0", "text": "Phase 3 trial met its primary and key secondary endpoints, noted September 11, 2024.", "triplets": [["endpoint", "met", "POS"], ["phase", "met", "POS"], ["financial", "met", "POS"]]}
{"row_id": 1899, "sent_id": "1899_0", "text": "Phase 3 trial met its primary and key secondary endpoints, noted September 11, 2024.", "triplets": [["endpoint", "met", "POS"], ["phase", "met", "POS"], ["financial", "met", "POS"]]}
{"row_id": 1903, "sent_id": "1903_0", "text": "Approved September 11, 2024.", "triplets": [["catalyst", "Approved", "POS"]]}
{"row_id": 1904, "sent_id": "1904_0", "text": "Approved September 11, 2024.", "triplets": [["catalyst", "Approved", "POS"]]}
{"row_id": 1907, "sent_id": "1907_0", "text": "Phase 3 trial study failed to show an improvement in relative surface area (RSA), a measure of reachable workspace (RWS), versus placebo at week 48, study did not meet primary endpoint.", "triplets": [["endpoint", "did not meet", "NEG"], ["phase", "did not meet", "NEG"]]}
{"row_id": 1908, "sent_id": "1908_0", "text": "Phase 3 trial study failed to show an improvement in relative surface area (RSA), a measure of reachable workspace (RWS), versus placebo at week 48, study did not meet primary endpoint.", "triplets": [["endpoint", "did not meet", "NEG"], ["phase", "did not meet", "NEG"]]}
{"row_id": 1916, "sent_id": "1916_0", "text": "Phase 1a pharmacokinetic results demonstrated dose-dependent exposure of VYN202 in blood, study was generally well tolerated with no drug-related adverse events, noted September 12, 2024.", "triplets": [["safety", "well tolerated", "POS"]]}
{"row_id": 1917, "sent_id": "1917_0", "text": "Phase 3 enrollment completed, noted September 12, 2024.", "triplets": [["phase", "enrollment completed", "POS"], ["enrollment", "enrollment completed", "POS"]]}
{"row_id": 1918, "sent_id": "1918_0", "text": "Phase 1 data from ESMO noted that treatment was safe and well-tolerated with preliminary signals of monotherapy antitumor activity, noted September 12, 2024.", "triplets": [["safety", "well-tolerated", "POS"], ["phase", "well-tolerated", "POS"]]}
{"row_id": 1919, "sent_id": "1919_0", "text": "Phase 2 trial failed to meet its primary endpoint, noted September 12, 2024.", "triplets": [["endpoint", "failed to meet", "NEG"], ["phase", "failed to meet", "NEG"]]}
{"row_id": 1921, "sent_id": "1921_0", "text": "Approved September 12, 2024.", "triplets": [["catalyst", "Approved", "POS"]]}
{"row_id": 1923, "sent_id": "1923_0", "text": "Phase 1 data presented at ESMO showed signs of anti-tumor activity, including partial responses in 3 of 26 patients with heavily pre-treated NSCLC or esophageal cancer, and additional patients with pr", "triplets": [["endpoint", "data presented at ESMO", "POS"], ["sample", "data presented at ESMO", "POS"], ["phase", "data presented at ESMO", "POS"], ["clinical", "data presented at ESMO", "POS"]]}
{"row_id": 1924, "sent_id": "1924_0", "text": "Phase 1 data presented at ESMO showed signs of anti-tumor activity, including partial responses in 3 of 26 patients with heavily pre-treated NSCLC or esophageal cancer, and additional patients with pr", "triplets": [["endpoint", "data presented at ESMO", "POS"], ["sample", "data presented at ESMO", "POS"], ["phase", "data presented at ESMO", "POS"], ["clinical", "data presented at ESMO", "POS"]]}
{"row_id": 1925, "sent_id": "1925_0", "text": "FDA approval on September 13, 2024.", "triplets": [["regulatory", "FDA approval", "POS"]]}
{"row_id": 1926, "sent_id": "1926_0", "text": "FDA approved on September 13, 2024.", "triplets": [["regulatory", "FDA approved", "POS"]]}
{"row_id": 1927, "sent_id": "1927_0", "text": "Approved September 13, 2024.", "triplets": [["catalyst", "Approved", "POS"]]}
{"row_id": 1928, "sent_id": "1928_0", "text": "Phase 1 dose escalation data presented at ESMO showed it was well-tolerated across all doses with no dose-limiting toxicities and achieved dose-proportional pharmacokinetics, noted September 13, 2024.", "triplets": [["safety", "achieved", "POS"], ["phase", "achieved", "POS"], ["clinical", "achieved", "POS"]]}
{"row_id": 1929, "sent_id": "1929_0", "text": "Phase 1 data presented at ESMO reported that treatment was generally well tolerated with no unexpected adverse events, and encouraging antitumor activity, noted September 13, 2023.", "triplets": [["safety", "well tolerated", "POS"], ["phase", "well tolerated", "POS"], ["clinical", "well tolerated", "POS"]]}
{"row_id": 1936, "sent_id": "1936_0", "text": "Phase 1/2 preliminary safety, efficacy, and quality of life outcomes at ESOPRS reported that patients in cohort 1 (40 mg Q3W) achieved early clinical responses across manifestations of disease, noted", "triplets": [["safety", "achieved", "POS"], ["phase", "achieved", "POS"]]}
{"row_id": 1937, "sent_id": "1937_0", "text": "Phase 1b/2 data from ESMO showed a manageable safety profile and encouraging efficacy in patients with heavily pretreated HR+/HER2- breast cancer, noted September 14, 2024.", "triplets": [["safety", "manageable safety", "POS"], ["phase", "manageable safety", "POS"]]}
{"row_id": 1941, "sent_id": "1941_0", "text": "Phase 2 data from ESMO reported that treatment with ozuriftamab vedotin achieved durable responses and promising tumor control among a patient population with a median of 3 prior lines of therapy, not", "triplets": [["phase", "achieved", "POS"]]}
{"row_id": 1949, "sent_id": "1949_0", "text": "Phase 1b data presented at ESMO reported that 30 pts had confirmed partial responses, with an overall response rate of 75%, noted September 15, 2024.", "triplets": [["phase", "data presented at ESMO", "POS"], ["clinical", "data presented at ESMO", "POS"]]}
{"row_id": 1951, "sent_id": "1951_0", "text": "Additional Phase 2b data presented at ESMO reported that E+P resulted in numerically higher ORR & DCR compared to P only in CPS \u00e2\u2030\u00a51 pts noted September 15, 2024.", "triplets": [["endpoint", "data presented at ESMO", "POS"], ["phase", "data presented at ESMO", "POS"], ["clinical", "data presented at ESMO", "POS"]]}
{"row_id": 1953, "sent_id": "1953_0", "text": "Phase 2 clinical hold lifted by the FDA, noted September 16, 2024.", "triplets": [["phase", "clinical hold", "NEG"], ["regulatory", "clinical hold", "NEG"]]}
{"row_id": 1955, "sent_id": "1955_0", "text": "Phase 2 clinical hold lifted by the FDA, noted September 16, 2024.", "triplets": [["phase", "clinical hold", "NEG"], ["regulatory", "clinical hold", "NEG"]]}
{"row_id": 1957, "sent_id": "1957_0", "text": "Phase 1/2 data from ESMO reported a 45% overall response rate (ORR), 11.1 months median duration of response and a generally well-tolerated safety profile, noted September 16, 2024.", "triplets": [["endpoint", "well-tolerated", "POS"], ["safety", "well-tolerated", "POS"], ["phase", "well-tolerated", "POS"]]}
{"row_id": 1958, "sent_id": "1958_0", "text": "Phase 1/2 data from ESMO reported that 75% of patients achieved disease control, including two patients who achieved Partial Responses, noted September 16, 2024.", "triplets": [["phase", "achieved", "POS"]]}
{"row_id": 1959, "sent_id": "1959_0", "text": "Phase 2 data presented at ESMO 24 showed a 69% overall response rate (ORR), with tumor reductions in 15 out of 16 patients and a 79% rate of targeted immune responses to the vaccine's neoantigens, not", "triplets": [["endpoint", "data presented at ESMO", "POS"], ["sample", "data presented at ESMO", "POS"], ["phase", "data presented at ESMO", "POS"], ["clinical", "data presented at ESMO", "POS"]]}
{"row_id": 1960, "sent_id": "1960_0", "text": "Phase 2 data presented at ESMO 24 showed a 69% overall response rate (ORR), with tumor reductions in 15 out of 16 patients and a 79% rate of targeted immune responses to the vaccine's neoantigens, not", "triplets": [["endpoint", "data presented at ESMO", "POS"], ["sample", "data presented at ESMO", "POS"], ["phase", "data presented at ESMO", "POS"], ["clinical", "data presented at ESMO", "POS"]]}
{"row_id": 1962, "sent_id": "1962_0", "text": "Phase 1/2 data to be presented at ISFTD showed sustained increases in cerebrospinal fluid (CSF) progranulin levels in all treated patients for up to 12 months, with no serious adverse events observed", "triplets": [["safety", "serious adverse events", "NEG"], ["phase", "serious adverse events", "NEG"]]}
{"row_id": 1964, "sent_id": "1964_0", "text": "Phase 1/2 initial clinical results presented at ESMO 2024 showed anti-tumor responses in 29% (4/14) of efficacy-evaluable, heavily pre-treated patients with platinum-resistant ovarian cancer (PROC) wh", "triplets": [["phase", "results presented at ESMO", "POS"], ["clinical", "results presented at ESMO", "POS"]]}
{"row_id": 1965, "sent_id": "1965_0", "text": "Phase 3 topline data presented at ESMO demonstrated a significant increase in annualized growth velocity (AGV) compared to placebo, with an LS mean treatment difference of 1.49 cm/year at Week 52.", "triplets": [["effect", "data presented at ESMO", "POS"], ["phase", "data presented at ESMO", "POS"], ["clinical", "data presented at ESMO", "POS"]]}
{"row_id": 1968, "sent_id": "1968_0", "text": "Phase 3 study presented data shared at ESMO demonstrated a substantial reduction in Grade 4 neutropenia (over 80% reduction) and a favorable safety profile, with fewer serious adverse events and impro", "triplets": [["safety", "favorable safety", "NEU"], ["phase", "favorable safety", "NEU"]]}
{"row_id": 1970, "sent_id": "1970_0", "text": "Phase 2 data from the 303 Study at ESMO 2024 showed that among 19 evaluable patients, the combination achieved a 21.1% overall response rate (ORR), a median progression-free survival (PFS) of 8.63 mon", "triplets": [["endpoint", "achieved", "POS"], ["phase", "achieved", "POS"]]}
{"row_id": 1971, "sent_id": "1971_0", "text": "Phase 2 data from the 303 Study at ESMO 2024 showed that among 19 evaluable patients, the combination achieved a 21.1% overall response rate (ORR), a median progression-free survival (PFS) of 8.63 mon", "triplets": [["endpoint", "achieved", "POS"], ["phase", "achieved", "POS"]]}
{"row_id": 1972, "sent_id": "1972_0", "text": "Phase 3 final analysis of OS showed a numerical but not statistically significant improvement favoring cabozantinib in combination with atezolizumab, noted September 16, 2024.", "triplets": [["endpoint", "statistically significant", "NEU"], ["phase", "statistically significant", "NEU"], ["clinical", "statistically significant", "NEU"]]}
{"row_id": 1983, "sent_id": "1983_0", "text": "Phase 2 full data presented at ESMO reported that the median OS was 30 months (95% CI 18.4, NE), ORR of 36% and the 12-month OS rate was 77%, noted September 16, 2024.", "triplets": [["endpoint", "data presented at ESMO", "POS"], ["phase", "data presented at ESMO", "POS"], ["clinical", "data presented at ESMO", "POS"]]}
{"row_id": 1984, "sent_id": "1984_0", "text": "Phase 1b/2 data presented at ESMO showed clinical activity in hard-to-treat cancers, including ovarian cancer and immune checkpoint inhibitor (ICI)-na\u00c3\u00afve and refractory microsatellite stable (MSS)/mic", "triplets": [["phase", "data presented at ESMO", "POS"], ["clinical", "data presented at ESMO", "POS"]]}
{"row_id": 1985, "sent_id": "1985_0", "text": "Phase 1 study determined the recommended Phase 2 dose to be 8-12 mg/kg, with givastomig being well-tolerated up to the highest study doses.", "triplets": [["safety", "well-tolerated", "POS"], ["phase", "well-tolerated", "POS"]]}
{"row_id": 1986, "sent_id": "1986_0", "text": "Phase 3 data presented at ESMO reported that ORR was 72.6% vs 60.1% with pembro + SOC vs pbo + SOC, noted September 16, 2024.", "triplets": [["endpoint", "data presented at ESMO", "POS"], ["phase", "data presented at ESMO", "POS"], ["clinical", "data presented at ESMO", "POS"]]}
{"row_id": 1987, "sent_id": "1987_0", "text": "Phase 2 data presented at ESMO showed a confirmed objective response rate (cORR) of 84%, a median duration of response (DoR) of 18.7 months, a median progression-free survival (mPFS) of 15.2 months, a", "triplets": [["endpoint", "data presented at ESMO", "POS"], ["phase", "data presented at ESMO", "POS"], ["clinical", "data presented at ESMO", "POS"]]}
{"row_id": 1988, "sent_id": "1988_0", "text": "Phase 3 data reported a statistically significant progression-free survival improvement in this EGFR-mutated non-small cell lung cancer population with high unmet need following prior EGFR TKI treatme", "triplets": [["phase", "statistically significant", "POS"]]}
{"row_id": 1989, "sent_id": "1989_0", "text": "Phase 1 partial clinical hold removed by the FDA, noted September 17, 2024.", "triplets": [["phase", "partial clinical hold", "NEG"], ["regulatory", "partial clinical hold", "NEG"]]}
{"row_id": 1991, "sent_id": "1991_0", "text": "Phase 2 enrollment completed, noted September 17, 2024", "triplets": [["phase", "enrollment completed", "POS"], ["enrollment", "enrollment completed", "POS"]]}
{"row_id": 1992, "sent_id": "1992_0", "text": "Phase 1 dosing initiated September 17, 2024.", "triplets": [["phase", "dosing initiated", "POS"], ["clinical", "dosing initiated", "POS"]]}
{"row_id": 1994, "sent_id": "1994_0", "text": "Phase 2a trial dosing initiated, noted September 17, 2024.", "triplets": [["phase", "dosing initiated", "POS"], ["clinical", "dosing initiated", "POS"]]}
{"row_id": 1997, "sent_id": "1997_0", "text": "FDA Approved on September 17, 2024.", "triplets": [["regulatory", "FDA Approved", "POS"]]}
{"row_id": 2000, "sent_id": "2000_0", "text": "FDA Approved on September 18, 2024.", "triplets": [["regulatory", "FDA Approved", "POS"]]}
{"row_id": 2001, "sent_id": "2001_0", "text": "Phase 3b additional data presented at ECTRIMS showed that 30-minute BRIUMVI infusions were well-tolerated, with only mild (Grade 1) infusion-related reactions, and patients switching from prior anti-", "triplets": [["safety", "well-tolerated", "POS"], ["phase", "well-tolerated", "POS"]]}
{"row_id": 2002, "sent_id": "2002_0", "text": "FDA granted Expanded Access Policy (EAP), noted September 18, 2024.", "triplets": [["regulatory", "FDA granted", "POS"]]}
{"row_id": 2004, "sent_id": "2004_0", "text": "CRL issued by the FDA on September 18, 2024.", "triplets": [["regulatory", "CRL", "NEG"]]}
{"row_id": 2008, "sent_id": "2008_0", "text": "Phase 2a topline data reported that the trial met the primary endpoint with statistically significant reductions in liver fat at Week 12 as measured by MRI-PDFF, noted September 19, 2024.", "triplets": [["endpoint", "met", "POS"], ["phase", "met", "POS"], ["clinical", "met", "POS"]]}
{"row_id": 2009, "sent_id": "2009_0", "text": "Approved September 19, 2024.", "triplets": [["catalyst", "Approved", "POS"]]}
{"row_id": 2010, "sent_id": "2010_0", "text": "Approved September 20, 2024.", "triplets": [["catalyst", "Approved", "POS"]]}
{"row_id": 2011, "sent_id": "2011_0", "text": "Phase 2a trial data reported that all doses of monlunabant achieved a statistically significant weight loss compared to placebo, noted September 20, 2024.", "triplets": [["phase", "achieved", "POS"]]}
{"row_id": 2012, "sent_id": "2012_0", "text": "Approved September 20, 2024.", "triplets": [["catalyst", "Approved", "POS"]]}
{"row_id": 2013, "sent_id": "2013_0", "text": "Approval announced September 20, 2024.", "triplets": [["regulatory", "Approval", "POS"]]}
{"row_id": 2014, "sent_id": "2014_0", "text": "Additional Phase 3 data reported that statistically significant mean differences in the change in PANSS total scores from baseline to week 8 of -9.71 points, -11.25 points, and -9.69 points versus pla", "triplets": [["phase", "statistically significant", "POS"]]}
{"row_id": 2016, "sent_id": "2016_0", "text": "Phase 2 results showed that a 200 mg daily dose was selected for pivotal development, demonstrating a favorable safety profile and a 42% objective response rate (ORR) in 19 evaluable patients, noted S", "triplets": [["endpoint", "favorable safety", "POS"], ["safety", "favorable safety", "POS"], ["phase", "favorable safety", "POS"]]}
{"row_id": 2018, "sent_id": "2018_0", "text": "Phase 3 trial did not meet its primary endpoint, noted September 23, 2024.", "triplets": [["endpoint", "did not meet", "NEG"], ["phase", "did not meet", "NEG"]]}
{"row_id": 2020, "sent_id": "2020_0", "text": "Phase 3 study achieved the primary endpoint and showed statistically significant improvements on the f-SARA at years 1 and 2 , noted September 23, 2024.", "triplets": [["endpoint", "achieved", "POS"], ["phase", "achieved", "POS"]]}
{"row_id": 2023, "sent_id": "2023_0", "text": "Phase 1a interim data reported that treatment was well-tolerated, with a favorable safety profile observed with exposure of up to 70 days, noted September 23, 2024.", "triplets": [["safety", "well-tolerated", "POS"]]}
{"row_id": 2024, "sent_id": "2024_0", "text": "IND Cleared by the FDA, noted September 23, 2024.", "triplets": [["regulatory", "Cleared by the FDA", "POS"]]}
{"row_id": 2025, "sent_id": "2025_0", "text": "Phase 3 trial met its primary endpoint, noted September 24, 2024.", "triplets": [["endpoint", "met", "POS"], ["phase", "met", "POS"]]}
{"row_id": 2027, "sent_id": "2027_0", "text": "Phase 2a initial results reported that three participants have completed the four-week treatment with LP-310, an oral rinse, with encouraging findings: The treatment was well tolerated and had no unpl", "triplets": [["safety", "well tolerated", "POS"], ["phase", "well tolerated", "POS"]]}
{"row_id": 2028, "sent_id": "2028_0", "text": "Preclinical data showed that monotherapy (700 mg) demonstrated statistically significant fibrosis reversal compared to an isotype IgG4 control arm, noted September 24, 2024.", "triplets": [["catalyst", "statistically significant", "POS"]]}
{"row_id": 2030, "sent_id": "2030_0", "text": "Phase 1a was well-tolerated with no observed immunogenicity, and demonstrated a favorable PK/PD relationship, noted September 24, 2024.", "triplets": [["safety", "well-tolerated", "POS"]]}
{"row_id": 2034, "sent_id": "2034_0", "text": "Phase 3 HOPE-3 clinical trial to combine Cohorts A and B, study planned to serve as a post-approval study and does not intend to unblind Cohort A at this time, which was expected to occur in the 4Q 20", "triplets": [["phase", "approval", "POS"], ["regulatory", "approval", "POS"]]}
{"row_id": 2035, "sent_id": "2035_0", "text": "Phase 3 trial did not meet its primary endpoint, noted September 25, 2024.", "triplets": [["endpoint", "did not meet", "NEG"], ["phase", "did not meet", "NEG"]]}
{"row_id": 2039, "sent_id": "2039_0", "text": "Approved September 25, 2024.", "triplets": [["catalyst", "Approved", "POS"]]}
{"row_id": 2041, "sent_id": "2041_0", "text": "Type A Meeting requested to FDA regarding clinical hold after new financing, noted September 25, 2024.", "triplets": [["regulatory", "clinical hold", "NEG"]]}
{"row_id": 2042, "sent_id": "2042_0", "text": "Phase 2 52-week results from EADV reported that 71% of patients (150 mg Q4W) achieved complete response at Week 52, noted September 25, 2024.", "triplets": [["phase", "achieved", "POS"]]}
{"row_id": 2043, "sent_id": "2043_0", "text": "Preclinical data reported a synergistic and statistically significant reduction of several cytokines (TNF-alpha, IL-17, IL-6, IFN-gamma) in the blood compared to each treatment alone, noted September", "triplets": [["catalyst", "statistically significant", "POS"]]}
{"row_id": 2046, "sent_id": "2046_0", "text": "Approved September 26, 2024.", "triplets": [["catalyst", "Approved", "POS"]]}
{"row_id": 2047, "sent_id": "2047_0", "text": "FDA Approved on September 26, 2024.", "triplets": [["regulatory", "FDA Approved", "POS"]]}
{"row_id": 2050, "sent_id": "2050_0", "text": "Phase 2a topline data reported that trial met its primary and secondary endpoints, noted September 26, 2024.", "triplets": [["endpoint", "met", "POS"], ["phase", "met", "POS"], ["financial", "met", "POS"], ["clinical", "met", "POS"]]}
{"row_id": 2052, "sent_id": "2052_0", "text": "Phase 3 trial data reported that trial met its primary endpoint, noted September 26, 2024.", "triplets": [["endpoint", "met", "POS"], ["phase", "met", "POS"]]}
{"row_id": 2054, "sent_id": "2054_0", "text": "Clinical hold lifted September 26, 2024.", "triplets": [["regulatory", "Clinical hold", "NEG"]]}
{"row_id": 2055, "sent_id": "2055_0", "text": "Clinical hold lifted September 26, 2024", "triplets": [["regulatory", "Clinical hold", "NEG"]]}
{"row_id": 2056, "sent_id": "2056_0", "text": "Approved September 27, 2024.", "triplets": [["catalyst", "Approved", "POS"]]}
{"row_id": 2057, "sent_id": "2057_0", "text": "Approved September 27, 2024.", "triplets": [["catalyst", "Approved", "POS"]]}
{"row_id": 2059, "sent_id": "2059_0", "text": "Phase 2 28-week data presented at EADV 2024 show ESK-001 was generally well tolerated, and most patients treated with the top dose of 40 mg twice daily achieved PASI 75, noted September 27, 2024.", "triplets": [["safety", "achieved", "POS"], ["phase", "achieved", "POS"]]}
{"row_id": 2060, "sent_id": "2060_0", "text": "FDA granted Expanded Access Program (EAP), noted September 27, 2024.", "triplets": [["regulatory", "FDA granted", "POS"]]}
{"row_id": 2061, "sent_id": "2061_0", "text": "Approved September 27, 2024.", "triplets": [["catalyst", "Approved", "POS"]]}
{"row_id": 2062, "sent_id": "2062_0", "text": "Phase 1/2 first patient achieved a complete response (CR) one month after receiving dose, noted September 27, 2024.", "triplets": [["endpoint", "achieved", "POS"], ["phase", "achieved", "POS"]]}
{"row_id": 2065, "sent_id": "2065_0", "text": "BLA submitted to the FDA, and it was noted on September 27, 2024.", "triplets": [["regulatory", "BLA submitted", "POS"]]}
{"row_id": 2066, "sent_id": "2066_0", "text": "FDA Approved on September 27, 2024.", "triplets": [["regulatory", "FDA Approved", "POS"]]}
{"row_id": 2067, "sent_id": "2067_0", "text": "FDA Approved on September 27, 2024.", "triplets": [["regulatory", "FDA Approved", "POS"]]}
{"row_id": 2070, "sent_id": "2070_1", "text": "The drug was well tolerated with no serious adverse e", "triplets": [["safety", "well tolerated", "POS"]]}
{"row_id": 2072, "sent_id": "2072_0", "text": "Phase 2 enrollment completed, noted September 30, 2024.", "triplets": [["phase", "enrollment completed", "POS"], ["enrollment", "enrollment completed", "POS"]]}
{"row_id": 2073, "sent_id": "2073_0", "text": "Phase 2 enrollment completed, noted September 30, 2024.", "triplets": [["phase", "enrollment completed", "POS"], ["enrollment", "enrollment completed", "POS"]]}
{"row_id": 2075, "sent_id": "2075_0", "text": "Phase 3 study dosing initiated, noted September 30, 2024.", "triplets": [["phase", "dosing initiated", "POS"], ["clinical", "dosing initiated", "POS"]]}
{"row_id": 2077, "sent_id": "2077_0", "text": "Phase 3 study dosing initiated, noted September 30, 2024.", "triplets": [["phase", "dosing initiated", "POS"], ["clinical", "dosing initiated", "POS"]]}
{"row_id": 2078, "sent_id": "2078_0", "text": "Phase 3 study dosing initiated, noted September 30, 2024.", "triplets": [["phase", "dosing initiated", "POS"], ["clinical", "dosing initiated", "POS"]]}
{"row_id": 2087, "sent_id": "2087_0", "text": "Fast track designation granted by FDA, noted October 1, 2024.", "triplets": [["regulatory", "Fast track", "POS"]]}
{"row_id": 2088, "sent_id": "2088_0", "text": "FDA granted Breakthrough Therapy designation, noted October 1, 2024.", "triplets": [["regulatory", "Breakthrough Therapy", "POS"]]}
{"row_id": 2089, "sent_id": "2089_0", "text": "Phase 2b data from CNS reported a statistically significant reduction in tumor volume rate change was seen in tumors receiving > 100 Gy absorbed dose, noted October 1, 2024.", "triplets": [["phase", "statistically significant", "POS"]]}
{"row_id": 2093, "sent_id": "2093_1", "text": "Notably, 88% of patients achieved a complete metabolic r", "triplets": [["catalyst", "achieved", "POS"]]}
{"row_id": 2094, "sent_id": "2094_0", "text": "IND cleared by the FDA, noted October 2, 2024.", "triplets": [["regulatory", "cleared by the FDA", "POS"]]}
{"row_id": 2095, "sent_id": "2095_0", "text": "Additional Phase 1b/2a data from post hoc analysis emonstrated statistically significant difference in time-to-first-relapse for corticosteroid use in therapeutic (3.0 and 5.0 mg/kg efzofitimod) vs su", "triplets": [["phase", "statistically significant", "POS"]]}
{"row_id": 2096, "sent_id": "2096_0", "text": "Phase 3 trial dosing initiated, noted October 2, 2024.", "triplets": [["phase", "dosing initiated", "POS"], ["clinical", "dosing initiated", "POS"]]}
{"row_id": 2099, "sent_id": "2099_0", "text": "Approved October 3, 2024.", "triplets": [["catalyst", "Approved", "POS"]]}
{"row_id": 2101, "sent_id": "2101_0", "text": "Phase 3 partial clinical hold removed by the FDA, noted October 3, 2024.", "triplets": [["phase", "partial clinical hold", "NEG"], ["regulatory", "partial clinical hold", "NEG"]]}
{"row_id": 2106, "sent_id": "2106_0", "text": "Approved October 4, 2024.", "triplets": [["catalyst", "Approved", "POS"]]}
{"row_id": 2109, "sent_id": "2109_0", "text": "Phase 2b IND placed on clinical hold, noted October 4, 2024.", "triplets": [["phase", "clinical hold", "NEG"], ["regulatory", "clinical hold", "NEG"]]}
{"row_id": 2111, "sent_id": "2111_0", "text": "Phase 3 study met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in motor function, as measured by the Hammersmith Functional Motor Scale Expande", "triplets": [["endpoint", "met", "POS"], ["phase", "met", "POS"]]}
{"row_id": 2112, "sent_id": "2112_0", "text": "Breakthrough Therapy Designation granted by the FDA, noted October 7, 2024.", "triplets": [["regulatory", "Breakthrough Therapy", "POS"]]}
{"row_id": 2114, "sent_id": "2114_0", "text": "Approved October 7, 2024.", "triplets": [["catalyst", "Approved", "POS"]]}
{"row_id": 2115, "sent_id": "2115_0", "text": "Phase 1 data demonstrated a favorable safety profile with no dose-limiting toxicities, noted October 7, 2024.", "triplets": [["safety", "favorable safety", "POS"], ["phase", "favorable safety", "POS"]]}
{"row_id": 2117, "sent_id": "2117_0", "text": "Preclinical data from the Oligonucleotide Therapeutics Society reported that treatment achieved AAT levels between MM and MZ in rodents as early as Week 1, noted October 7, 2024.", "triplets": [["catalyst", "achieved", "POS"]]}
{"row_id": 2118, "sent_id": "2118_0", "text": "Phase 3 trial met primary endpoint, noted October 7, 2024.", "triplets": [["endpoint", "met", "POS"], ["phase", "met", "POS"]]}
{"row_id": 2119, "sent_id": "2119_0", "text": "Phase 3 trial met its primary endpoint, noted October 8, 2024.", "triplets": [["endpoint", "met", "POS"], ["phase", "met", "POS"]]}
{"row_id": 2120, "sent_id": "2120_0", "text": "Phase 2 topline data reported that the trial did not demonstrate a statistically significant difference from baseline in participants treated with dalzanemdor versus placebo on the primary endpoint, n", "triplets": [["endpoint", "statistically significant", "POS"], ["phase", "statistically significant", "POS"], ["clinical", "statistically significant", "POS"]]}
{"row_id": 2121, "sent_id": "2121_0", "text": "Phase 2 topline data reported that the trial did not demonstrate a statistically significant difference from baseline in participants treated with dalzanemdor versus placebo on the primary endpoint, n", "triplets": [["endpoint", "statistically significant", "POS"], ["phase", "statistically significant", "POS"], ["clinical", "statistically significant", "POS"]]}
{"row_id": 2128, "sent_id": "2128_0", "text": "Phase 3 trial met pre-specified endpoint for two different FA long-term extension studie with highly statistically significant evidence of durable treatment benefit on disease progression, noted Octob", "triplets": [["phase", "met", "POS"]]}
{"row_id": 2130, "sent_id": "2130_0", "text": "Phase 3 additional data presented at CHEST 2024 showed that treatment was well-tolerated, noted October 8, 2024.", "triplets": [["safety", "well-tolerated", "POS"], ["phase", "well-tolerated", "POS"]]}
{"row_id": 2131, "sent_id": "2131_0", "text": "FDA biosimilar approved on October 8, 2024.", "triplets": [["catalyst", "approved", "POS"]]}
{"row_id": 2132, "sent_id": "2132_0", "text": "Phase 3 data presented at CHEST showed that trial met primary endpoint, noted October 8, 2024.", "triplets": [["endpoint", "met", "POS"], ["phase", "met", "POS"]]}
{"row_id": 2133, "sent_id": "2133_0", "text": "Phase 2b with topline data reported that the trial achieved both its primary and secondary outcomes.", "triplets": [["phase", "achieved", "POS"], ["financial", "achieved", "POS"], ["clinical", "achieved", "POS"]]}
{"row_id": 2134, "sent_id": "2134_0", "text": "Clinical hold lifted October 9, 2024.", "triplets": [["regulatory", "Clinical hold", "NEG"]]}
{"row_id": 2135, "sent_id": "2135_0", "text": "IND cleared by the FDA, noted October 9, 2024.", "triplets": [["regulatory", "cleared by the FDA", "POS"]]}
{"row_id": 2136, "sent_id": "2136_0", "text": "Phase 1b results after 28 days of once-daily dosing, treatment shown to be safe and well-tolerated, with significant reductions in very long-chain fatty acids (VLCFAs), key biomarkers of X-ALD, noted", "triplets": [["safety", "well-tolerated", "POS"], ["phase", "well-tolerated", "POS"]]}
{"row_id": 2137, "sent_id": "2137_1", "text": "Priority review voucher utilized to accelerate review period", "triplets": [["regulatory", "Priority review", "POS"]]}
{"row_id": 2139, "sent_id": "2139_0", "text": "Breakthrough Therapy Designation granted by the FDA, noted October 9, 2024.", "triplets": [["regulatory", "Breakthrough Therapy", "POS"]]}
{"row_id": 2142, "sent_id": "2142_0", "text": "Phase 3 study met primary and all secondary efficacy endpoints, noted October 9, 2024.", "triplets": [["phase", "met", "POS"], ["financial", "met", "POS"]]}
{"row_id": 2148, "sent_id": "2148_0", "text": "FDA Approved on October 10, 2024.", "triplets": [["regulatory", "FDA Approved", "POS"]]}
{"row_id": 2149, "sent_id": "2149_0", "text": "FDA Approved on October 10, 2024.", "triplets": [["regulatory", "FDA Approved", "POS"]]}
{"row_id": 2154, "sent_id": "2154_0", "text": "Phase 2b study showed 36% of patients on denifanstat achieved MASH resolution without worsening fibrosis, and 52% had a \u00e2\u2030\u00a52-point NAS reduction.", "triplets": [["phase", "achieved", "POS"]]}
{"row_id": 2154, "sent_id": "2154_1", "text": "With secondary endpoints and a favorable safety profile,", "triplets": [["endpoint", "favorable safety", "POS"], ["safety", "favorable safety", "POS"], ["financial", "favorable safety", "POS"]]}
{"row_id": 2158, "sent_id": "2158_0", "text": "Approved October 11, 2024.", "triplets": [["catalyst", "Approved", "POS"]]}
{"row_id": 2160, "sent_id": "2160_0", "text": "Phase 3 1-year data reported that a greater number of patients that achieved histologic response were observed with mirikizumab at Week 52 in the overall population (58.2% versus 48.8%; p=0.0075), not", "triplets": [["pvalue", "achieved", "POS"], ["phase", "achieved", "POS"]]}
{"row_id": 2161, "sent_id": "2161_0", "text": "Phase 3 data reported that trial met primary endpoint, noted October 14, 2024.", "triplets": [["endpoint", "met", "POS"], ["phase", "met", "POS"]]}
{"row_id": 2163, "sent_id": "2163_0", "text": "IRB approval on US clinical sites for part A of Phase 1/2a, noted October 14, 2024.", "triplets": [["phase", "approval", "POS"], ["regulatory", "approval", "POS"]]}
{"row_id": 2165, "sent_id": "2165_0", "text": "Phase 3 trial met its primary endpoint, noted October 15, 2024.", "triplets": [["endpoint", "met", "POS"], ["phase", "met", "POS"]]}
{"row_id": 2166, "sent_id": "2166_1", "text": "During the meeting, the FDA granted clearance to proceed with pivotal Phase 3 studies, based on the Company's Phase 2/3 clinical data showing symptomatic improvement in early AD", "triplets": [["phase", "FDA granted", "POS"], ["regulatory", "FDA granted", "POS"]]}
{"row_id": 2169, "sent_id": "2169_0", "text": "Phase 1 met its primary endpoint, noted October 15, 2024.", "triplets": [["endpoint", "met", "POS"], ["phase", "met", "POS"]]}
{"row_id": 2170, "sent_id": "2170_0", "text": "FDA approved by the FDA, noted October 15, 2024.", "triplets": [["regulatory", "FDA approved", "POS"]]}
{"row_id": 2171, "sent_id": "2171_0", "text": "FDA approved by the FDA, noted October 15, 2024.", "triplets": [["regulatory", "FDA approved", "POS"]]}
{"row_id": 2172, "sent_id": "2172_0", "text": "Phase 1 portion to continue following review from safety review committee approval to advance to highest dose, noted October 15, 2024.", "triplets": [["safety", "approval", "POS"], ["phase", "approval", "POS"], ["regulatory", "approval", "POS"]]}
{"row_id": 2173, "sent_id": "2173_0", "text": "Phase 3 topline data demonstrated a statistically significant improvement in the primary endpoints of overall survival (OS) and progression-free survival (PFS), as assessed by an independent review f", "triplets": [["endpoint", "statistically significant", "POS"], ["phase", "statistically significant", "POS"], ["clinical", "statistically significant", "POS"]]}
{"row_id": 2177, "sent_id": "2177_0", "text": "Phase 2 interim data from ID week reported that treatment was well-tolerated and immunogenic against both RSV and hMPV in older adults 60 to 85 years of age, noted October 16, 2024.", "triplets": [["safety", "well-tolerated", "POS"], ["phase", "well-tolerated", "POS"]]}
{"row_id": 2179, "sent_id": "2179_0", "text": "IND Cleared by the FDA, noted October 16, 2024.", "triplets": [["regulatory", "Cleared by the FDA", "POS"]]}
{"row_id": 2184, "sent_id": "2184_0", "text": "Second Phase 3 trial met primary endpoint, noted October 16, 2024.", "triplets": [["endpoint", "met", "POS"], ["phase", "met", "POS"]]}
{"row_id": 2187, "sent_id": "2187_0", "text": "Phase 3 data at the NCS showed that the trial met one of its two co-primary endpoints, with 80% of patients achieving SE cessation within 30 minutes.", "triplets": [["endpoint", "met", "POS"], ["phase", "met", "POS"]]}
{"row_id": 2188, "sent_id": "2188_0", "text": "Phase 3 data at the NCS showed that the trial met one of its two co-primary endpoints, with 80% of patients achieving SE cessation within 30 minutes.", "triplets": [["endpoint", "met", "POS"], ["phase", "met", "POS"]]}
{"row_id": 2189, "sent_id": "2189_0", "text": "Phase 1 data reported that patient #3 has achieved 13 months OS to date, with six months progression free survival (PFS).", "triplets": [["endpoint", "achieved", "POS"], ["phase", "achieved", "POS"]]}
{"row_id": 2189, "sent_id": "2189_1", "text": "Patient #4 has not progressed and achieved 12 months PFS and 12 months OS to d", "triplets": [["endpoint", "achieved", "POS"]]}
{"row_id": 2194, "sent_id": "2194_0", "text": "Approved October 17, 2024.", "triplets": [["catalyst", "Approved", "POS"]]}
{"row_id": 2198, "sent_id": "2198_0", "text": "Approved October 17, 2024.", "triplets": [["catalyst", "Approved", "POS"]]}
{"row_id": 2199, "sent_id": "2199_0", "text": "Phase 2b IND placed on clinical hold, noted October 4, 2024.", "triplets": [["phase", "clinical hold", "NEG"], ["regulatory", "clinical hold", "NEG"]]}
{"row_id": 2199, "sent_id": "2199_1", "text": "Phase 2b will be discontinued after clinical hold following the recommendation of the IDMC after its assessment of four Grade 5 (fatal), no", "triplets": [["phase", "clinical hold", "NEG"], ["regulatory", "clinical hold", "NEG"]]}
{"row_id": 2201, "sent_id": "2201_0", "text": "Approved October 18, 2024.", "triplets": [["catalyst", "Approved", "POS"]]}
{"row_id": 2202, "sent_id": "2202_0", "text": "Phase 3 extension data reported that 88% of EYLEA HD patients had a last assigned dosing interval of \u00e2\u2030\u00a512 weeks at week 156, while sustaining visual and anatomic improvements achieved in the first 96 w", "triplets": [["phase", "achieved", "POS"]]}
{"row_id": 2204, "sent_id": "2204_0", "text": "Approved October 21, 2024.", "triplets": [["catalyst", "Approved", "POS"]]}
{"row_id": 2206, "sent_id": "2206_0", "text": "Phase 3 data published at the Journal of Surgery trial showed that despite study did not meet its primary endpoint due to COVID-19-related impacts, pre-specified and post-hoc analyses indicated poten", "triplets": [["endpoint", "did not meet", "NEG"], ["phase", "did not meet", "NEG"]]}
{"row_id": 2207, "sent_id": "2207_0", "text": "Preclinical data reported statistically significant increases in grip strength, motor function and body composition in aged C57BL/6J mouse model, noted October 21, 2024.", "triplets": [["catalyst", "statistically significant", "POS"]]}
{"row_id": 2209, "sent_id": "2209_0", "text": "Preclinical data has shown greater pain relief compared to FDA-approved treatments Gabapentin (Neurontin) and Pregabalin (Lyrica), noted October 21, 2024.", "triplets": [["catalyst", "approved", "POS"]]}
{"row_id": 2210, "sent_id": "2210_0", "text": "Trial data reported that trial met its primary endpoint, noted October 21, 2024.", "triplets": [["endpoint", "met", "POS"]]}
{"row_id": 2213, "sent_id": "2213_0", "text": "Fast Track Designation graned by the FDA, noted October 21, 2024.", "triplets": [["regulatory", "Fast Track", "POS"]]}
{"row_id": 2214, "sent_id": "2214_0", "text": "NDA Approved by the FDA, noted October 21, 2024.", "triplets": [["regulatory", "Approved", "POS"]]}
{"row_id": 2215, "sent_id": "2215_0", "text": "Phase 3 enrollment completed, noted October 21, 2024.", "triplets": [["phase", "enrollment completed", "POS"], ["enrollment", "enrollment completed", "POS"]]}
{"row_id": 2216, "sent_id": "2216_0", "text": "Phase 1/2a long-term results reported that treatment was well-tolerated with 78% of patiences injection-free and 97% reduction in anti-VEGF treatment burden, noted October 21, 2024.", "triplets": [["safety", "well-tolerated", "POS"], ["phase", "well-tolerated", "POS"]]}
{"row_id": 2217, "sent_id": "2217_0", "text": "Phase 1/2a long-term results reported that treatment was well-tolerated with 78% of patiences injection-free and 97% reduction in anti-VEGF treatment burden, noted October 21, 2024.", "triplets": [["safety", "well-tolerated", "POS"], ["phase", "well-tolerated", "POS"]]}
{"row_id": 2218, "sent_id": "2218_0", "text": "Phase 1/2a long-term results reported that treatment was well-tolerated with 78% of patiences injection-free and 97% reduction in anti-VEGF treatment burden, noted October 21, 2024.", "triplets": [["safety", "well-tolerated", "POS"], ["phase", "well-tolerated", "POS"]]}
{"row_id": 2220, "sent_id": "2220_0", "text": "Phase 1/2 DSMB convened and approved enrollment for the second phase, noted October 21, 2024.", "triplets": [["phase", "approved", "POS"]]}
{"row_id": 2221, "sent_id": "2221_0", "text": "Phase 2 final results reported no SAEs and that all subjects challenged had ETEC negative stool at discharge, noted October 22, 2024.", "triplets": [["safety", "no SAEs", "POS"], ["phase", "no SAEs", "POS"]]}
{"row_id": 2222, "sent_id": "2222_0", "text": "FDA Biosimilar approval on October 22, 2024.", "triplets": [["regulatory", "approval", "POS"]]}
{"row_id": 2223, "sent_id": "2223_0", "text": "FDA Biosimilar approval on October 22, 2024.", "triplets": [["regulatory", "approval", "POS"]]}
{"row_id": 2224, "sent_id": "2224_0", "text": "Phase 3 trial had positive outcome of the non-binding, interim futility analysis, noted October 22, 2024.", "triplets": [["phase", "futility", "NEG"]]}
{"row_id": 2230, "sent_id": "2230_0", "text": "FDA Approved on October 22, 2024.", "triplets": [["regulatory", "FDA Approved", "POS"]]}
{"row_id": 2232, "sent_id": "2232_0", "text": "Phase 2 dosing initiated, noted October 22, 2024.", "triplets": [["phase", "dosing initiated", "POS"], ["clinical", "dosing initiated", "POS"]]}
{"row_id": 2246, "sent_id": "2246_1", "text": "The Safety Review Committee approved the move after a favorable safety assessment of Cohort 1, with no significant safety issues or dose-limiting toxicities observed, n", "triplets": [["safety", "favorable safety", "POS"]]}
{"row_id": 2255, "sent_id": "2255_0", "text": "Phase 2 presented data at the Fall Clinical Dermatology Conference highlighting that approximately 51% of tumors treated in Part 2 achieved complete histological clearance and patients with residual t", "triplets": [["phase", "achieved", "POS"]]}
{"row_id": 2257, "sent_id": "2257_0", "text": "Preclinical data reported that of the eight Study groups reported on today, DehydraTECH-CBD group B and the sole DehydraTECH-liraglutide group H were both successful in reducing blood sugar levels, wh", "triplets": [["catalyst", "successful", "POS"]]}
{"row_id": 2260, "sent_id": "2260_0", "text": "Phase 3 data reported that dupixent significantly reduced itch and hive activity from baseline; 41% of patients achieved well-controlled disease status, noted October 24, 2024.", "triplets": [["phase", "achieved", "POS"]]}
{"row_id": 2261, "sent_id": "2261_0", "text": "Phase 3 data reported that dupixent significantly reduced itch and hive activity from baseline; 41% of patients achieved well-controlled disease status, noted October 24, 2024.", "triplets": [["phase", "achieved", "POS"]]}
{"row_id": 2264, "sent_id": "2264_0", "text": "Phase 3 study did not meet the primary endpoint of percent change in 28-day TSC-associated seizure frequency, noted October 24, 2024.", "triplets": [["endpoint", "did not meet", "NEG"], ["phase", "did not meet", "NEG"]]}
{"row_id": 2266, "sent_id": "2266_0", "text": "Phase 2 data presentation at ACAAI showed that deep attack rate reductions achieved in both dose levels tested; a single 50 mg dose resulted in a mean monthly attack rate reduction of 77% and 81% comp", "triplets": [["effect", "achieved", "POS"], ["phase", "achieved", "POS"]]}
{"row_id": 2268, "sent_id": "2268_0", "text": "Preclinical data reported that targeted gene insertion can be achieved using ARCUS in greater than 85% of T cells and 39% of non-dividing primary human hepatocytes, noted October 24, 2024.", "triplets": [["catalyst", "achieved", "POS"]]}
{"row_id": 2276, "sent_id": "2276_0", "text": "Phase 1/2 trial dosing initiated, noted November 29, 2022.", "triplets": [["phase", "dosing initiated", "POS"], ["clinical", "dosing initiated", "POS"]]}
{"row_id": 2276, "sent_id": "2276_1", "text": "Phase 1/2 data presented at EORTC-NCI-AACR reported that 6 out of 11 (54.5%) patients with FGFR3+ mUC achieved a confirmed partial response", "triplets": [["phase", "achieved", "POS"]]}
{"row_id": 2278, "sent_id": "2278_0", "text": "Approved October 25, 2025.", "triplets": [["catalyst", "Approved", "POS"]]}
{"row_id": 2281, "sent_id": "2281_0", "text": "Approved October 25, 2024.", "triplets": [["catalyst", "Approved", "POS"]]}
{"row_id": 2285, "sent_id": "2285_0", "text": "Phase 3 data presented at ACAAI reported that patients treated with sebetralstat 300mg (n=49, P=0.002) and sebetralstat 600mg (n=52, P=0.034) achieved a faster reduction in substantial symptom burden", "triplets": [["pvalue", "achieved", "POS"], ["sample", "achieved", "POS"], ["phase", "achieved", "POS"]]}
{"row_id": 2287, "sent_id": "2287_0", "text": "Phase 1b/2 data presented at the ACAAI reported rapid inhibition of plasma kallikrein was associated with reductions in HAE attacks and with a favorable safety profile during the first 28 days of the", "triplets": [["safety", "favorable safety", "POS"], ["phase", "favorable safety", "POS"]]}
{"row_id": 2288, "sent_id": "2288_0", "text": "Phase 1 preliminary safety data presented at AACR-NCI-EORTC reported acceptable tolerability and encouraging initial antitumor activity, with durability assessment pending longer follow-up, noted Octo", "triplets": [["safety", "data presented at AACR", "POS"], ["phase", "data presented at AACR", "POS"], ["clinical", "data presented at AACR", "POS"]]}
{"row_id": 2294, "sent_id": "2294_0", "text": "Phase 2 efficacy and safety data from ACAAI reported that trial met all primary end secondary endpoints, noted October 26, 2024.", "triplets": [["endpoint", "met", "POS"], ["safety", "met", "POS"], ["phase", "met", "POS"], ["financial", "met", "POS"]]}
{"row_id": 2295, "sent_id": "2295_0", "text": "Phase 3 study results presented at ASN Kidney Week reported a statistically significant 68% (p<0.0001) proteinuria reduction compared to placebo, with reduction observed as early as Week 4, noted Octo", "triplets": [["pvalue", "statistically significant", "POS"], ["effect", "statistically significant", "POS"], ["phase", "statistically significant", "POS"]]}
{"row_id": 2300, "sent_id": "2300_0", "text": "Phase 3 expanded access data reported a statistically significant difference in favor of debamestrocel (LRT, p= 0.0379) with a median survival time of 46.6 months for the debamestrocel group compared", "triplets": [["pvalue", "statistically significant", "POS"], ["phase", "statistically significant", "POS"]]}
{"row_id": 2301, "sent_id": "2301_0", "text": "Phase 3 expanded access data reported a statistically significant difference in favor of debamestrocel (LRT, p= 0.0379) with a median survival time of 46.6 months for the debamestrocel group compared", "triplets": [["pvalue", "statistically significant", "POS"], ["phase", "statistically significant", "POS"]]}
{"row_id": 2303, "sent_id": "2303_0", "text": "IND cleared by the FDA, noted October 28, 2024.", "triplets": [["regulatory", "cleared by the FDA", "POS"]]}
{"row_id": 2304, "sent_id": "2304_0", "text": "Preclinical data reported that on Day 9, at the optimal dose of 300 mg/kg, Ketamir-2 led to near-complete normalization of pain sensitivity, outperforming FDA-approved gabapentin by 60%, which provide", "triplets": [["catalyst", "approved", "POS"]]}
{"row_id": 2305, "sent_id": "2305_0", "text": "Phase 3 portion of the study enrollment completed, noted October 23, 2024.", "triplets": [["phase", "enrollment completed", "POS"], ["enrollment", "enrollment completed", "POS"]]}
{"row_id": 2307, "sent_id": "2307_0", "text": "Phase 3 results reported that a greater number of patients treated with subcutaneous TREMFYA induction and maintenance achieved clinical and endoscopic remission at 48 weeks in the Phase 3 GRAVITI stu", "triplets": [["phase", "achieved", "POS"]]}
{"row_id": 2308, "sent_id": "2308_0", "text": "Phase 3 data reported that 81% of patients maintained long-term clinical remission and 82% achieved long-term endoscopic remission, noted October 28, 2024.", "triplets": [["phase", "achieved", "POS"]]}
{"row_id": 2313, "sent_id": "2313_0", "text": "Phase 1 results presented at ACG Meeting showed no opioid withdrawal effects, reinforcing safety profile, noted October 28, 2024.", "triplets": [["safety", "withdrawal", "NEG"], ["phase", "withdrawal", "NEG"]]}
{"row_id": 2315, "sent_id": "2315_0", "text": "Phase 2 trial met primary and secondary endpoints, noted October 29, 2024.", "triplets": [["endpoint", "met", "POS"], ["phase", "met", "POS"], ["financial", "met", "POS"]]}
{"row_id": 2316, "sent_id": "2316_0", "text": "Phase 3 trial demonstrated a statistically significant 9.2-point reduction in PANSS Total score from baseline at Week 5 compared to placebo, noted October 29, 2024.", "triplets": [["phase", "statistically significant", "POS"]]}
{"row_id": 2317, "sent_id": "2317_0", "text": "BLA resubmitted on October 29, 2024.", "triplets": [["regulatory", "BLA resubmitted", "POS"]]}
{"row_id": 2322, "sent_id": "2322_0", "text": "Phase 2a data presented at CTAD in late breaking presentation showed that that Lomecel-B's ability to inhibit MMP14 activity correlates with improved clinical and biomarker outcomes in Alzheimer's pat", "triplets": [["phase", "data presented at CTAD", "POS"], ["clinical", "data presented at CTAD", "POS"]]}
{"row_id": 2324, "sent_id": "2324_0", "text": "FDA Approved on October 29, 2024.", "triplets": [["regulatory", "FDA Approved", "POS"]]}
{"row_id": 2325, "sent_id": "2325_0", "text": "Phase 2 results presented at CTAD showed a significant slowdown in cognitive decline, particularly in participants with lower plasma p-tau217 levels, an Alzheimer\u00e2\u20ac\u2122s biomarker, noted October 29, 2024.", "triplets": [["phase", "results presented at CTAD", "POS"], ["clinical", "results presented at CTAD", "POS"]]}
{"row_id": 2326, "sent_id": "2326_0", "text": "Phase 2 study did not meet its primary endpoint, based on the planned interim analysis of 16 patients; current development was suspended, noted on October 29, 2024.", "triplets": [["endpoint", "did not meet", "NEG"], ["sample", "did not meet", "NEG"], ["phase", "did not meet", "NEG"]]}
{"row_id": 2329, "sent_id": "2329_0", "text": "Phase 1a topline data from 5 cohorts reported that generally well tolerated and achieved concentrations in the cerebrospinal fluid indicating its potential for target engagement in AD patients, noted", "triplets": [["safety", "achieved", "POS"], ["clinical", "achieved", "POS"]]}
{"row_id": 2330, "sent_id": "2330_0", "text": "Phase 3 enrollment completed, noted October 30, 2024.", "triplets": [["phase", "enrollment completed", "POS"], ["enrollment", "enrollment completed", "POS"]]}
{"row_id": 2335, "sent_id": "2335_0", "text": "Phase 3 data reported statistically significant improvements in mean SBP at 22 weeks, noted October 30, 2024.", "triplets": [["phase", "statistically significant", "POS"]]}
{"row_id": 2338, "sent_id": "2338_0", "text": "Trial development ceased as company non-bidding term-sheet terminated following notification from the prospective partner, company looking for potential asset sale to avoid wind-down or dissolution, n", "triplets": [["partner", "terminated", "NEG"]]}
{"row_id": 2339, "sent_id": "2339_0", "text": "Trial development ceased as company non-bidding term-sheet terminated following notification from the prospective partner, company looking for potential asset sale to avoid wind-down or dissolution, n", "triplets": [["partner", "terminated", "NEG"]]}
{"row_id": 2344, "sent_id": "2344_0", "text": "Phase 2 study met the primary endpoint at 10mg once daily, noted October 31, 2024.", "triplets": [["endpoint", "met", "POS"], ["phase", "met", "POS"]]}
{"row_id": 2347, "sent_id": "2347_0", "text": "Phase 3 data reported primary and secondary endpoints were all highly statistically significant, noted October 31, 2024.", "triplets": [["endpoint", "statistically significant", "POS"], ["phase", "statistically significant", "POS"], ["financial", "statistically significant", "POS"]]}
{"row_id": 2348, "sent_id": "2348_0", "text": "Phase 1/2 data presented at CTAD reported that the expression of plasma GFAP and p-tau 217 biomarkers appears to increase predominantly during MCI and that this is inhibited by pepinemab treatment, no", "triplets": [["phase", "data presented at CTAD", "POS"], ["clinical", "data presented at CTAD", "POS"]]}
{"row_id": 2352, "sent_id": "2352_0", "text": "Phase 3 trial met its primary endpoint, noted November 1, 2024.", "triplets": [["endpoint", "met", "POS"], ["phase", "met", "POS"]]}
{"row_id": 2356, "sent_id": "2356_0", "text": "FDA approved on November 4, 2024.", "triplets": [["regulatory", "FDA approved", "POS"]]}
{"row_id": 2357, "sent_id": "2357_0", "text": "FDA approved on November 4, 2024.", "triplets": [["regulatory", "FDA approved", "POS"]]}
{"row_id": 2363, "sent_id": "2363_0", "text": "Phase 2a data presented at CTAD confirmed recent scientific literature indicating that plasma glial fibrillary acid protein (GFAP) is a robust measure of neurodegenerative disease activity in DLB.", "triplets": [["phase", "data presented at CTAD", "POS"], ["clinical", "data presented at CTAD", "POS"]]}
{"row_id": 2364, "sent_id": "2364_0", "text": "Preclinical preliminary data from a diet-induced obesity (DIO) model in mice, achieved significant dose-dependent weight loss of up to 16% compared to vehicle, highlighting a novel peripherally-driven", "triplets": [["catalyst", "achieved", "POS"]]}
{"row_id": 2366, "sent_id": "2366_0", "text": "The FDA cleared the Phase 2 trial, noted on November 4, 2024.", "triplets": [["phase", "FDA cleared", "POS"], ["regulatory", "FDA cleared", "POS"]]}
{"row_id": 2372, "sent_id": "2372_0", "text": "Preclinical data presented at SITC demonstrated strong anti-tumor activity in multiple CDX and PDX tumor models.", "triplets": [["clinical", "data presented at SITC", "POS"]]}
{"row_id": 2373, "sent_id": "2373_0", "text": "Phase 2 trial showed that patients with acquired hypothalamic obesity who were on therapy for more than one year achieved a mean overall percent reduction in fat mass of 29.6%, versus a reduction in l", "triplets": [["phase", "achieved", "POS"], ["partner", "achieved", "POS"]]}
{"row_id": 2374, "sent_id": "2374_0", "text": "Phase 3 study demonstrated a statistically significant (p=0.0002) longer time to relapse in schizophrenia patients treated with lumateperone compared to placebo, noted November 5, 2024.", "triplets": [["pvalue", "statistically significant", "POS"], ["phase", "statistically significant", "POS"]]}
{"row_id": 2376, "sent_id": "2376_0", "text": "Phase 1/2 data presented at SITC reported a disease control rates were 86% and 47% for the 200 mg and 100 mg NC410 doses, respectively, noted November 6, 2024.", "triplets": [["phase", "data presented at SITC", "POS"], ["clinical", "data presented at SITC", "POS"]]}
{"row_id": 2377, "sent_id": "2377_0", "text": "Phase 3 data presented at ESMO Asia with an overall response was achieved by 81%, noted November 6, 2024.", "triplets": [["phase", "achieved", "POS"], ["clinical", "achieved", "POS"]]}
{"row_id": 2384, "sent_id": "2384_0", "text": "Phase 1 data presented at SITC revealed the clinical potential of the tumor-activated IL-12 prodrug WTX-330, with favorable tolerability profile and encouraging efficacy signal, noted November 7, 2024", "triplets": [["safety", "data presented at SITC", "POS"], ["phase", "data presented at SITC", "POS"], ["clinical", "data presented at SITC", "POS"]]}
{"row_id": 2386, "sent_id": "2386_0", "text": "Preclinical data presented at SITC reported durable disease control in majority of heavily pretreated patients, noted November 7, 2024.", "triplets": [["clinical", "data presented at SITC", "POS"]]}
{"row_id": 2387, "sent_id": "2387_0", "text": "Phase 2 data presented at SITC reported an overall response rate of 55% unconfirmed/48% confirmed, disease control rate of 81%, and approximately 50% of patients without disease progression at 12 mont", "triplets": [["phase", "data presented at SITC", "POS"], ["clinical", "data presented at SITC", "POS"]]}
{"row_id": 2392, "sent_id": "2392_0", "text": "Phase 2 data reported at SITC demonstrated statistically significant superiority of the eight-week absolute lymphocyte count with NKTR-255 post chemoradiation and in combination with durvalumab versus", "triplets": [["phase", "statistically significant", "POS"]]}
{"row_id": 2395, "sent_id": "2395_0", "text": "Preclnical PoC data presented at SITC supports the potential of CD3 Switch-DARPin platform to activate and boost T cells in the presence of tumor targets only, November 7, 2024.", "triplets": [["clinical", "data presented at SITC", "POS"]]}
{"row_id": 2396, "sent_id": "2396_0", "text": "Phase 3 trial did not meet primary endpoint, noted November 7, 2024.", "triplets": [["endpoint", "did not meet", "NEG"], ["phase", "did not meet", "NEG"]]}
{"row_id": 2397, "sent_id": "2397_0", "text": "Phase 2 data presented at SITC reported a 35% improvement in overall survival and 25% improvement in progression-free survival versus standard-of-care alone, noted November 8, 2024.", "triplets": [["phase", "data presented at SITC", "POS"], ["clinical", "data presented at SITC", "POS"]]}
{"row_id": 2400, "sent_id": "2400_0", "text": "Phase 1a data presented at SITC reported that the highest three quartiles of T cell responders have not yet reached mDFS, whereas the lowest quartile achieved a mDFS of 3.1 months, noted November 8, 2", "triplets": [["clinical", "achieved", "POS"]]}
{"row_id": 2401, "sent_id": "2401_0", "text": "Phase 3 data reported a statistically significant and clinically meaningful reduction in nasal polyp size and reduced nasal congestion compared to placebo, noted November 8, 2024.", "triplets": [["phase", "statistically significant", "POS"]]}
{"row_id": 2402, "sent_id": "2402_0", "text": "Phase 3 data reported a statistically significant and clinically meaningful reduction in nasal polyp size and reduced nasal congestion compared to placebo, noted November 8, 2024.", "triplets": [["phase", "statistically significant", "POS"]]}
{"row_id": 2403, "sent_id": "2403_0", "text": "Phase 3 trial had a statistically significant and clinically meaningful reduction in the size of nasal polyps and reduced nasal congestion compared to placebo, noted November 8, 2024.", "triplets": [["phase", "statistically significant", "POS"]]}
{"row_id": 2409, "sent_id": "2409_0", "text": "Phase 1 new data presented at SITC showed a correlation between the levels of neural cell adhesion molecule (NCAM or CD56) expression and response and disease control in patients treated with CTX-471", "triplets": [["phase", "data presented at SITC", "POS"], ["clinical", "data presented at SITC", "POS"]]}
{"row_id": 2410, "sent_id": "2410_0", "text": "Phase 1a additional data presented at SITC showed that vaccine was safe and well tolerated by participants in all 3 cohorts, noted November 8, 2024.", "triplets": [["safety", "well tolerated", "POS"], ["clinical", "well tolerated", "POS"]]}
{"row_id": 2412, "sent_id": "2412_0", "text": "FDA Approved on November 8, 2024.", "triplets": [["regulatory", "FDA Approved", "POS"]]}
{"row_id": 2417, "sent_id": "2417_0", "text": "Preclinical data reported that the combined treatment demonstrated significant improvement in behavioral outcomes related to severe stress-induced conditions as compared to using either agent alone, n", "triplets": [["clinical", "significant improvement", "POS"]]}
{"row_id": 2418, "sent_id": "2418_0", "text": "Phase 1/2 data presented at SITC showed a three-fold increased active (e.g., cleaved) drug exposure in homogenized tumor tissue samples at 10 mg/kg versus a single dose of ipilimumab at 1 mg/kg while", "triplets": [["phase", "data presented at SITC", "POS"], ["clinical", "data presented at SITC", "POS"]]}
{"row_id": 2420, "sent_id": "2420_0", "text": "Phase 3 data presented at SITC reported that the median overall survival for the trial has not been reached, however, one-, two-, and three-year survival rates were 75.3%, 63.3%, and 54.8%, respective", "triplets": [["phase", "data presented at SITC", "POS"], ["clinical", "data presented at SITC", "POS"]]}
{"row_id": 2421, "sent_id": "2421_0", "text": "Phase 1 data presented at SITC demonstrated durable antitumor activity in heavily pretreated patients with anti\u00e2\u20ac\u201cPD-1\u00e2\u20ac\u201cresistant cancer across multiple cancer types , noted November 9, 2024.", "triplets": [["phase", "data presented at SITC", "POS"], ["clinical", "data presented at SITC", "POS"]]}
{"row_id": 2423, "sent_id": "2423_0", "text": "Phase 1 data presented at SITC 2024 reported that a dose range between 8-12 mg/kg Q2W was identified as the preferred dose range for heavily pre-treated GEC patients., noted November 9, 2024.", "triplets": [["phase", "data presented at SITC", "POS"], ["clinical", "data presented at SITC", "POS"]]}
{"row_id": 2424, "sent_id": "2424_0", "text": "Phase 1b/2 data presented at SITC reported that OS was greater with zim than with chemo, noted November 9, 2024.", "triplets": [["endpoint", "data presented at SITC", "POS"], ["phase", "data presented at SITC", "POS"], ["clinical", "data presented at SITC", "POS"]]}
{"row_id": 2426, "sent_id": "2426_0", "text": "Phase 2a dosing initiated, noted November 11, 2024.", "triplets": [["phase", "dosing initiated", "POS"], ["clinical", "dosing initiated", "POS"]]}
{"row_id": 2431, "sent_id": "2431_0", "text": "Phase 2 hold removed, FDA cleared study to begin enrolling in planned Phase 3 trial, noted November 11, 2024.", "triplets": [["phase", "FDA cleared", "POS"], ["regulatory", "FDA cleared", "POS"]]}
{"row_id": 2433, "sent_id": "2433_0", "text": "Phase 2 trial did not meet their primary endpoint, noted November 11, 2024.", "triplets": [["endpoint", "did not meet", "NEG"], ["phase", "did not meet", "NEG"]]}
{"row_id": 2434, "sent_id": "2434_0", "text": "Phase 1 data presented at SITC indicated that trial endpoints of adequate exposure, safety, tolerability and biological activity were met, noted November 11, 2024.", "triplets": [["safety", "met", "POS"], ["phase", "met", "POS"], ["clinical", "met", "POS"]]}
{"row_id": 2435, "sent_id": "2435_0", "text": "IRB approval on track as scheduled, company plans new phase of treatment evaluation expected 1Q 2025, noted November 11, 2024.", "triplets": [["regulatory", "approval", "POS"]]}
{"row_id": 2437, "sent_id": "2437_0", "text": "Phase 1 data reported that treatment was well-tolerated with no DLTs and no events of any grade of CRS, ICANS, or GvHD, noted November 11, 2024.", "triplets": [["safety", "well-tolerated", "NEU"], ["phase", "well-tolerated", "NEU"]]}
{"row_id": 2438, "sent_id": "2438_0", "text": "Phase 1/2 data reported statistically significant separation between the GTX-102 and sham arms, noted November 11, 2024.", "triplets": [["phase", "statistically significant", "POS"]]}
{"row_id": 2440, "sent_id": "2440_0", "text": "Preclinical data presented at SITC showed robust antigen-mediated expansion, functional persistence, and durable anti-tumor activity in the presence of alloreactive T cells, noted November 11, 2024.", "triplets": [["clinical", "data presented at SITC", "POS"]]}
{"row_id": 2445, "sent_id": "2445_0", "text": "Phase 2 topline results showed that the trial met its primary endpoint.", "triplets": [["endpoint", "met", "POS"], ["phase", "met", "POS"], ["clinical", "met", "POS"]]}
{"row_id": 2445, "sent_id": "2445_1", "text": "Revumenib demonstrated a favorable safety profile with only 5% treatment-related discontinuation, noted November 12, 2024.", "triplets": [["safety", "favorable safety", "POS"]]}
{"row_id": 2450, "sent_id": "2450_0", "text": "Voluntarily withdrawn November 12, 2024.", "triplets": [["catalyst", "withdrawn", "NEG"]]}
{"row_id": 2451, "sent_id": "2451_0", "text": "BLA submitted November 12, 2024.", "triplets": [["regulatory", "BLA submitted", "POS"]]}
{"row_id": 2452, "sent_id": "2452_0", "text": "108 patients have completed 1-year of treatment which is generally well tolerated to date in patients with acute and stable schizophrenia, noted November 12, 2024.", "triplets": [["safety", "well tolerated", "POS"], ["sample", "well tolerated", "POS"]]}
{"row_id": 2454, "sent_id": "2454_0", "text": "Phase 1 interim data showed a favorable safety profile and strong pharmacokinetics with a half-life over 90 days\u00e2\u20ac\u201dfour times longer than vedolizumab, noted November 12, 2024.", "triplets": [["safety", "favorable safety", "POS"], ["phase", "favorable safety", "POS"]]}
{"row_id": 2457, "sent_id": "2457_0", "text": "Phase 3 52 week extension data indicated that LYR-210 was generally well tolerated over the extended treatment period, including among patients who received repeat dosing for a total of 12 months.", "triplets": [["safety", "well tolerated", "POS"], ["phase", "well tolerated", "POS"]]}
{"row_id": 2465, "sent_id": "2465_0", "text": "Approved November 13, 2024.", "triplets": [["catalyst", "Approved", "POS"]]}
{"row_id": 2466, "sent_id": "2466_0", "text": "Approved November 13, 2024.", "triplets": [["catalyst", "Approved", "POS"]]}
{"row_id": 2467, "sent_id": "2467_0", "text": "Additional Phase 3 data reported that the trial met the key secondary endpoint of overall survival (OS), noted November 14, 2024.", "triplets": [["endpoint", "met", "POS"], ["phase", "met", "POS"], ["financial", "met", "POS"]]}
{"row_id": 2474, "sent_id": "2474_0", "text": "Phase 2 data reported nominally statistically significant improvements in MACrO2 measured from baseline to month 6 in post-hoc analysis, noted November 14, 2024.", "triplets": [["phase", "statistically significant", "POS"]]}
{"row_id": 2477, "sent_id": "2477_0", "text": "Phase 2b data presented at AASLD reported that treatment improved patients' FAST scores but also achieved both MASH resolution and fibrosis improvement, noted November 15, 2024.", "triplets": [["phase", "achieved", "POS"], ["clinical", "achieved", "POS"]]}
{"row_id": 2478, "sent_id": "2478_0", "text": "IND cleared by the FDA, noted November 15, 2024.", "triplets": [["regulatory", "cleared by the FDA", "POS"]]}
{"row_id": 2479, "sent_id": "2479_0", "text": "Phase 2a data presented at AASLD reported that 50% of patients who had baseline HBsAg levels less than 1000 IU/mL achieved functional cure in Cohort A1, noted November 15, 2024.", "triplets": [["phase", "achieved", "POS"], ["clinical", "achieved", "POS"]]}
{"row_id": 2480, "sent_id": "2480_0", "text": "Phase 3 data reported that 81% (30 out of 37) of participants with primary biliary cholangitis (PBC) treated with Livdelzi\u00c2\u00ae (seladelpar) achieved a composite biochemical response, noted November 15, 2", "triplets": [["phase", "achieved", "POS"]]}
{"row_id": 2482, "sent_id": "2482_0", "text": "Phase 1b data presented at AASLD reported that treatment reduced LFC relative to baseline by up to 68.5% and decreased total cholesterol and triglycerides by up to 12.2% and 44.6%, respectively, after", "triplets": [["phase", "data presented at AASLD", "POS"], ["clinical", "data presented at AASLD", "POS"]]}
{"row_id": 2483, "sent_id": "2483_0", "text": "Phase 2 data reported that 39% of participants with low baseline Hepatitis B surface antigen (HBsAg) achieved HBsAg loss with tobevibart + elebsiran, and 46% with tobevibart + elebsiran + pegylated in", "triplets": [["phase", "achieved", "POS"]]}
{"row_id": 2484, "sent_id": "2484_0", "text": "Phase 2 data reported that 39% of participants with low baseline Hepatitis B surface antigen (HBsAg) achieved HBsAg loss with tobevibart + elebsiran, and 46% with tobevibart + elebsiran + pegylated in", "triplets": [["phase", "achieved", "POS"]]}
{"row_id": 2485, "sent_id": "2485_0", "text": "FDA approved on November 15, 2024.", "triplets": [["regulatory", "FDA approved", "POS"]]}
{"row_id": 2486, "sent_id": "2486_0", "text": "Phase 3 data presented at ACR Convergence with statistically significant 87% reduction in the risk of IgG4-RD flare compared to placebo, noted November 15, 2024.", "triplets": [["phase", "statistically significant", "POS"]]}
{"row_id": 2489, "sent_id": "2489_0", "text": "Phase 2b additional 96-Week data presented at AASLD reported an over 40% of participants treated with EFX 50mg for 96 weeks, compared with 0% for placebo, showed regression of liver fibrosis by all of", "triplets": [["phase", "data presented at AASLD", "POS"], ["clinical", "data presented at AASLD", "POS"]]}
{"row_id": 2490, "sent_id": "2490_0", "text": "Phase 2b additional 96-Week data presented at AASLD reported an over 40% of participants treated with EFX 50mg for 96 weeks, compared with 0% for placebo, showed regression of liver fibrosis by all of", "triplets": [["phase", "data presented at AASLD", "POS"], ["clinical", "data presented at AASLD", "POS"]]}
{"row_id": 2492, "sent_id": "2492_0", "text": "Phase 1 additional data from AHA reported mean reductions of greater than 90% from baseline achieved at Day 15 and sustained through at least Day 180, noted November 17, 2024.", "triplets": [["phase", "achieved", "POS"]]}
{"row_id": 2495, "sent_id": "2495_0", "text": "Phase 2a data presented at AASLD reported that 50% percent of patients saw their HbA1c levels below 6.5% at week 24 following treatment with lanifibranor alone or in combination with empagliflozin, no", "triplets": [["phase", "data presented at AASLD", "POS"], ["clinical", "data presented at AASLD", "POS"]]}
{"row_id": 2499, "sent_id": "2499_0", "text": "Phase 3 data presented at ACR Convergence demonstrated statistically significant improvement in the primary endpoint of fibromyalgia neoplastic pain and in all six key secondary endpoints, including s", "triplets": [["endpoint", "statistically significant", "POS"], ["phase", "statistically significant", "POS"], ["financial", "statistically significant", "POS"], ["clinical", "statistically significant", "POS"]]}
{"row_id": 2508, "sent_id": "2508_0", "text": "IND cleared by the FDA, noted November 18, 2024.", "triplets": [["regulatory", "cleared by the FDA", "POS"]]}
{"row_id": 2514, "sent_id": "2514_0", "text": "NDA submitted November 18, 2024.", "triplets": [["regulatory", "NDA submitted", "POS"]]}
{"row_id": 2521, "sent_id": "2521_0", "text": "Phase 3 data presented at AHA showed that the trial met its primary endpoint with an LDL-C mean reduction versus placebo of 36.3% at day 84 and 41.5% at day 365, noted November 18, 2024.", "triplets": [["endpoint", "met", "POS"], ["effect", "met", "POS"], ["phase", "met", "POS"]]}
{"row_id": 2523, "sent_id": "2523_0", "text": "Phase 3 study met its co-primary endpoints in patients with moderate to severe plaque psoriasis, noted November 18, 2024.", "triplets": [["endpoint", "met", "POS"], ["phase", "met", "POS"]]}
{"row_id": 2524, "sent_id": "2524_0", "text": "Phase 3 study met its co-primary endpoints in patients with moderate to severe plaque psoriasis, noted November 18, 2024.", "triplets": [["endpoint", "met", "POS"], ["phase", "met", "POS"]]}
{"row_id": 2525, "sent_id": "2525_0", "text": "Phase 3 study showed once daily icotrokinra met the primary endpoint of IGA of 0/1 at week 16 compared to placebo, noted November 18, 2024.", "triplets": [["endpoint", "met", "POS"], ["phase", "met", "POS"]]}
{"row_id": 2526, "sent_id": "2526_0", "text": "Phase 3 study showed once daily icotrokinra met the primary endpoint of IGA of 0/1 at week 16 compared to placebo, noted November 18, 2024.", "triplets": [["endpoint", "met", "POS"], ["phase", "met", "POS"]]}
{"row_id": 2527, "sent_id": "2527_0", "text": "Phase 2 enrollment paused, noted November 18, 2024.", "triplets": [["phase", "enrollment paused", "NEG"]]}
{"row_id": 2530, "sent_id": "2530_0", "text": "Phase 2a data presented at AASLD reported a stable ELF score from Week 12 to Week 24, with a reduction in participants with an ELF score of >9.8 at baseline, noted November 18, 2024.", "triplets": [["phase", "data presented at AASLD", "POS"], ["clinical", "data presented at AASLD", "POS"]]}
{"row_id": 2534, "sent_id": "2534_0", "text": "Phase 2b data presented at AASLD reported rapid and statistically significant reductions in cholestatic pruritus were observed after treatment, noted November 18, 2024.", "triplets": [["phase", "statistically significant", "POS"], ["clinical", "statistically significant", "POS"]]}
{"row_id": 2536, "sent_id": "2536_0", "text": "Phase 2 study met at the 12-week its primary endpoint, noted November 18, 2024.", "triplets": [["endpoint", "met", "POS"], ["phase", "met", "POS"]]}
{"row_id": 2538, "sent_id": "2538_0", "text": "Phase 1b data presenteed at ACR showed patient treated with fludarabine-free conditioning and single-dose FT819; favorable safety profile with no grade \u00e2\u2030\u00a53 adverse events and no events of CRS, ICANS, o", "triplets": [["safety", "favorable safety", "POS"], ["phase", "favorable safety", "POS"]]}
{"row_id": 2539, "sent_id": "2539_0", "text": "Phase 1 initial data showed a favorable safety profile, complete responses, and persistence of FT522 live cells, noted November 18, 2024.", "triplets": [["safety", "favorable safety", "POS"], ["phase", "favorable safety", "POS"]]}
{"row_id": 2540, "sent_id": "2540_0", "text": "Phase 2 data presented at AASLD met the trial's primary endpoint, demonstrating a favorable safety profile over the 15-week treatment period on November 19, 2024.", "triplets": [["endpoint", "met", "POS"], ["safety", "met", "POS"], ["phase", "met", "POS"], ["clinical", "met", "POS"]]}
{"row_id": 2541, "sent_id": "2541_0", "text": "Phase 3 data reported that the trial met its primary endpoint, noted November 19, 2024.", "triplets": [["endpoint", "met", "POS"], ["phase", "met", "POS"]]}
{"row_id": 2543, "sent_id": "2543_0", "text": "Phase 3 trial met primary endpoint, noted November 19, 2024.", "triplets": [["endpoint", "met", "POS"], ["phase", "met", "POS"]]}
{"row_id": 2546, "sent_id": "2546_0", "text": "Phase 3a data reported that treatment had safe and well-tolerated profile, noted November 19, 2024.", "triplets": [["safety", "well-tolerated", "POS"]]}
{"row_id": 2547, "sent_id": "2547_0", "text": "Phase 2 DSMB review of interim data completed, the DSMB determined that, while the mRNA control arm of the study failed to meet the predetermined primary endpoint, the study should continue enrollment", "triplets": [["endpoint", "failed to meet", "NEG"], ["phase", "failed to meet", "NEG"]]}
{"row_id": 2549, "sent_id": "2549_0", "text": "Phase 2 additional expansion cohort dosing initiated, noted November 19, 2024.", "triplets": [["phase", "dosing initiated", "POS"], ["clinical", "dosing initiated", "POS"]]}
{"row_id": 2552, "sent_id": "2552_0", "text": "Phase 2b 52 week data presented at AASLD summarized results including successful achievement of study's primary and secondary endpoints, noted November 19, 2024.", "triplets": [["endpoint", "successful", "POS"], ["phase", "successful", "POS"], ["financial", "successful", "POS"], ["clinical", "successful", "POS"]]}
{"row_id": 2553, "sent_id": "2553_0", "text": "Phase 2b 52 week data presented at AASLD summarized results including successful achievement of study's primary and secondary endpoints, noted November 19, 2024.", "triplets": [["endpoint", "successful", "POS"], ["phase", "successful", "POS"], ["financial", "successful", "POS"], ["clinical", "successful", "POS"]]}
{"row_id": 2555, "sent_id": "2555_0", "text": "Phase 2 topline data reported that the trial did not meet its primary endpoint, noted November 20, 2024.", "triplets": [["endpoint", "did not meet", "NEG"], ["phase", "did not meet", "NEG"], ["clinical", "did not meet", "NEG"]]}
{"row_id": 2556, "sent_id": "2556_0", "text": "Phase 2 topline data reported that the trial did not meet its primary endpoint, noted November 20, 2024.", "triplets": [["endpoint", "did not meet", "NEG"], ["phase", "did not meet", "NEG"], ["clinical", "did not meet", "NEG"]]}
{"row_id": 2557, "sent_id": "2557_0", "text": "Phase 2/3 data reported that the trial met its primary endpoint, noted November 20, 2024.", "triplets": [["endpoint", "met", "POS"], ["phase", "met", "POS"]]}
{"row_id": 2559, "sent_id": "2559_0", "text": "Phase 3 partial topline data indicated that PRF-110 demonstrated statistically significant superiority over placebo in reducing pain during the first 48 hours following surgery, noted November 20, 202", "triplets": [["phase", "statistically significant", "POS"], ["clinical", "statistically significant", "POS"]]}
{"row_id": 2561, "sent_id": "2561_0", "text": "Phase 3 study achieved all co-primary endpoints of LS mean reduction in LDL-C on top of maximally tolerated lipid-modifying therapies versus each of placebo, ezetimibe 10 mg, and obicetrapib 10 mg mon", "triplets": [["endpoint", "achieved", "POS"], ["effect", "achieved", "POS"], ["phase", "achieved", "POS"]]}
{"row_id": 2562, "sent_id": "2562_0", "text": "Phase 1b/2a study achieved a 90% reduction in leukemic blasts within the first 30 days of treatment, continuing the overall efficacy trend seen in prior studies, noted November 20, 2024.", "triplets": [["phase", "achieved", "POS"]]}
{"row_id": 2563, "sent_id": "2563_0", "text": "Phase 1b/2a study achieved a 90% reduction in leukemic blasts within the first 30 days of treatment, continuing the overall efficacy trend seen in prior studies, noted November 20, 2024.", "triplets": [["phase", "achieved", "POS"]]}
{"row_id": 2566, "sent_id": "2566_0", "text": "Phase 1 preliminary clinical data achieved a confirmed 50% objective response rate (ORR) based on RECIST 1.1 criteria, including one complete response and a disease control rate (DCR) of 100% in six h", "triplets": [["endpoint", "achieved", "POS"], ["phase", "achieved", "POS"]]}
{"row_id": 2567, "sent_id": "2567_1", "text": "This recommendation was based on the absence of any dose limiting toxicities (DLT's),", "triplets": [["safety", "DLT", "NEG"]]}
{"row_id": 2572, "sent_id": "2572_0", "text": "Approved November 21, 2024.", "triplets": [["catalyst", "Approved", "POS"]]}
{"row_id": 2573, "sent_id": "2573_0", "text": "Approved November 21, 2024.", "triplets": [["catalyst", "Approved", "POS"]]}
{"row_id": 2574, "sent_id": "2574_0", "text": "Approved November 21, 2024.", "triplets": [["catalyst", "Approved", "POS"]]}
{"row_id": 2579, "sent_id": "2579_0", "text": "FDA approved on November 22, 2024.", "triplets": [["regulatory", "FDA approved", "POS"]]}
{"row_id": 2580, "sent_id": "2580_0", "text": "FDA approved on November 22, 2024.", "triplets": [["regulatory", "FDA approved", "POS"]]}
{"row_id": 2583, "sent_id": "2583_0", "text": "Phase 3 trial met primary endpoint, noted November 25, 2024.", "triplets": [["endpoint", "met", "POS"], ["phase", "met", "POS"]]}
{"row_id": 2584, "sent_id": "2584_0", "text": "Phase 3 trial data demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of radiographic progression-free survival (rPFS), noted November 25, 2024.", "triplets": [["endpoint", "statistically significant", "POS"], ["phase", "statistically significant", "POS"]]}
{"row_id": 2587, "sent_id": "2587_0", "text": "Phase 3 trial did not meet primary endpoint, noted November 25, 2024.", "triplets": [["endpoint", "did not meet", "NEG"], ["phase", "did not meet", "NEG"]]}
{"row_id": 2588, "sent_id": "2588_0", "text": "Phase 3 EoP Type C Meeting with the FDA resulted in clear, constructive, and actionable guidance underscoring a pathway to support a future NDA submission, noted November 25, 2024.", "triplets": [["phase", "NDA submission", "POS"], ["regulatory", "NDA submission", "POS"]]}
{"row_id": 2593, "sent_id": "2593_0", "text": "Phase 2 failed to meet primary and secondary endpoints.", "triplets": [["endpoint", "failed to meet", "NEG"], ["phase", "failed to meet", "NEG"], ["financial", "failed to meet", "NEG"]]}
{"row_id": 2594, "sent_id": "2594_0", "text": "Phase 2 failed to meet primary and secondary endpoints.", "triplets": [["endpoint", "failed to meet", "NEG"], ["phase", "failed to meet", "NEG"], ["financial", "failed to meet", "NEG"]]}
{"row_id": 2598, "sent_id": "2598_0", "text": "Phase 2 study failed to meet primary and secondary efficacy endpoints.", "triplets": [["phase", "failed to meet", "NEG"], ["financial", "failed to meet", "NEG"]]}
{"row_id": 2599, "sent_id": "2599_0", "text": "BLA submitted, noted November 26, 2024.", "triplets": [["regulatory", "BLA submitted", "POS"]]}
{"row_id": 2601, "sent_id": "2601_0", "text": "Phase 2b enrollment completed, noted November 26, 2024.", "triplets": [["phase", "enrollment completed", "POS"], ["enrollment", "enrollment completed", "POS"]]}
{"row_id": 2602, "sent_id": "2602_0", "text": "NORSE EIGHT trial did not meet the SPA primary endpoint, noted November 27, 2024.", "triplets": [["endpoint", "did not meet", "NEG"]]}
{"row_id": 2605, "sent_id": "2605_0", "text": "CRL announced November 27, 2024.", "triplets": [["regulatory", "CRL", "NEG"]]}
{"row_id": 2608, "sent_id": "2608_0", "text": "Phase 1 PK data reported that treatment was well-tolerated with half-life of approximately 55 days, supporting potential for 2- to 3- month dosing and demonstrating deep and sustained inhibition of bi", "triplets": [["safety", "well-tolerated", "POS"], ["phase", "well-tolerated", "POS"]]}
{"row_id": 2609, "sent_id": "2609_0", "text": "Phase 1 initial data reported that 2 of 3 patients achieved MRD negative CR in the first dose level evaluated in the trial with a generally well-tolerated preliminary safety profile, noted December 2,", "triplets": [["endpoint", "achieved", "POS"], ["safety", "achieved", "POS"], ["phase", "achieved", "POS"]]}
{"row_id": 2610, "sent_id": "2610_0", "text": "Phase 3 final data showed that study met its primary endpoint with a statistically significant improvement in overall survival for patients, noted December 2, 2024.", "triplets": [["endpoint", "met", "POS"], ["phase", "met", "POS"], ["clinical", "met", "POS"]]}
{"row_id": 2615, "sent_id": "2615_0", "text": "FDA Fast track designation granted by the FDA, noted December 2, 2024.", "triplets": [["regulatory", "Fast track", "POS"]]}
{"row_id": 2616, "sent_id": "2616_0", "text": "BLA submission on December 2, 2024.", "triplets": [["regulatory", "BLA submission", "POS"]]}
{"row_id": 2617, "sent_id": "2617_0", "text": "Phase 1a interim update achieved 100% PSA50 declines, 63% PSA90 declines, and 31% PSA99 declines, with durable responses observed at \u00e2\u2030\u00a512 weeks.", "triplets": [["catalyst", "achieved", "POS"]]}
{"row_id": 2618, "sent_id": "2618_0", "text": "Phase 1b/2a dosing initiated, noted December 2, 2024.", "triplets": [["phase", "dosing initiated", "POS"], ["clinical", "dosing initiated", "POS"]]}
{"row_id": 2620, "sent_id": "2620_0", "text": "Phase 1 dosing initiated, noted December 2, 2024.", "triplets": [["phase", "dosing initiated", "POS"], ["clinical", "dosing initiated", "POS"]]}
{"row_id": 2623, "sent_id": "2623_0", "text": "Fast Track Designation granted by the FDA, noted December 3, 2024.", "triplets": [["regulatory", "Fast Track", "POS"]]}
{"row_id": 2625, "sent_id": "2625_0", "text": "Phase 2 data did not meet its primary endpoints.", "triplets": [["endpoint", "did not meet", "NEG"], ["phase", "did not meet", "NEG"]]}
{"row_id": 2627, "sent_id": "2627_0", "text": "The phase 1 study showed statistically significant lower \"Drug Liking\" scores for clinical doses of oral nalbuphine (81mg and 162mg) compared to IV butorphanol (6mg), supporting its low abuse potentia", "triplets": [["phase", "statistically significant", "POS"]]}
{"row_id": 2628, "sent_id": "2628_0", "text": "FDA granted Fast Track Designation on December 3, 2024.", "triplets": [["regulatory", "Fast Track", "POS"]]}
{"row_id": 2630, "sent_id": "2630_0", "text": "Phase 1 dosing initiated, noted December 3, 2024.", "triplets": [["phase", "dosing initiated", "POS"], ["clinical", "dosing initiated", "POS"]]}
{"row_id": 2631, "sent_id": "2631_0", "text": "Phase 2 enrollment completed, noted December 3, 2024", "triplets": [["phase", "enrollment completed", "POS"], ["enrollment", "enrollment completed", "POS"]]}
{"row_id": 2634, "sent_id": "2634_0", "text": "Phase 2 data met its primary endpoints of safety and sustained virologic response at 12 weeks post-treatment (SVR12), noted December 4, 2024.", "triplets": [["endpoint", "met", "POS"], ["safety", "met", "POS"], ["phase", "met", "POS"]]}
{"row_id": 2637, "sent_id": "2637_0", "text": "Phase 2b 18-month data showed statistically significant results.", "triplets": [["phase", "statistically significant", "POS"]]}
{"row_id": 2639, "sent_id": "2639_0", "text": "Approved December 5, 2024.", "triplets": [["catalyst", "Approved", "POS"]]}
{"row_id": 2640, "sent_id": "2640_0", "text": "Phase 2 initial data demonstrated a favorable safety profile and targeted levels of GSPT1 degradation using a 21 days on, 7 days off drug dosing schedule in heavily pretreated solid tumor patients, no", "triplets": [["safety", "favorable safety", "POS"], ["phase", "favorable safety", "POS"]]}
{"row_id": 2643, "sent_id": "2643_0", "text": "Approved December 5, 2024.", "triplets": [["catalyst", "Approved", "POS"]]}
{"row_id": 2644, "sent_id": "2644_0", "text": "Approved December 5, 2024.", "triplets": [["catalyst", "Approved", "POS"]]}
{"row_id": 2653, "sent_id": "2653_0", "text": "Phase 3 OLE long-term safety and efficacy data presented at AES showed that drug achieved 85% sustained monthly seizure reduction at 36 months and one-year seizure freedom in 33% of patients.", "triplets": [["safety", "achieved", "POS"], ["phase", "achieved", "POS"]]}
{"row_id": 2657, "sent_id": "2657_0", "text": "Phase 2 data presented at ASH reported a clinically significant 2-point decrease on the VAS scale to mild by Week 13 (VAS<4), in S\u00c3\u00a9zary Syndrome Patients, and improvement in Itch intensity from Week 5", "triplets": [["phase", "data presented at ASH", "POS"], ["clinical", "data presented at ASH", "POS"]]}
{"row_id": 2658, "sent_id": "2658_0", "text": "Phase 1/2 data presented at ASH reported that all seven patients treated with BEAM-101 achieved hemoglobin F (HbF) induction of >60%, noted December 7, 2024.", "triplets": [["phase", "achieved", "POS"], ["clinical", "achieved", "POS"]]}
{"row_id": 2660, "sent_id": "2660_0", "text": "Phase 1/2 escalation data from ASH reported that across all dose levels explored, cemsidomide achieved a 38 percent ORR and 19 percent CMR rate, and in patients with PTCL, cemsidomide achieved a 44 pe", "triplets": [["endpoint", "achieved", "POS"], ["phase", "achieved", "POS"]]}
{"row_id": 2661, "sent_id": "2661_0", "text": "Phase 1b data presented at ASH reported that 68% of baseline nTD patients achieved a hemoglobin increase of \u00e2\u2030\u00a51.5 g/dL during study period and 50% had sustained increases for \u00e2\u2030\u00a512 weeks, noted December", "triplets": [["phase", "achieved", "POS"], ["clinical", "achieved", "POS"]]}
{"row_id": 2662, "sent_id": "2662_0", "text": "Preclinical data presented at ASH reported that all NHPs achieved >40% \u00ce\u00b3-globin, a key constituent of HbF, post-transplant, noted December 8, 2024.", "triplets": [["clinical", "achieved", "POS"]]}
{"row_id": 2663, "sent_id": "2663_0", "text": "Phase 3 data presented at ASH reported that TRR was achieved by 30.4% (n=52/171) of patients in the mitapivat arm compared to 12.6% (n=11/87) of patients in the placebo arm, noted December 8, 2024.", "triplets": [["sample", "achieved", "POS"], ["phase", "achieved", "POS"], ["clinical", "achieved", "POS"]]}
{"row_id": 2666, "sent_id": "2666_0", "text": "Phase 2 data presented at ASH reported 30.2-month median progression-free survival with a median follow-up of 38.1 months in the Phase 1 study of anito-cel; median overall survival not reached, noted", "triplets": [["phase", "data presented at ASH", "POS"], ["clinical", "data presented at ASH", "POS"]]}
{"row_id": 2667, "sent_id": "2667_0", "text": "Phase 2 data presented at ASH reported 30.2-month median progression-free survival with a median follow-up of 38.1 months in the Phase 1 study of anito-cel; median overall survival not reached, noted", "triplets": [["phase", "data presented at ASH", "POS"], ["clinical", "data presented at ASH", "POS"]]}
{"row_id": 2668, "sent_id": "2668_0", "text": "Breakthrough Therapy designation (BTD) granted by the FDA, noted December 9, 2024.", "triplets": [["regulatory", "Breakthrough Therapy", "POS"]]}
{"row_id": 2670, "sent_id": "2670_0", "text": "Phase 1a interim data presented at ASH showed 100% CR rate in NPM1-m and 83% CR rate in KMT2A-r 1L adverse risk AML with 7+3, noted December 9, 2024.", "triplets": [["endpoint", "data presented at ASH", "POS"], ["clinical", "data presented at ASH", "POS"]]}
{"row_id": 2671, "sent_id": "2671_0", "text": "Phase 3 data reported that trial met its primary endpoint, noted December 9, 2024.", "triplets": [["endpoint", "met", "POS"], ["phase", "met", "POS"]]}
{"row_id": 2673, "sent_id": "2673_0", "text": "Phase 2 data presented at ASH included a 56% mean improvement in Total Symptom Score (TSS) at 24 weeks, with 76% of patients achieving a \u00e2\u2030\u00a550% TSS reduction and 95% of patients with elevated serum tryp", "triplets": [["phase", "data presented at ASH", "POS"], ["clinical", "data presented at ASH", "POS"]]}
{"row_id": 2675, "sent_id": "2675_0", "text": "Phase 1/2 preliminary data presented at ASH suggests improved relapse-free survival compared to published groups of acute myeloid leukemia (AML) patients at high risk of relapse post-transplant, noted", "triplets": [["phase", "data presented at ASH", "POS"], ["clinical", "data presented at ASH", "POS"]]}
{"row_id": 2679, "sent_id": "2679_0", "text": "Phase 2 data presented at ASH from subgroup analyses (N=64) showed responses across all major subgroups, including heavily pretreated patients, noted December 9, 2024.", "triplets": [["sample", "data presented at ASH", "POS"], ["phase", "data presented at ASH", "POS"], ["clinical", "data presented at ASH", "POS"]]}
{"row_id": 2680, "sent_id": "2680_0", "text": "Additional Phase 2 data presented at ASH showed best ORR of 97% and CR rate of 77% with 12-month PFS of 95%, data also presented at ASH on ZYNLONTA monotherapy in marginal zone lymphoma shows ORR of", "triplets": [["endpoint", "data presented at ASH", "POS"], ["phase", "data presented at ASH", "POS"], ["clinical", "data presented at ASH", "POS"]]}
{"row_id": 2682, "sent_id": "2682_0", "text": "Phase 1 topline data in 21 evaluable patients, 48% achieved stable disease at four months, including one partial response with a 45% tumor reduction at the MTD.", "triplets": [["phase", "achieved", "POS"], ["clinical", "achieved", "POS"]]}
{"row_id": 2682, "sent_id": "2682_1", "text": "SON-1010 demonstrated favorable safety,", "triplets": [["safety", "favorable safety", "POS"]]}
{"row_id": 2683, "sent_id": "2683_0", "text": "Phase 3 data reported that 85 percent of patients who achieved MRD negativity (10-6) with DARZALEX FASPRO\u00c2\u00ae were progression free at 4.5 years, noted December 9, 2024.", "triplets": [["phase", "achieved", "POS"]]}
{"row_id": 2685, "sent_id": "2685_0", "text": "Additional preclinical data presented at ASH reported that treatment demonstrated intended mechanism in vivo, achieving killing of cKit+ cells while reducing off-target effects seen with systemic anti", "triplets": [["clinical", "data presented at ASH", "POS"]]}
{"row_id": 2687, "sent_id": "2687_0", "text": "Phase 3 data presented at ASH reported that treatment reduced the risk of disease progression or death by 58% versus standard of care, noted December 9, 2024.", "triplets": [["phase", "data presented at ASH", "POS"], ["clinical", "data presented at ASH", "POS"]]}
{"row_id": 2689, "sent_id": "2689_0", "text": "Phase 3 data reported that 96% achieved adequate LDH control (\u00e2\u2030\u00a41.5 x ULN) across study visits, noted December 9, 2024.", "triplets": [["phase", "achieved", "POS"]]}
{"row_id": 2690, "sent_id": "2690_0", "text": "Phase 1/2 data presented at ASH reported that all 8 of 8 efficacy-evaluable patients responded to treatment (ORR and CRR 100%), noted December 9, 2024.", "triplets": [["endpoint", "data presented at ASH", "POS"], ["phase", "data presented at ASH", "POS"], ["clinical", "data presented at ASH", "POS"]]}
{"row_id": 2691, "sent_id": "2691_0", "text": "Phase 2 trial data reported that 73% of the NKTR-255 treatment group compared to 50% of the placebo group achieved a complete response at 6 months, noted December 9, 2024.", "triplets": [["phase", "achieved", "POS"]]}
{"row_id": 2692, "sent_id": "2692_0", "text": "Phase 2 trial data reported that 73% of the NKTR-255 treatment group compared to 50% of the placebo group achieved a complete response at 6 months, noted December 9, 2024.", "triplets": [["phase", "achieved", "POS"]]}
{"row_id": 2694, "sent_id": "2694_0", "text": "Phase 3 data reported that the trial met its primary endpoint of overall survival (OS) and all secondary endpoints, noted December 9, 2024.", "triplets": [["endpoint", "met", "POS"], ["phase", "met", "POS"], ["financial", "met", "POS"]]}
{"row_id": 2695, "sent_id": "2695_0", "text": "Phase 3 data reported that the trial met its primary endpoint of overall survival (OS) and all secondary endpoints, noted December 9, 2024.", "triplets": [["endpoint", "met", "POS"], ["phase", "met", "POS"], ["financial", "met", "POS"]]}
{"row_id": 2698, "sent_id": "2698_0", "text": "Phase 1 data reported that treatment demonstrated neuroprotective activity through the MET receptor; following siRNA-mediated knockdown of MET, the neuroprotective effects of ATH-1105 on neuronal surv", "triplets": [["phase", "MET", "POS"]]}
{"row_id": 2700, "sent_id": "2700_0", "text": "FDA approved, noted December 9, 2024.", "triplets": [["regulatory", "FDA approved", "POS"]]}
{"row_id": 2701, "sent_id": "2701_0", "text": "Phase 1b data presented at ASH showed that all 3 patients treated in first dose cohort administered fludarabine-free conditioning and show rapid, deep, and sustained B-cell depletion with favorable sa", "triplets": [["phase", "data presented at ASH", "POS"], ["clinical", "data presented at ASH", "POS"]]}
{"row_id": 2703, "sent_id": "2703_0", "text": "Phase 1b updated data from investigators concluded that the encouraging oncologic outcomes coupled with a favorable safety profile warrant further evaluation in a randomized trial, 23 months median Ov", "triplets": [["safety", "favorable safety", "POS"], ["phase", "favorable safety", "POS"]]}
{"row_id": 2704, "sent_id": "2704_0", "text": "Phase 2 final results presented at ASH showed that 54% of patients experience more than 2.5 years of durable hematocrit (Hct) control (<45%), decreased phlebotomy use, long-term tolerability, and impr", "triplets": [["safety", "results presented at ASH", "POS"], ["phase", "results presented at ASH", "POS"], ["clinical", "results presented at ASH", "POS"]]}
{"row_id": 2705, "sent_id": "2705_0", "text": "Phase 2 data presented at ASH showed that bitopertin significantly reduced protoporphyrin IX (PPIX) at low and high doses and in both adult and adolescent populations, noted December 9, 2024.", "triplets": [["phase", "data presented at ASH", "POS"], ["clinical", "data presented at ASH", "POS"]]}
{"row_id": 2706, "sent_id": "2706_0", "text": "Phase 2 trial updated analysis presented at ASH showed that bitopertin reduced PPIX in all prespecified subgroups across demographic and baseline patient characteristics, noted December 9, 2024.", "triplets": [["phase", "analysis presented at ASH", "POS"], ["clinical", "analysis presented at ASH", "POS"]]}
{"row_id": 2707, "sent_id": "2707_0", "text": "Preliminary data presented at ASH demonstrated that CTX112 has the potential to provide meaningful clinical benefit with a well-tolerated safety profile using a standard lymphodepletion protocol, note", "triplets": [["safety", "well-tolerated", "POS"], ["clinical", "well-tolerated", "POS"]]}
{"row_id": 2708, "sent_id": "2708_0", "text": "Phase 1 initial data presented at ASH demonstrated signs of preliminary clinical activity in elderly heavily pretreated LR-MDS patients, RBC-TI/HI-E responses occurred in 40% of evaluable TD patients", "triplets": [["phase", "data presented at ASH", "POS"], ["clinical", "data presented at ASH", "POS"]]}
{"row_id": 2709, "sent_id": "2709_0", "text": "Additional Phase 1/2 data presented at ASH was well-tolerated and continued to demonstrate a safety profile consistent with myeloablative busulfan conditioning and autologous hematopoietic stem cell t", "triplets": [["safety", "well-tolerated", "POS"], ["phase", "well-tolerated", "POS"], ["clinical", "well-tolerated", "POS"]]}
{"row_id": 2710, "sent_id": "2710_0", "text": "Preclinical data presented at ASH reported that the mean FVIII activity of months 13-16.5 following LNP dosing was 71%, 7%, and 27% compared to mean FVIII activity of months 3-6 of 76%, 8% and 30%, no", "triplets": [["clinical", "data presented at ASH", "POS"]]}
{"row_id": 2712, "sent_id": "2712_0", "text": "Phase 1/1b data presented at ASH reported that the combination achieved a 99% overall response rate (ORR), noted December 9, 2024.", "triplets": [["endpoint", "achieved", "POS"], ["phase", "achieved", "POS"], ["clinical", "achieved", "POS"]]}
{"row_id": 2713, "sent_id": "2713_0", "text": "Phase 1 data presented at ASH reported an ORR of 94% at the 200mg dose, noted December 9, 2024.", "triplets": [["endpoint", "data presented at ASH", "POS"], ["phase", "data presented at ASH", "POS"], ["clinical", "data presented at ASH", "POS"]]}
{"row_id": 2714, "sent_id": "2714_0", "text": "Phase 2 data presented at ASH reported that 55.2% (n=48/87) of the mITT24 patients achieved an overall erythroid response over the first 24 weeks of treatment, noted December 9, 2024.", "triplets": [["sample", "achieved", "POS"], ["phase", "achieved", "POS"], ["clinical", "achieved", "POS"]]}
{"row_id": 2715, "sent_id": "2715_0", "text": "Phase 1a/1b data presented at ASH reported an 75.5% Objective Response Rate which increased to 84.2% in patients with at least two disease assessments, noted December 9, 2024.", "triplets": [["clinical", "data presented at ASH", "POS"]]}
{"row_id": 2717, "sent_id": "2717_0", "text": "Phase 3 data presented at ASH reported an objective response rate (ORR) of 89% and 67% CR rate, noted December 9, 2024.", "triplets": [["endpoint", "data presented at ASH", "POS"], ["phase", "data presented at ASH", "POS"], ["clinical", "data presented at ASH", "POS"]]}
{"row_id": 2718, "sent_id": "2718_0", "text": "Phase 3 data presented at ASH reported an objective response rate (ORR) of 89% and 67% CR rate, noted December 9, 2024.", "triplets": [["endpoint", "data presented at ASH", "POS"], ["phase", "data presented at ASH", "POS"], ["clinical", "data presented at ASH", "POS"]]}
{"row_id": 2719, "sent_id": "2719_0", "text": "Phase 2 proof of concept results presented at ASH showed that clinical data support Phase 3 enrollment to commence in early 2025, noted December 9, 2024.", "triplets": [["phase", "results presented at ASH", "POS"], ["clinical", "results presented at ASH", "POS"]]}
{"row_id": 2720, "sent_id": "2720_0", "text": "Phase 1/2 triplet data presented at ASH reported 10 objective responses (6 CRs, 2 CRi/CRh, and 2 MLFS) among 19 evaluable relapsed/refractory AML patients with FLT3 mutations, treated with the RP2D of", "triplets": [["phase", "data presented at ASH", "POS"], ["clinical", "data presented at ASH", "POS"]]}
{"row_id": 2724, "sent_id": "2724_0", "text": "Phase 3 study achieved primary endpoint of LS mean reduction vs placebo in LDL-C on top of maximally tolerated lipid modifying therapies at day 84 with statistically significant reduction, noted Decem", "triplets": [["endpoint", "achieved", "POS"], ["effect", "achieved", "POS"], ["phase", "achieved", "POS"]]}
{"row_id": 2725, "sent_id": "2725_0", "text": "Phase 2b topline data did not demonstrate statistically significant effects versus placebo on primary and secondary endpoints at 16 weeks, noted December 10, 2024.", "triplets": [["endpoint", "statistically significant", "POS"], ["phase", "statistically significant", "POS"], ["financial", "statistically significant", "POS"], ["clinical", "statistically significant", "POS"]]}
{"row_id": 2726, "sent_id": "2726_0", "text": "Preclinical proof-of-concept achieved for APG777 + APG333 combination with clinical trial planning underway in asthma and COPD patients, noted December 10, 2024.", "triplets": [["catalyst", "achieved", "POS"]]}
{"row_id": 2727, "sent_id": "2727_0", "text": "Phase 1b/2 new data presented at SABCS demonstrated promising clinical activity, a safety profile consistent with ribociclib and endocrine therapy, and favorable tolerability, noted December 10, 2024", "triplets": [["safety", "data presented at SABCS", "POS"], ["phase", "data presented at SABCS", "POS"], ["clinical", "data presented at SABCS", "POS"]]}
{"row_id": 2729, "sent_id": "2729_0", "text": "FDA agreed that data from ongoing Phase 1/2 studies compared to a natural history external control may serve as the primary basis for a Biologics License Application (BLA) for Accelerated Approval, no", "triplets": [["phase", "Approval", "POS"], ["partner", "Approval", "POS"], ["regulatory", "Approval", "POS"]]}
{"row_id": 2730, "sent_id": "2730_0", "text": "Phase 1/2 results were generally safe and well tolerated in individuals with Down syndrome with no serious adverse events related to the study drug.", "triplets": [["safety", "well tolerated", "NEU"], ["phase", "well tolerated", "NEU"]]}
{"row_id": 2731, "sent_id": "2731_0", "text": "Phase 1/2 results were generally safe and well tolerated in individuals with Down syndrome with no serious adverse events related to the study drug.", "triplets": [["safety", "well tolerated", "NEU"], ["phase", "well tolerated", "NEU"]]}
{"row_id": 2732, "sent_id": "2732_0", "text": "Phase 1b data presented at ASH continues to demonstrate durable complete remissions (CR) with no relapses observed in any acute myeloid leukemia (AML) patients including those with high-risk disease a", "triplets": [["endpoint", "data presented at ASH", "POS"], ["phase", "data presented at ASH", "POS"], ["clinical", "data presented at ASH", "POS"]]}
{"row_id": 2733, "sent_id": "2733_0", "text": "Phase 3 dosing initiated, noted December 10, 2024.", "triplets": [["phase", "dosing initiated", "POS"], ["clinical", "dosing initiated", "POS"]]}
{"row_id": 2735, "sent_id": "2735_0", "text": "Phase 1b/2a all cohorts enrollment completed December 10, 2024.", "triplets": [["phase", "enrollment completed", "POS"], ["enrollment", "enrollment completed", "POS"]]}
{"row_id": 2741, "sent_id": "2741_0", "text": "Phase 1 data presented at ASH reported that event-free survival strongly favors the treatment arm (HR=0.30; p=0.04), and treatment-arm patients trend towards lower probability of relapse (HR=0.28; p=0", "triplets": [["pvalue", "data presented at ASH", "POS"], ["effect", "data presented at ASH", "POS"], ["phase", "data presented at ASH", "POS"], ["clinical", "data presented at ASH", "POS"]]}
{"row_id": 2743, "sent_id": "2743_0", "text": "Phase 2b study did not meet its primary endpoint of reducing glucocorticoid (GC) usage, with a placebo-adjusted reduction of only 0.7 mg/day.", "triplets": [["endpoint", "did not meet", "NEG"], ["phase", "did not meet", "NEG"]]}
{"row_id": 2745, "sent_id": "2745_0", "text": "Phase 2b/3 trial of izokibep did not meet primary endpoint; secondary endpoints also did not achieve statistical significance, noted Decemeber 10, 2024.", "triplets": [["endpoint", "did not meet", "NEG"], ["phase", "did not meet", "NEG"], ["financial", "did not meet", "NEG"]]}
{"row_id": 2746, "sent_id": "2746_0", "text": "Phase 1/2 data presented at ASH showed that therapy demonstrated a 94% overall response rate, a favorable safety profile, and no grade 4 cytokine release syndrome or neurotoxicity events, noted Novemb", "triplets": [["safety", "favorable safety", "POS"], ["phase", "favorable safety", "POS"], ["clinical", "favorable safety", "POS"]]}
{"row_id": 2747, "sent_id": "2747_0", "text": "Phase 3 data presented at ASH showed that trial met its primary endpoint of progression-free survival (PFS) and key secondary endpoints, noted December 10, 2024.", "triplets": [["endpoint", "met", "POS"], ["phase", "met", "POS"], ["financial", "met", "POS"], ["clinical", "met", "POS"]]}
{"row_id": 2748, "sent_id": "2748_0", "text": "Phase 3 data presented at ASH showed that trial met its primary endpoint of progression-free survival (PFS) and key secondary endpoints, noted December 10, 2024.", "triplets": [["endpoint", "met", "POS"], ["phase", "met", "POS"], ["financial", "met", "POS"], ["clinical", "met", "POS"]]}
{"row_id": 2749, "sent_id": "2749_0", "text": "Phase 3 data presented at ASH showed that trial met its primary endpoint of progression-free survival (PFS) and key secondary endpoints, noted December 10, 2024.", "triplets": [["endpoint", "met", "POS"], ["phase", "met", "POS"], ["financial", "met", "POS"], ["clinical", "met", "POS"]]}
{"row_id": 2750, "sent_id": "2750_0", "text": "IND cleared by the FDA, noted December 10, 2024.", "triplets": [["regulatory", "cleared by the FDA", "POS"]]}
{"row_id": 2751, "sent_id": "2751_0", "text": "Phase 1b/2 data to be presented at SABCS suggest that HER2-positive patients whose cancer has been heavily pretreated may benefit from CD47 inhibition via evorpacept's unique mechanism when combined w", "triplets": [["phase", "data to be presented at SABCS", "POS"], ["clinical", "data to be presented at SABCS", "POS"]]}
{"row_id": 2752, "sent_id": "2752_0", "text": "Phase 1b/2 data to be presented at SABCS suggest that HER2-positive patients whose cancer has been heavily pretreated may benefit from CD47 inhibition via evorpacept's unique mechanism when combined w", "triplets": [["phase", "data to be presented at SABCS", "POS"], ["clinical", "data to be presented at SABCS", "POS"]]}
{"row_id": 2754, "sent_id": "2754_0", "text": "Preclinical data presented at ASH showed that treatment has the potential to be a safe and effective preventative therapeutic using innovative nonclinical models, noted December 10, 2024.", "triplets": [["clinical", "data presented at ASH", "POS"]]}
{"row_id": 2755, "sent_id": "2755_0", "text": "Preclinical data presented at ASH demonstrated that single intravenous injections of RLYB332 to humanized FcRn mice had rapid and sustained effects on pharmacodynamic (PD) parameters, including serum", "triplets": [["clinical", "data presented at ASH", "POS"]]}
{"row_id": 2759, "sent_id": "2759_0", "text": "Phase 3 results for CAN-2409 viral immunotherapy in intermediate-to-high-risk localized prostate cancer, achieved its primary endpoint of significantly improved disease-free survival (DFS) when combin", "triplets": [["endpoint", "achieved", "POS"], ["phase", "achieved", "POS"]]}
{"row_id": 2765, "sent_id": "2765_0", "text": "Phase 1b/2 data results demonstrated reduction in the mean monthly attack rate of 90-95% at 6 months, favorable safety and tolerability profile, noted December 11, 2024.", "triplets": [["safety", "favorable safety", "POS"], ["phase", "favorable safety", "POS"]]}
{"row_id": 2766, "sent_id": "2766_0", "text": "IND cleared by the FDA, noted December 10, 2024.", "triplets": [["regulatory", "cleared by the FDA", "POS"]]}
{"row_id": 2774, "sent_id": "2774_0", "text": "Phase 2 trial did not meet its primary endpoint, noted December 11, 2024.", "triplets": [["endpoint", "did not meet", "NEG"], ["phase", "did not meet", "NEG"]]}
{"row_id": 2775, "sent_id": "2775_0", "text": "Phase 2 data showed that the 1 mg dose reduced MBD by 17.3 percentage points, while the 2 mg dose achieved a reduction of 23.5 percentage points, compared to a minimal change in the placebo group of 0", "triplets": [["effect", "achieved", "POS"], ["phase", "achieved", "POS"]]}
{"row_id": 2777, "sent_id": "2777_0", "text": "Phase 3 data presented at SABCS significantly reduced the risk of progression or death by 38% compared to standard endocrine therapy (ET) in patients with ESR1 mutations, noted December 11, 2024.", "triplets": [["phase", "data presented at SABCS", "POS"], ["clinical", "data presented at SABCS", "POS"]]}
{"row_id": 2781, "sent_id": "2781_0", "text": "Phase 2 data from SABCS reported that 50 percent of patients (3/6) in the group that received 80 mg of (Z)-endoxifen with goserelin met the target steady-state plasma concentrations (Css) of 500\u00e2\u20ac\u201c1000", "triplets": [["phase", "met", "POS"]]}
{"row_id": 2782, "sent_id": "2782_0", "text": "Phase 2 data from SABCS reported that 50 percent of patients (3/6) in the group that received 80 mg of (Z)-endoxifen with goserelin met the target steady-state plasma concentrations (Css) of 500\u00e2\u20ac\u201c1000", "triplets": [["phase", "met", "POS"]]}
{"row_id": 2787, "sent_id": "2787_0", "text": "Phase 2b did not meet the primary and secondary endpoints in any of the doses studied in the global, AD trial and all further investment in ANB032 will be discontinued, noted December 12, 2024.", "triplets": [["endpoint", "did not meet", "NEG"], ["phase", "did not meet", "NEG"], ["financial", "did not meet", "NEG"]]}
{"row_id": 2789, "sent_id": "2789_0", "text": "Phase 1b/2a data reported that 100% of patients achieved remission within 30 days, noted December 12, 2024.", "triplets": [["phase", "achieved", "POS"]]}
{"row_id": 2790, "sent_id": "2790_0", "text": "Phase 1b/2a data reported that 100% of patients achieved remission within 30 days, noted December 12, 2024.", "triplets": [["phase", "achieved", "POS"]]}
{"row_id": 2797, "sent_id": "2797_0", "text": "Phase 1 data reported that no serious adverse events have been reported, noted December 12, 2024.", "triplets": [["safety", "serious adverse events", "NEG"], ["phase", "serious adverse events", "NEG"]]}
{"row_id": 2799, "sent_id": "2799_0", "text": "Phase 4 trial met primary endpoint, noted December 12, 2024.", "triplets": [["endpoint", "met", "POS"]]}
{"row_id": 2800, "sent_id": "2800_0", "text": "Data presented at SABCS reported an 60% overall response rate, noted December 12, 2024.", "triplets": [["clinical", "Data presented at SABCS", "POS"]]}
{"row_id": 2802, "sent_id": "2802_0", "text": "Phase 1 trial achieved 25.9% overall response rate (ORR) in endometrial cancer and 37.5% in platinum-resistant ovarian cancer, noted December 13, 2024.", "triplets": [["endpoint", "achieved", "POS"], ["phase", "achieved", "POS"]]}
{"row_id": 2803, "sent_id": "2803_0", "text": "Approved December 13, 2024.", "triplets": [["catalyst", "Approved", "POS"]]}
{"row_id": 2804, "sent_id": "2804_0", "text": "Approved December 16, 2024.", "triplets": [["catalyst", "Approved", "POS"]]}
{"row_id": 2805, "sent_id": "2805_0", "text": "Approved December 16, 2024.", "triplets": [["catalyst", "Approved", "POS"]]}
{"row_id": 2807, "sent_id": "2807_1", "text": "However, the observed response rate did not meet the Company's thresho", "triplets": [["catalyst", "did not meet", "NEG"]]}
{"row_id": 2810, "sent_id": "2810_0", "text": "Phase 3 dosing initiated, noted December 16, 2024.", "triplets": [["phase", "dosing initiated", "POS"], ["clinical", "dosing initiated", "POS"]]}
{"row_id": 2812, "sent_id": "2812_0", "text": "Phase 2 enrollment completed with a registrational trial planned for 2H 2024.", "triplets": [["phase", "enrollment completed", "POS"], ["enrollment", "enrollment completed", "POS"]]}
{"row_id": 2814, "sent_id": "2814_0", "text": "Phase 2 trial met its primary endpoint of reduction in circulating levels of creatine kinase (CK), a biomarker associated with skeletal muscle damage, in the largest Becker interventional trial to dat", "triplets": [["endpoint", "met", "POS"], ["phase", "met", "POS"]]}
{"row_id": 2815, "sent_id": "2815_0", "text": "Phase 2 trial received a clinical hold notice from the FDA regarding its IND application, noted December 16, 2024.", "triplets": [["phase", "clinical hold", "NEG"], ["regulatory", "clinical hold", "NEG"]]}
{"row_id": 2816, "sent_id": "2816_0", "text": "Phase 1 achieved deep lowering of targeted IgG, with reductions > 60% in the lowest subcutaneous dose tested in the MAD, noted December 16, 2024.", "triplets": [["phase", "achieved", "POS"]]}
{"row_id": 2818, "sent_id": "2818_0", "text": "Phase 3 long-term topline data from OLE demonstrated favorable long-term safety and robust broad-spectrum efficacy sustained over 1-year, the treatment generally well-tolerated with low rates of adver", "triplets": [["safety", "well-tolerated", "POS"], ["phase", "well-tolerated", "POS"], ["clinical", "well-tolerated", "POS"]]}
{"row_id": 2819, "sent_id": "2819_0", "text": "Approved December 17, 2024.", "triplets": [["catalyst", "Approved", "POS"]]}
{"row_id": 2820, "sent_id": "2820_0", "text": "Phase 2b topline data reported that the trial met its primary endpoints, noted December 17, 2024.", "triplets": [["endpoint", "met", "POS"], ["phase", "met", "POS"], ["clinical", "met", "POS"]]}
{"row_id": 2821, "sent_id": "2821_0", "text": "Phase 2b topline data reported that the trial met its primary endpoints, noted December 17, 2024.", "triplets": [["endpoint", "met", "POS"], ["phase", "met", "POS"], ["clinical", "met", "POS"]]}
{"row_id": 2822, "sent_id": "2822_0", "text": "Phase 1 data presented at SABCS reported that the best response rates (response only) were, CTC: 88% (7/8), noted December 17, 2024.", "triplets": [["phase", "data presented at SABCS", "POS"], ["clinical", "data presented at SABCS", "POS"]]}
{"row_id": 2823, "sent_id": "2823_0", "text": "Phase 1/2 preliminary data from three patients in the first dose cohort of 3E13 vg/kg (Cohort 1) showed that TN-201 was generally well tolerated, with readily detectable vector DNA in the heart, evide", "triplets": [["safety", "well tolerated", "POS"], ["phase", "well tolerated", "POS"]]}
{"row_id": 2824, "sent_id": "2824_0", "text": "NDA accepted December 17, 2024.", "triplets": [["regulatory", "NDA accepted", "POS"]]}
{"row_id": 2825, "sent_id": "2825_0", "text": "Phase 2 study met the primary endpoint, displaying a meaningful statistically significant placebo-corrected mean reduction in HbA1c in the prespecified per protocol patient population, noted December", "triplets": [["endpoint", "met", "POS"], ["phase", "met", "POS"]]}
{"row_id": 2827, "sent_id": "2827_0", "text": "Phase 1 met primary endpoint of 1 year survival rate and median overall survival, noted December 17, 2024.", "triplets": [["endpoint", "met", "POS"], ["phase", "met", "POS"]]}
{"row_id": 2828, "sent_id": "2828_0", "text": "Fast track designation granted by the FDA, noted December 17, 2024.", "triplets": [["regulatory", "Fast track", "POS"]]}
{"row_id": 2829, "sent_id": "2829_0", "text": "Phase 3 long term extension data demonstrated that patients treated with relacorilant experienced clinically meaningful and durable cardiometabolic improvements and relacorilant was well-tolerated, w", "triplets": [["safety", "well-tolerated", "POS"], ["phase", "well-tolerated", "POS"]]}
{"row_id": 2831, "sent_id": "2831_0", "text": "Preclinical studies with ACCG-2671 demonstrate potent target engagement, robust weight loss, favorable safety profile and PK properties supportive of once-daily dosing in humans, noted December 17, 20", "triplets": [["safety", "favorable safety", "POS"]]}
{"row_id": 2837, "sent_id": "2837_0", "text": "Phase 2a data reported that DA-1241 (100mg) demonstrated a statistically significant reduction in alanine transaminase (ALT) levels at weeks 4 and 8, with a near statistically significant reduction at", "triplets": [["phase", "statistically significant", "POS"]]}
{"row_id": 2838, "sent_id": "2838_0", "text": "Phase 2 trial met its primary endpoint, noted December 18, 2024.", "triplets": [["endpoint", "met", "POS"], ["phase", "met", "POS"]]}
{"row_id": 2843, "sent_id": "2843_0", "text": "Phase 1/2 data reported no dose-limiting toxicities (DLTs) have been observed in the triplet combination, noted December 18, 2024.", "triplets": [["safety", "DLTs", "NEG"], ["phase", "DLTs", "NEG"]]}
{"row_id": 2844, "sent_id": "2844_0", "text": "Phase 1/2 data reported no dose-limiting toxicities (DLTs) have been observed in the triplet combination, noted December 18, 2024.", "triplets": [["safety", "DLTs", "NEG"], ["phase", "DLTs", "NEG"]]}
{"row_id": 2845, "sent_id": "2845_0", "text": "Rolling BLA submission initiated December 18, 2024.", "triplets": [["regulatory", "BLA submission", "POS"]]}
{"row_id": 2846, "sent_id": "2846_0", "text": "Approved December 19, 2024.", "triplets": [["catalyst", "Approved", "POS"]]}
{"row_id": 2847, "sent_id": "2847_0", "text": "Phase 2b trial failed to meet its primary endpoint, noted December 19, 2024.", "triplets": [["endpoint", "failed to meet", "NEG"], ["phase", "failed to meet", "NEG"]]}
{"row_id": 2848, "sent_id": "2848_0", "text": "Approved December 19, 2024.", "triplets": [["catalyst", "Approved", "POS"]]}
{"row_id": 2849, "sent_id": "2849_0", "text": "Approved December 19, 2024.", "triplets": [["catalyst", "Approved", "POS"]]}
{"row_id": 2850, "sent_id": "2850_0", "text": "Phase 2 trial met its primary endpoint, noted December 19, 2024.", "triplets": [["endpoint", "met", "POS"], ["phase", "met", "POS"]]}
{"row_id": 2852, "sent_id": "2852_0", "text": "Phase 1/2 DSMB review noted no serious adverse events, noted December 19, 2024.", "triplets": [["safety", "serious adverse events", "NEG"], ["phase", "serious adverse events", "NEG"]]}
{"row_id": 2854, "sent_id": "2854_0", "text": "Phase 3 met primary efficacy endpoint at Week 48, the study demonstrated to be non-inferior to BIC/FTC/TAF in double-blind trial.", "triplets": [["phase", "met", "POS"]]}
{"row_id": 2854, "sent_id": "2854_1", "text": "The superiority criteria were not met in trial MK-8591A-052.", "triplets": [["catalyst", "met", "POS"]]}
{"row_id": 2860, "sent_id": "2860_0", "text": "Phase 2 trial results demonstrated that inhaled AP-PA02 provides a durable reduction of Pseudomonas aeruginosa in the lung, with a favorable safety and tolerability profile, noted December 19, 2024.", "triplets": [["safety", "favorable safety", "POS"], ["phase", "favorable safety", "POS"]]}
{"row_id": 2863, "sent_id": "2863_0", "text": "Phase 1 showed that 78% of patients achieved objective response rates, with 44.4% demonstrating complete response (CR), noted December 19, 2024.", "triplets": [["endpoint", "achieved", "POS"], ["phase", "achieved", "POS"]]}
{"row_id": 2864, "sent_id": "2864_0", "text": "NDA submitted to the FDA, noted December 19, 2024.", "triplets": [["regulatory", "NDA submitted", "POS"]]}
{"row_id": 2867, "sent_id": "2867_0", "text": "Trial met primary endpoint, noted December 19, 2024.", "triplets": [["endpoint", "met", "POS"]]}
{"row_id": 2868, "sent_id": "2868_0", "text": "Approved December 19, 2024.", "triplets": [["catalyst", "Approved", "POS"]]}
{"row_id": 2871, "sent_id": "2871_0", "text": "Phase 3 trial met its primary endpoint, noted December 20, 2024.", "triplets": [["endpoint", "met", "POS"], ["phase", "met", "POS"]]}
{"row_id": 2872, "sent_id": "2872_0", "text": "Phase 3 trial met primary endpoint, noted December 20, 2024.", "triplets": [["endpoint", "met", "POS"], ["phase", "met", "POS"]]}
{"row_id": 2873, "sent_id": "2873_0", "text": "Approval announced December 20, 2024.", "triplets": [["regulatory", "Approval", "POS"]]}
{"row_id": 2874, "sent_id": "2874_0", "text": "Phase 2b/3 topline data reported a statistically significant reduction (p-value < 0.05) in development of esophageal varices in 2mg/kg cohort compared to placebo, noted December 20, 2024.", "triplets": [["phase", "statistically significant", "POS"], ["clinical", "statistically significant", "POS"]]}
{"row_id": 2875, "sent_id": "2875_0", "text": "Approved December 20, 2024.", "triplets": [["catalyst", "Approved", "POS"]]}
{"row_id": 2876, "sent_id": "2876_0", "text": "Approved December 20, 2024.", "triplets": [["catalyst", "Approved", "POS"]]}
{"row_id": 2877, "sent_id": "2877_0", "text": "FDA approved on December 20, 2024.", "triplets": [["regulatory", "FDA approved", "POS"]]}
{"row_id": 2878, "sent_id": "2878_0", "text": "CRL issued by FDA on December 20, 2024.", "triplets": [["regulatory", "CRL", "NEG"]]}
{"row_id": 2879, "sent_id": "2879_0", "text": "FDA Approved on December 20, 2024.", "triplets": [["regulatory", "FDA Approved", "POS"]]}
{"row_id": 2880, "sent_id": "2880_0", "text": "FDA Approved on December 20, 2024.", "triplets": [["regulatory", "FDA Approved", "POS"]]}
{"row_id": 2881, "sent_id": "2881_0", "text": "Phase 3 trial met its primary endpoint, noted December 23, 2024.", "triplets": [["endpoint", "met", "POS"], ["phase", "met", "POS"]]}
{"row_id": 2882, "sent_id": "2882_0", "text": "Phase 3 trial met its primary endpoint, noted December 23, 2024.", "triplets": [["endpoint", "met", "POS"], ["phase", "met", "POS"]]}
{"row_id": 2885, "sent_id": "2885_0", "text": "Phase 1a topline results demonstrated a favorable safety and tolerability profile with no drug-related adverse events historically associated with earlier generation, less selective BET inhibitors, no", "triplets": [["safety", "favorable safety", "POS"], ["clinical", "favorable safety", "POS"]]}
{"row_id": 2887, "sent_id": "2887_0", "text": "NDA filing submitted to the FDA, noted December 23, 2024.", "triplets": [["regulatory", "NDA filing", "POS"]]}
{"row_id": 2888, "sent_id": "2888_0", "text": "Phase 2 trial did not meet its primary endpoint, noted December 23, 2024.", "triplets": [["endpoint", "did not meet", "NEG"], ["phase", "did not meet", "NEG"]]}
{"row_id": 2890, "sent_id": "2890_0", "text": "FDA Approved on December 27, 2024.", "triplets": [["regulatory", "FDA Approved", "POS"]]}
{"row_id": 2891, "sent_id": "2891_0", "text": "Phase 3 trial did not meet the primary 72-hour endpoint due to unresolved data from the final 24-hour period.", "triplets": [["phase", "did not meet", "NEG"]]}
{"row_id": 2891, "sent_id": "2891_1", "text": "However, the drug showed statistically significant pain reduction in the first 48 hours, n", "triplets": [["catalyst", "statistically significant", "POS"]]}
{"row_id": 2894, "sent_id": "2894_0", "text": "NDA filing submitted December 30, 2024.", "triplets": [["regulatory", "NDA filing", "POS"]]}
{"row_id": 2895, "sent_id": "2895_0", "text": "Phase 3 trial met primary endpoint, noted December 30, 2024.", "triplets": [["endpoint", "met", "POS"], ["phase", "met", "POS"]]}
{"row_id": 2897, "sent_id": "2897_0", "text": "NDA submitted to FDA, noted December 30, 2024.", "triplets": [["regulatory", "NDA submitted", "POS"]]}
{"row_id": 2899, "sent_id": "2899_0", "text": "Phase 3 KOASTAL-1 data reported that the trial did not meet its primary endpoint with statistical significance, noted January 2, 2025.", "triplets": [["endpoint", "did not meet", "NEG"], ["phase", "did not meet", "NEG"]]}
{"row_id": 2900, "sent_id": "2900_0", "text": "FDA ANDA approved on January 2, 2025.", "triplets": [["catalyst", "approved", "POS"]]}
{"row_id": 2901, "sent_id": "2901_0", "text": "FDA feedback reported that data on OS would generally not be appropriate for accelerated approval, noted January 2, 2025.", "triplets": [["endpoint", "approval", "POS"], ["regulatory", "approval", "POS"]]}
{"row_id": 2902, "sent_id": "2902_0", "text": "Phase 2a data reported no SAEs and no drug-related discontinuations by study participants, noted January 2, 2025.", "triplets": [["safety", "no SAEs", "POS"], ["phase", "no SAEs", "POS"]]}
{"row_id": 2904, "sent_id": "2904_0", "text": "BLA submission to the FDA completed, noted January 2, 2024.", "triplets": [["regulatory", "BLA submission", "POS"]]}
{"row_id": 2906, "sent_id": "2906_0", "text": "Phase 2 trial met primary safety endpoint, noted January 6, 2025.", "triplets": [["safety", "met", "POS"], ["phase", "met", "POS"]]}
{"row_id": 2908, "sent_id": "2908_0", "text": "Phase 2b enrollment completed, noted January 6, 2024.", "triplets": [["phase", "enrollment completed", "POS"], ["enrollment", "enrollment completed", "POS"]]}
